Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof

ABSTRACT

The invention relates to substituted aminoindanes and analogs thereof of formula (I) and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders.

The invention relates to substituted aminoindanes and analogs thereof,and to the pharmaceutical use thereof. Medicaments comprising compoundsof this type are suitable for the prevention or treatment of diversedisorders.

Previously disclosed NHE3 inhibitors are derived for example fromcompounds of the acylguanidine type (EP 0 825 178), norbornylamine type(WO 01/44164), 2-guanidino-quinazoline type (WO 01/79186, WO 03/051866),benzamidine type (WO 01/21582, WO 01/72742),4-phenyltetrahydroisoquinoline type (WO 06/074813) or benzimidazole type(WO 03/101984). Squalamine, which is likewise described as NHE3inhibitor (M. Donowitz et al. Am. J. Physiol. 276 (Cell Physiol. 45):C136-C144), appears to act not directly but by an indirect mechanism andthus reaches its maximum strength of effect only after one hour.

Starting from this, it has surprisingly been found that compounds of theformula I represent excellent inhibitors of the sodium-hydrogenexchanger (NHE), especially of the sodium-hydrogen exchanger of subtype3 (NHE3). The invention consequently relates to compounds of the formulaI

in which

-   A is a 6 to 10 membered aryl radical or a 5 to 10 membered    heteroaryl radical, where the aryl and heteroaryl radical may be    mono- or bicyclic, and the heteroaryl radical may comprise one or    more heteroatoms selected from the group of nitrogen, oxygen and    sulfur;    -   where one or more hydrogen atoms in said mono- or bicyclic aryl        or heteroaryl radicals may be replaced by substituents R1 which        are selected independently of one another from the group of F,        Cl, Br, I, (C₁-C₁₀)-alkyl-, (C₂-C₁₀)-alkenyl-,        (C₂-C₁₀)-alkynyl-, (C₃-C₁₄)-cycloalkyl-,        (C₄-C₂₀)-cycloalkylalkyl-, (C₄-C₂₀)-cycloalkylalkyloxy-,        (C₁-C₁₀)-alkoxy-, (C₁-C₁₀)-alkylthio-, (C₆-C₁₄)-aryl-,        (C₂-C₁₃)-heteroaryl, —CN, —NR13R14, —C(O)R12, —SF₅,        —S(O)_(n)R12, —C(O)OR12, —C(O)NR13R14, —S(O)_(n)NR13R14;        -   where two adjacent radicals R1 may also form a saturated or            partly unsaturated (C₅-C₁₀)-cycloalkyl radical or a            saturated or partly unsaturated (C₂-C₉)-cycloheteroalkyl            radicals, where the cycloheteroalkyl radical may comprise 1,            2 or 3 nitrogen, 1 or 2 oxygen, 1 or 2 sulfur, 1 or 2            nitrogen and 1 oxygen or 1 sulfur atom;            -   where said alkyl, alkenyl, alkynyl, cycloalkyl,                cycloalkylalkyl, cycloalkylalkyloxy, cycloheteroalkyl,                alkoxy, and alkylthio radicals may be substituted                independently of one another one or more times by F, OH                or (C₁-C₁₀)-alkoxy;-   B is a mono- or fused bicyclic radical selected from the group of    -   6 to 10 membered aryl radicals,    -   of 5 to 10 membered heteroaryl radicals,    -   of 3 to 10 membered cycloalkyl radicals,    -   of 9 to 14 membered cycloalkylaryl radicals,    -   of 8 to 14 membered cycloalkylheteroaryl radicals,    -   of 3 to 10 membered cycloheteroalkyl radicals,    -   of 9 to 14 membered cycloheteroalkylaryl radicals and    -   of 8 to 14 membered cycloheteroalkylheteroaryl radicals,        -   where the cycloalkyl or cycloheteroalkyl units may be            saturated or partly unsaturated, and where the heterocyclic            groups may comprise one or more heteroatoms selected from            the group of nitrogen, oxygen and sulfur;        -   where one or more hydrogen atoms in the radicals B may be            replaced by substituents R5 which are selected independently            of one another from the group of (C₁-C₁₀)-alkyl radicals, of            (C₂-C₁₀)-alkenyl radicals, of (C₂-C₁₀)-alkynyl radicals, of            (C₁-C₁₀)-alkoxy radicals, of (C₁-C₁₀)-alkylthio radicals, of            (C₃-C₁₄)-cycloalkyl radicals, of (C₄-C₂₀)-cycloalkylalkyl            radicals, of (C₄-C₂₀)-cycloalkylalkyloxy, of            (C₂-C₁₉)-cycloheteroalkyl radicals, of            (C₃-C₁₉)-cycloheteroalkylalkyl radicals, of            (C₃-C₁₁)-cycloalkyloxy radicals, of            (C₂-C₁₁)-cycloheteroalkyloxy radicals, of (C₆-C₁₀)-aryl            radicals, of (C₁-C₉)-heteroaryl radicals, of            (C₉-C₁₄)-cycloalkylaryl radicals, of            (C₅-C₁₃)-cycloalkylheteroaryl radicals,            (C₇-C₁₃)-cycloheteroalkylaryl radicals,            (C₄-C₁₂)-cycloheteroalkylheteroaryl radicals, where            -   the cycloalkyl and cycloheteroalkyl units may be                saturated or partly unsaturated,            -   and where one or more hydrogen atoms in said radicals R5                may be replaced by further radicals which are selected                independently of one another from the group of R11                radicals,        -   it is further possible for R5 to be one or more radicals            which are selected independently of one another from the            group of OH, (═O), NH₂, F, Cl, Br, I, CN, NO₂, —NR17R18,            —NR16COR17, —NR16COOR17, —NR16CONR17R18, —NR16-S(O)₂—R17,            —NR16-S(O)₂—NR17R18, —COOR16, —COR16; —CO(NR17R18),            S(O)_(n)R16, —S(O)₂NR17R18,            -   where R16, R17 and R18 independently of one another for                a radical selected from the group of H,                (C₂-C₁₉)-cycloheteroalkyl, (C₃-C₁₄)-cycloalkyl,                (C₆-C₁₀)-aryl, (C₁-C₁₀)-alkyl radicals,                -   all of which may be substituted independently of one                    another by OH, (═O), F, Cl, Br, I, CN, NO₂,                    —NR13R14, —NR13COR12, —NR13COOR12, —NR12CONR13R14,                    —NR13-S(O)₂—R12, —NR12-S(O)₂—R13R14, —COOR12,                    —COR12; —CO(NR13R14), —S(O)_(n)R12, —S(O)₂NR13R14,                    (C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl,                    (C₂-C₁₉)-cycloheteroalkyl,                    (C₃-C₁₉)-cycloheteroalkylalkyl, (C₆-C₁₀)-aryl and                    (C₁-C₉)-heteroaryl,            -   and where R17 and R18 can form together with the                nitrogen to which they are bonded a 4-7 membered,                saturated, unsaturated or partly unsaturated heterocycle                having 1 to 13 carbon atoms which may additionally                comprise one or more heteroatoms from the list —O—,                —S(O)_(n)—, ═N— and —NR15-,                -   where the heterocycle formed may be substituted                    independently of one another one or more times by F,                    OH, (═O), NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN                    or (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-alkyl,                    (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl,                    (C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl,                    (C₂-C₂₀)-cycloheteroalkyl,                    (C₃-C₁₉)-cycloheteroalkylalkyl, each of which may in                    turn carry independently of one another one or more                    radicals F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,                    N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy;-   L is a covalent bond or an alkylene bridge having 1 to 10 carbon    atoms, which may carry independently of one another one or more    substituents from the group of radicals (C₁-C₁₀)-alkyl,    (C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl radical, —COR12,    —CO(NR13R14), S(O)_(n)R12, —S(O)₂NR13R14, (═O) and F; where the    alkyl, cycloalkyl and cycloalkyl radicals may be substituted one or    more times by F;-   X is a group —N(R6)-, —O—, —S(O)_(n)—, or alkylene having 1 to 5    carbon atoms, where    -   R6 may be hydrogen or may be (C₁-C₁₀)-alkyl,        (C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl radical, all of        which may be substituted independently of one another one or        more times by F, or R6 may be —COR12; —CO(NR13R14), S(O)_(n)R12,        —S(O)₂NR13R14;-   R2 is absent or is one or more substituents which may be selected    independently of one another from the group of F, (C₁-C₁₀)-alkyl and    (C₁-C₁₀)-alkoxy radical, where the alkyl and alkoxy radicals may be    substituted independently of one another one or more times by F;-   R3 and R4 are independently of one another a hydrogen radical or a    radical which is selected from the group of (C₁-C₁₀)-alkyl radicals,    of (C₂-C₁₀)-alkenyl radicals, of (C₂-C₁₀)-alkynyl radicals, of    (C₃-C₁₄)-cycloalkyl radicals, of (C₄-C₂₀)-cycloalkylalkyl radicals,    of (C₂-C₁₉)-cycloheteroalkyl radicals, of    (C₃-C₁₉)-cycloheteroalkylalkyl radicals, of (C₆-C₁₀)-aryl radicals,    of (C₇-C₂₀)-arylalkyl radicals, of (C₁-C₉)-heteroaryl radicals, of    (C₂-C₁₉)-heteroarylalkyl radicals, where    -   the radicals R3 and R4 may be substituted independently of one        another one or more times by a radical from the group of OH,        NH₂, (═O), F, Cl, Br, I, CN, NO₂, —NR13R14, —NR13COR12,        —NR13COOR12, —NR12CONR13R14, —NR13-S(O)₂—R12,        —NR13-S(O)₂—NR13R14, —COOR12, —COR12; —CO(NR13R14), S(O)_(n)R12,        —S(O)₂R13R14, or-   R3 and R4 form together with the nitrogen to which they are bonded a    4-10 membered, saturated, unsaturated or partly unsaturated    heterocycle which may additionally comprise one or more heteroatoms    from the list —O—, —S(O)_(n)—, ═N— and —NR8-, where    -   the heterocyclic radicals may be substituted independently of        one another one or more times by radicals selected from the        group of R7 and R9, and where    -   the heterocyclic radicals may be bridged by a bond, by a        saturated or unsaturated (C₁-C₁₀)-alkyl or (C₁-C₉)-heteroalkyl        chain or by —NR15-, —O—, —S—, and where        -   the alkyl and heteroalkyl chains may also form a spirocyclic            ring system with the ring system formed by R3 and R4, where            the alkyl and heteroalkyl bridges may be substituted            independently of one another one or more times by radicals            selected from the group of R7 and R9,    -   and where    -   R8 in the group NR8 may form with the ring which R3 and R4 may        form a further saturated, unsaturated or partly unsaturated        heterocycle which may be substituted independently of one        another one or more times by radicals selected from the group of        R7 and R9, and may additionally comprise one or more heteroatoms        from the list —O—, —S(O)_(n)—, —N═ and —NR19-;-   R7 are a (C₁-C₁₀)-alkyl radical or (C₁-C₁₄)-cycloalkyl radical,    where the alkyl radical may be substituted independently of one    another one or more times by R9;-   R8 is an H, a (C₁-C₁₀)-alkyl radical or (C₁-C₁₄)-cycloalkyl radical,    COR12, —CO(NR13R14), S(O)_(n)R12, —S(O)₂NR13R14, where the alkyl    radical may be substituted independently of one another one or more    times by R10;-   R9 is a radical selected from the group of OH, (═O), F, Cl, Br, I,    CN, NO₂, —NR13R14, —NR13COR12, —NR13COOR12, —NR12CONR13R14,    —NR13-S(O)₂—R12, —NR13-S(O)₂—NR13R14, —COOR12, —COR12, —CO(NR13R14),    S(O)_(n)R12, —S(O)₂NR13R14, (C₃-C₁₄)-cycloalkyl,    (C₄-C₂₀)-cycloalkylalkyl, (C₁-C₁₀)-alkoxy,    (C₂-C₁₉)-cycloheteroalkyl, (C₃-C₁₉)-cycloheteroalkylalkyl,    (C₆-C₁₀)-aryl radicals, of (C₁-C₉)-heteroaryl radicals;-   R10 is a radical selected from the group of F, OH, CN,    (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-alkylthio, NO₂, —NR13R14, —NR13COR12,    —NR13COOR12, —NR13CONR13R14, —NR13-S(O)₂—R12, —NR12-S(O)₂—NR13R14,    —COOR12, —COR12, —CO(NR13R14), S(O)_(n)R12, —S(O)₂NR13R14;-   R11 is a radical selected from the group of (C₁-C₁₀)-alkyl,    (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-alkoxy,    (C₁-C₂₀)-alkylthio, (C₃-C₁₄)-cycloalkyl, (C₄-C₁₀)— cycloalkylalkyl,    (C₂-C₁₃)-cycloheteroalkyl, (C₄-C₁₉)-cycloheteroalkylalkyl,    (C₃-C₁₄)-cycloalkyloxy, (C₂-C₁₃)-cycloheteroalkyloxy,    -   all of which may be substituted independently of one another one        or more times by R10;    -   (═O), Cl, Br, I and R10;-   R12, R13 and R14 may independently of one another be H,    (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl,    (C₃-C₁₄)-cycloalkyl, (C₄-C₁₀)-cycloalkylalkyl,    (C₂-C₁₃)-cycloheteroalkyl, (C₃-C₁₉)-cycloheteroalkylalkyl,    (C₆-C₁₀)-aryl, each of which may be substituted independently of one    another one or more times by F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,    N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy; or where R13 and R14 may    form together with the nitrogen to which they are bonded a 4-7    membered, saturated, unsaturated or partly unsaturated heterocycle    having 1 to 13 carbon atoms, which may additionally comprise one or    more heteroatoms from the list —O—, —S(O)_(n)—, ═N— and —NR15-,    where    -   the formed heterocycle may be substituted independently of one        another one or more times by F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,        N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-alkyl,        (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₃-C₁₄)-cycloalkyl,        (C₄-C₂₀)-cycloalkylalkyl, (C₂-C₂₀)-cycloheteroalkyl,        (C₃-C₁₉)-cycloheteroalkylalkyl, each of which may in turn carry        independently of one another one or more radicals F, OH, (═O),        NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy;-   R15 is a radical selected from the group of H, (C₁-C₁₀)-alkyl,    (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₃-C₁₄)-cycloalkyl,    (C₄-C₂₀)-cycloalkylalkyl, (C₂-C₁₃)-cycloheteroalkyl,    (C₃-C₁₉)-cycloheteroalkylalkyl, each of which may be substituted    independently of one another one or more times by F, OH, CN or    (C₁-C₁₀)-alkoxy;-   R19 is an H, a (C₁-C₁₀)-alkyl radical or (C₁-C₁₄)-cycloalkyl    radical, COR12, —CO(NR13R14), S(O)_(n)R12, —S(O)₂NR13R14, where the    alkyl radical may be substituted independently of one another one or    more times by R10;    and in which    n is 0, 1 or 2;    p is 1 or 2 and    q is 0 or 1,    and the pharmaceutically acceptable salts thereof,    and in which    i) in the case where A is phenyl, B is phenyl or benzodioxolanyl, X    is —O— or —S—, L is a bond and R3 and R4 are H, (C₁-C₁₀)-alkyl,    (C₃-C₁₄)-cycloalkyl, (C₇-C₂₀)-arylalkyl or R3 and R4 together are an    unsubstituted pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl    radical or 4-methylpiperazinyl radical, at least one R5 radical    which is not a (C₁-C₁₀)-alkyl, (C₁-C₁₀)-alkoxy, OH, CF₃, F, Cl, Br    or I radical must be present,    ii) in the case where A is phenyl, X is —O—, —S— or —NH— and R3 and    R4 are a (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl or a    (C₄-C₂₀)-cycloalkylalkyl radical, at least one R5 radical which is    not an F, Cl, Br, I, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, CF₃, OCF₃, CN,    NO₂, NH₂, —NH((C₁-C₁₀)-alkyl), —N((C₁-C₁₀-alkyl)₂, unsubstituted or    substituted benzoyl or an unsubstituted or substituted    phenyl-(CH₂)_(r)—Y—(CH₂)_(s)— radical, with Y being a bond or an    oxygen and r and s being 0 to 4, where r+s is not greater than 4,    must be present.

In one embodiment compounds of the formula I and the pharmaceuticallyacceptable salts thereof are preferred wherein

L is a covalent bond;X is a group —O—;andq is 0.

Preferred substances of the invention are compounds having the formulaIa and the pharmaceutically acceptable salts thereof

-   -   where    -   A is a phenyl or 5 to 6 membered heteroaryl radical, where the        heteroaryl radical may comprise as heteroatoms 1, 2 or 3        nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or 2 nitrogen        and 1 oxygen or 1 sulfur atom, where one or more hydrogen atoms        in said phenyl or heteroaryl radical may be replaced        independently of one another by a radical R1, and/or    -   B is a 6 to 10 membered monocyclic or fused bicyclic aryl group,        a 5 to 10 membered monocyclic or fused bicyclic heteroaryl        group, a 9 to 14 membered fused bicyclic cycloalkylaryl group,        an 8 to 14 membered fused bicyclic cycloalkylheteroaryl group, a        9 to 14 membered fused bicyclic cycloheteroalkylaryl group or an        8 to 14 membered fused bicyclic cylcoheteroalkylheteroaryl        group, each of which may be substituted independently of one        another one or more times by R5        -   where the cycloalkyl and cycloheteroalkyl units may be            saturated or partly unsaturated, and        -   where the cycloheteroalkylaryl groups may comprise as            heteroatoms 1 or 2 nitrogen atoms, 1 or 2 oxygen atoms, 1 or            2 sulfur atoms, 1 nitrogen atom and 1 oxygen or 1 sulfur            atom or 1 oxygen and 1 sulfur atom,        -   and the heteroaryl and cycloalkylheteroaryl groups may            comprise 1, 2, 3 or 4 nitrogen atoms, 1 oxygen atom, 1            sulfur atom, 1 or 2 nitrogen atoms and 1 oxygen or sulfur            atom or 1 oxygen and 1 sulfur atom,        -   and the cycloheteroalkylheteroaryl group may comprise as            heteroatoms 1, 2, 3 or 4 nitrogen atoms, 1 or 2 oxygen            atoms, 1 or 2 sulfur atoms, 1, 2 or 3 nitrogen atom and 1            oxygen or 1 sulfur atom or 1 oxygen and 1 sulfur atom,            and/or    -   X is a group —N(R6)-, —O— or —S(O)_(n)—,        -   where R6 is H or (C₁-C₅)-alkyl and n is 1 or 2, and/or    -   R2 is absent or is one or more substituents which may be        selected independently of one another from the group of F and of        (C₁-C₆)-alkyl radicals, where the alkyl radicals may be        substituted independently of one another one or more times by F,        and/or    -   L is a covalent bond, a —C(O)— bridge or a methylene bridge in        which one or two hydrogen atoms may be replaced by F;    -   where the radicals R1, R3, R4 and R5 have the abovementioned        meaning.

In one embodiment compounds of the formula Ia and the pharmaceuticallyacceptable salts thereof are preferred wherein

L is a covalent bond;andX is a group —O—.

Particularly preferred compounds of the invention aretetrahydronaphthalenes of the formula Ib and the pharmaceuticallyacceptable salts thereof

-   -   where    -   B may be a phenyl group, a naphthyl group, a pyridinyl group, a        quinolinyl group, an isoquinolinyl group, an indolyl group, a        benzothiophenyl group, a benzodihydrothiophenyl group, a        benzofuranyl group, a benzodihydrofuranyl group, an        isobenzodihydrofuranyl group, a benzopyrrolidinyl group, a        benzoimidazolyl group, a benzopyrazolyl group, a benzotriazolyl        group, a benzothiazolyl group, a benzoxathiolyl group, an        indolinyl group, benzodioxolyl group, a tetrahydroisoquinolinyl        group, a tetrahydroquinolinyl group, where one, two, three or        four hydrogen atoms in group B may be replaced by radicals from        the group of R5, where    -   each R5 radical is selected independently of one another from        the group of        -   (C₁-C₄)-alkyl which may be wholly or partly fluorinated, or            a hydrogen may be replaced by a CN, NH₂, OH, NH(C₁-C₄)alkyl,            N((C₁-C₄)-alkyl)₂, (C₁-C₄)-alkoxy,        -   (C₁-C₄)-alkoxy which may be wholly or partly fluorinated,        -   (C₁-C₄)-alkylthio which may be wholly or partly fluorinated,        -   (C₂-C₅)-cycloheteroalkyl and            (C₂-C₅)-cycloheteroalkyl-(C₁-C₄)-alkyl, where the            cycloheteroalkyl ring may be monocyclic, bicyclic, saturated            or partly unsaturated, and may comprise 1 or 2 nitrogen            atoms, 1 oxygen atoms, 1 nitrogen and 1 sulfur atom or 1            nitrogen and 1 oxygen atom, and            -   where the cycloheteroalkyl ring may carry further                substituents from the group of —F, —Cl, —Br, ═O, —NH₂,                NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, (C₁-C₄)-alkoxy, —CN,                (C₁-C₄)-alkyl, (C₃-C₁₀)— cycloalkyl,        -   phenyl, naphthyl,        -   (C₁-C₆)-heteroaryl, where the heteroaryl ring may be a            monocyclic or fused bicyclic ring which may comprise 1, 2, 3            or 4 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or 2            nitrogen atoms and 1 oxygen or sulfur atom, and            -   where the heteroaryl ring may carry further substituents                from the group of —F, —Cl, —Br, ═O, —OH, —NH₂,                NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, (C₁-C₄)-alkoxy, —CN,                (C₁-C₄)-alkyl, (C₃-C₁₀-cycloalkyl, —C(O)O—(C₁-C₄)-alkyl,        -   H, OH, (═O), F, Cl, Br, CN, NO₂, —NR17R18, —NR16COR17,            —NR16COOR17, —NR16CONR17R18, —NR16-S(O)₂—R17,            —NR16-S(O)₂—NR17R18, —COOR16, —COR16; —CO(NR17R18),            —S(O)_(n)R16, with n=1 or 2, —S(O)₂NR17R18, where            -   R16, R17 and R18 may independently of one another be a                hydrogen radical or a radical selected from the group of                unsubstituted or substituted (C₁-C₄)-alkyl radicals,                -   where the substituents of the alkyl radicals are                    selected from F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,                    N((C₁-C₄)alkyl)₂, —CN or (C₁-C₁₀)-alkoxy,            -   R17 and R18 may form together with the nitrogen to which                they are bonded a 5-6 membered, saturated, unsaturated                or partly unsaturated heterocycle having 1 to 5 carbon                atoms, which may additionally comprise one or more                heteroatoms from the list —O—, —S(O)_(n)— with n=0, 1 or                2, ═N—, —NH— and —N((C₁-C₄)alkyl), where the formed                heterocycle independently of one another may be                substituted one or more times by (C₁-C₁₀)-alkyl,                (C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl,                (C₂-C₂₀)-cycloheteroalkyl,                (C₃-C₁₉)-cycloheteroalkylalkyl, each of which may in                turn carry independently of one another one or more                radicals F, OH, (═O) or (C₁-C₁₀)-alkoxy,    -   R1 is absent or is one, two or three radicals which are selected        independently of one another from the group of F, Cl, Br, I,        (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, where the alkyl and alkoxy        radical may be substituted one or more times by F, and/or    -   L is a bond or —CH₂—, and/or    -   R3 and R4 are independently of one another a radical selected        from the group of H, (C₁-C₄)-alkyl-, (C₃-C₇)-cycloalkyl-,        (C₃-C₆)-cycloheteroalkyl, phenyl, phenyl-(C₁-C₄)-alkyl,        (C₁-C₆)-heteroaryl, where        -   the radicals R3 and R4 may be substituted independently of            one another one, two or three times by a radical from the            group of OH, (═O), F, Cl, Br, CN, NO₂, —NR13R14, —NR13COR12,            —NR13COOR12, —NR12CONR13R14, —NR13-S(O)₂—R12,            —NR13-S(O)₂—NR13R14, —COOR12, —COR12; —CO(NR13R14),            S(O)_(n)R12, —S(O)₂NR13R14,        -   where R12, R13 and R14 are H or (C₁-C₄)-alkyl,    -   or    -   R3 and R4 form together with the nitrogen to which they are        bonded a 4-8 membered, saturated, unsaturated or partly        unsaturated heterocycle which may additionally comprise one or        more heteroatoms from the list —O—, —S(O)_(n)— with n=0, 1 or 2,        ═N— and —NR8-, where        -   the heterocyclic radicals may be substituted independently            of one another one or more times by radicals selected from            the group of R7 and R9,        -   where the heterocyclic radicals may be bridged by a bond,            (C₁-C₇)-alkyl, saturated or unsaturated (C₁-C₆)-heteroalkyl            chains or by —NH—, —N(C₁-C₄)-alkyl)-, and where        -   the alkyl and heteroalkyl chains may also form a spirocyclic            ring system with the ring system formed by R3 and R4,    -   and where R8 may form with the ring which the radicals R3 and R4        may form a further saturated, unsaturated or partly unsaturated        heterocycle which may additionally comprise one or two        heteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1 or 2,        ═N—, —NH— and —N((C₁-C₄)-alkyl);    -   where R7, R8 and R9 have the meaning indicated above.

In one embodiment compounds of the formula Ib and the pharmaceuticallyacceptable salts thereof are preferred wherein

L is a covalent bond.

A further group of preferred compounds has a structure according toformula Ic and the pharmaceutically acceptable salts thereof

-   -   where    -   B is a 6 to 10 membered monocyclic or fused bicyclic aryl group,        a 5 to 10 membered monocyclic or fused bicyclic heteroaryl        group, a 9 to 14 membered fused bicyclic cycloalkylaryl group,        an 8 to 14 membered fused bicyclic cycloalkylheteroaryl group, a        fused 9 to 14 membered bicyclic cycloheteroalkylaryl group or an        8 to 14 membered fused bicyclic cycloheteroalkylheteroaryl        group, each of which may be substituted independently of one        another one or more times by R5        -   where the cycloalkyl and cycloheteroalkyl units may be            saturated or partly unsaturated, and        -   where the cycloheteroalkylaryl groups may comprise as            heteroatoms 1 or 2 nitrogen atoms, 1 or 2 oxygen atoms, 1 or            2 sulfur atoms, 1 nitrogen atom and 1 oxygen or 1 sulfur            atom or 1 oxygen and 1 sulfur atom,        -   and the heteroaryl and cycloalkylheteroaryl groups may            comprise 1, 2, 3 or 4 nitrogen atoms, 1 oxygen atom, 1            sulfur atom, 1 or 2 nitrogen atoms and 1 oxygen or 1 sulfur            atom or 1 oxygen and 1 sulfur atom,        -   and the cycloheteroalkylheteroaryl group may comprise as            heteroatoms 1, 2, 3 or 4 nitrogen atoms, 1 or 2 oxygen            atoms, 1 or 2 sulfur atoms, 1, 2 or 3 nitrogen atom and 1            oxygen or 1 sulfur atom or 1 oxygen and 1 sulfur atom,            and/or    -   X is a group —N(R6)-, —O— or —S(O)_(n)—,        -   where R6 is H or (C₁-C₅)-alkyl and n is 1 or 2, and/or    -   R2 is absent or is one or more substituents which may be        selected independently of one another from the group of F and of        (C₁-C₆)-alkyl radicals, where the alkyl radicals may be        substituted independently of one another one or more times by F,        and/or    -   L is a covalent bond, a —(C(O)-bridge or a methylene bridge        which may be substituted independently of one another one or        more times by F;    -   q is 0 or 1;    -   where the radicals A, R1, R3, R4 and R5 have the abovementioned        meaning.

Particularly preferred compounds have a structure according to formulaIc and the pharmaceutically acceptable salts thereof, where

-   -   A is a phenyl or a 5 to 6 membered heteroaryl radical, where the        heteroaryl radical may comprise as heteroatoms 1, 2 or 3        nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or 2 nitrogen        and 1 oxygen or 1 sulfur atom, where one or more hydrogen atoms        in the phenyl or heteroaryl radical may be replaced        independently of one another by a radical R1, and/or    -   B is a 6 to 10 membered monocyclic or fused bicyclic aryl group,        a 5 to 10 membered monocyclic or fused bicyclic heteroaryl        group, a 9 to 14 membered fused bicyclic cycloalkylaryl group,        an 8 to 14 membered fused bicyclic cycloalkylheteroaryl group, a        fused 9 to 14 membered bicyclic cycloheteroalkylaryl group or an        8 to 14 membered fused bicyclic cycloheteroalkylheteroaryl        group, each of which may be substituted independently of one        another one or more times by R5,        -   where the cycloalkyl and cycloheteroalkyl units may be            saturated or partly unsaturated, and        -   where the cycloheteroalkylaryl groups may comprise as            heteroatoms 1 nitrogen atom, 1 or 2 oxygen atoms, 1 or 2            sulfur atoms, 1 nitrogen atom and 1 oxygen or 1 sulfur atom            or 1 oxygen and 1 sulfur atom,        -   and the heteroaryl and cycloalkylheteroaryl groups may            comprise 1, 2 or 3 nitrogen atoms, 1 oxygen atom, 1 sulfur            atom, 1 nitrogen and 1 oxygen or sulfur atom or 1 oxygen and            one sulfur atom,        -   and the cycloheteroalkylheteroaryl group may comprise as            heteroatoms 1, 2, 3 or 4 nitrogen atoms, 1 or 2 oxygen            atoms, 1 or 2 sulfur atoms, 1 or 2 nitrogen atoms and 1            oxygen or 1 sulfur atom or 1 oxygen and 1 sulfur atom,            and/or    -   X is a group —N(R6)-, —O— or —S(O)_(n)—,        -   where R6 is H or (C₁-C₅)-alkyl and n is 1 or 2, and/or    -   R2 is absent or is one or more substituents which may be        selected independently of one another from the group of F and of        (C₁-C₆)-alkyl radicals, where the alkyl radicals may be        substituted independently of one another one or more times by F,        and/or    -   L is a covalent bond, a —C(O)— bridge or a methylene bridge        which may be substituted once or twice by F;    -   q is 0 or 1;    -   where said R1, R3, R4 and R5 radical has the abovementioned        meaning.

In one embodiment compounds of the formula Ic and the pharmaceuticallyacceptable salts thereof are preferred wherein

L is a covalent bond;X is a group —O—;andq is 0.

Aminoindanes of the formula Id and the pharmaceutically acceptable saltsthereof are particularly preferred

-   -   where    -   B may be a phenyl group, a naphthyl group, a pyridinyl group, a        quinolinyl group, an isoquinolinyl group, an indolyl group, a        benzothiophenyl group, a benzodihydrothiophenyl group, a        benzofuranyl group, a benzodihydrofuranyl group, an        isobenzodihydrofuranyl group, a benzopyrrolidinyl group, a        benzoimidazolyl group, a benzopyrazolyl group, a benzotriazolyl        group, a benzothiazolyl group, a benzoxathiolyl group, an        indolinyl group, benzodioxolyl group, a tetrahydroisoquinolinyl        group, a tetrahydroquinolinyl group, where one, two, three or        four hydrogen atoms in the group B may be replaced by radicals        from the group R5, where    -   each R5 radical is selected independently of one another from        the group of        -   (C₁-C₄)-alkyl which may be wholly or partly fluorinated, or            one hydrogen may be replaced by a CN, NH₂, OH,            NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, (C₁-C₄)alkoxy,        -   (C₁-C₄)-alkoxy which may be wholly or partly fluorinated,        -   (C₁-C₄)-alkylthio which may be wholly or partly fluorinated,        -   (C₂-C₅)-cycloheteroalkyl and            (C₂-C₅)-cycloheteroalkyl-(C₁-C₄)-alkyl, where the            cycloheteroalkyl ring may be saturated or partly unsaturated            and may comprise 1 or 2 nitrogen atoms, 1 oxygen atoms, 1            nitrogen and 1 sulfur atom or 1 nitrogen and 1 oxygen atom,            and            -   where the cycloheteroalkyl ring may carry further                substituents from the group of —F, —Cl, —Br, ═O, —NH₂,                —CN, (C₁-C₄)-alkyl, (C₃-C₁₀)-cycloalkyl, OH,                NH(C₁-C₄)-alkyl, N((C₁-C₄)-alkyl)₂, (C₁-C₁₀)-alkoxy,        -   phenyl, naphthyl,        -   (C₁-C₆)-heteroaryl, where the heteroaryl ring may be a            monocyclic or fused bicyclic ring which may comprise 1, 2, 3            or 4 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or 2            nitrogen atoms and 1 oxygen or sulfur atom, and            -   where the heteroaryl ring may carry further substituents                from the group of —F, —Cl, —Br, ═O, —NH₂, —CN,                (C₁-C₄)-alkyl, (C₃-C₁₀-cycloalkyl, OH, NH(C₁-C₄)-alkyl,                N((C₁-C₄)-alkyl)₂, (C₁-C₁₀-alkoxy, —C(O)O—(C₁-C₄)-alkyl,        -   H, OH, (═O), F, Cl, Br, CN, NO₂, —NR17R18, —NR16COR17,            —NR16COOR17, —NR16CONR17R18, —NR16-S(O)₂—R17,            —NR16-S(O)₂—NR17R18, —COOR16, —COR16; —CO(NR17R18),            S(O)_(n)R16, with n=1 or 2, —S(O)₂NR17R18, where            -   R16, R17 and R18 may be independently of one another a                hydrogen radical or a radical selected from the group of                unsubstituted or substituted (C₁-C₄)-alkyl radicals,                -   where the substituents of the alkyl radicals are                    selected from F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,                    N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy,            -   R17 and R18 may form together with the nitrogen to which                they are bonded a 5-6 membered, saturated, unsaturated                or partly unsaturated heterocycle having 1 to 5 carbon                atoms, which may additionally comprise one or more                heteroatoms from the list —O—, —S(O)_(n)— with n=0, 1 or                2, ═N—, —NH— and N((C₁-C₄)alkyl)-, where the formed                heterocycle independently of one another one or more                times by (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl,                (C₄-C₂₀)-cycloalkylalkyl, (C₂-C₂₀)-cycloheteroalkyl,                (C₃-C₁₉)-cycloheteroalkylalkyl, each of which may in                turn carry independently of one another one or more                radicals F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,                N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy,    -   R1 is absent or is one, two or three radicals which are selected        independently of one another from the group of F, Cl, Br, I,        (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, where the alkyl and alkoxy        radical may be substituted one or more times by F, and/or    -   R3 and R4 are independently of one another a radical selected        from the group of H, (C₁-C₄)-alkyl, (C₃-C₇)-cycloalkyl-,        (C₃-C₇)-cycloalkyl-(C₁-C₄)-alkyl-, (C₃-C₆)-cycloheteroalkyl-,        phenyl-, phenyl-(C₁-C₄)-alkyl-, (C₁-C₅)-heteroaryl, where        -   the radicals R3 and R4 may be substituted independently of            one another one, two or three times by a radical from the            group of OH, (═O), F, Cl, Br, CN, NO₂, —NR13R14, —NR13COR12,            —NR13COOR12, —NR12CONR13R14, —NR13-S(O)₂—R12,            —NR13-S(O)₂—NR13R14, —COOR12, —COR12; —CO(NR13R14),            —S(O)_(n)R12, —S(O)₂NR13R14,        -   where R12, R13 and R14 are H or (C₁-C₄)-alkyl,            or    -   R3 and R4 form together with the nitrogen to which they are        bonded a 4-8 membered, saturated, unsaturated or partly        unsaturated heterocycle which may additionally comprise one or        more heteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1 or        2, ═N— and —NR8-, where        -   the heterocyclic radicals may be substituted independently            of one another one or more times by a radical selected from            the group of radicals R7 and R9,        -   where the heterocyclic radicals may be bridged by a bond,            (C₁-C₇)-alkyl, (C₁-C₆)-saturated or unsaturated heteroalkyl            chains or by —NH—, —N(C₁-C₄)-alkyl-, and where the alkyl and            heteroalkyl chains may also form a spirocyclic ring system            with the ring system formed by R3 and R4,        -   and where R8 in the group NR8 may form with the ring which            the radicals R3 and R4 may form a further saturated,            unsaturated or partly unsaturated heterocycle which may            additionally comprise one or two heteroatoms from the list            —O—, —S(O)_(n)—, with n=0, 1 or 2, ═N— and —NR19-, with R19            equal to H or (C₁-C₄)-alkyl,    -   where the radicals R7, R8 and R9 have the abovementioned        meaning.

Preferred aminoindanes have a structure according to the formula Id andthe pharmaceutically acceptable salts thereof, where

-   -   B is a phenyl group, a naphthyl group, a pyridinyl group, a        quinolinyl group, an isoquinolinyl group, an indolyl group, a        benzothiophenyl group, a benzodihydrothiophenyl group, a        benzofuranyl group, a benzodihydrofuranyl group, an        isobenzodihydrofuranyl group, a benzopyrrolidinyl group, a        benzoimidazolyl group, a benzopyrazolyl group, a benzotriazolyl        group, a benzothiazolyl group, a benzoxathiolyl group, an        indolinyl group, benzodioxolyl group, a tetrahydroisoquinolinyl        group, a tetrahydroquinolinyl group, where one, two, three or        four hydrogen atoms in group B may be replaced by radicals from        the group R5, where    -   one of the R5 radicals is selected from the group of        -   (C₂-C₅)-cycloheteroalkyl,            -   where the cycloheteroalkyl ring may be saturated or                partly unsaturated and may comprise 1 or 2 nitrogen                atoms, 1 oxygen atoms, 1 nitrogen and 1 sulfur atom or 1                nitrogen and 1 oxygen atom, and            -   where the cycloheteroalkyl ring may carry further                substituents from the group of —F, —Cl, —Br, ═O, —NH₂—,                —CN, (C₁-C₄)-alkyl, (C₃-C₁₀)-cycloalkyl,        -   (C₁-C₆)-heteroaryl, where the heteroaryl ring may be a            monocyclic or fused bicyclic ring which may comprise 1, 2, 3            or 4 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or 2            nitrogen atoms and 1 oxygen or sulfur atom, and            -   where the heteroaryl ring may carry further substituents                from the group of —F, —Cl, —Br, ═O, —NH₂, —CN,                (C₁-C₄)-alkyl, (C₃-C₁₀)— cycloalkyl,                —C(O)O—(C₁-C₄)-alkyl,        -   OH, (═O), NH₂, NO₂, —NR17R18, —NR16COR17, —NR16COOR17,            —NR16CONR17R18, —NR16-S(O)₂—R17, —NR16-S(O)₂—NR17R18,            —COOR16, —COR16; —CO(NR17R18), S(O)₂R16, —S(O)₂NR17R18,            where            -   R16, R17 and R18 may be independently of one another a                hydrogen radical or a radical selected from the group of                unsubstituted or substituted (C₁-C₄)-alkyl radicals,                -   where the substituents of the alkyl radicals are                    selected from F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,                    N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy            -   R17 and R18 may form together with the nitrogen to which                they are bonded a 5-6 membered, saturated, unsaturated                or partly unsaturated heterocycle having 1 to 5 carbon                atoms which may additionally comprise one or more                heteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1                or 2, ═N—, —NH— and —N((C₁-C₄)-alkyl)-, where the formed                heterocycle independently of one another may be                substituted one or more times by (C₁-C₁₀)-alkyl,                (C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl,                (C₂-C₂₀)-cycloheteroalkyl,                (C₃-C₁₉)-cycloheteroalkylalkyl, each of which in turn                may carry independently of one another one or more                radicals F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,                N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy,    -   and    -   further radicals R5 is selected independently of one another        from the group of        -   (C₁-C₄)-alkyl which may be wholly or partly fluorinated, or            a hydrogen may be replaced by a CN, NH₂, OH, NH(C₁-C₄)alkyl,            N((C₁-C₄)alkyl)₂, (C₁-C₄)-alkoxy,        -   (C₁-C₄)-alkoxy which may be wholly or partly fluorinated,        -   (C₁-C₄)-alkylthio which may be wholly or partly fluorinated,        -   phenyl,        -   OH, (═O), F, Cl, Br, CN, —NR17R18, NR16COR17, —COOR16,            —COR16; —CO(NR17R18), where            -   R16, R17 and R18 may be independently of one another a                hydrogen radical or a radical selected from the group of                unsubstituted or substituted (C₁-C₄)-alkyl radicals,                -   where the substituents of the alkyl radicals are                    selected from F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,                    N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy-F,            -   R17 and R18 may form together with the nitrogen to which                they are bonded a 4-7 membered, saturated, unsaturated                or partly unsaturated heterocycle having 1 to 5 carbon                atoms, which may additionally comprise one or more                heteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1                or 2, ═N—, —NH— and N((C₁-C₄)alkyl)-, where the formed                heterocycle independently of one another may be                substituted one or more times by (C₁-C₁₀)-alkyl,                (C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl,                (C₂-C₂₀)-cycloheteroalkyl,                (C₃-C₁₉)-cycloheteroalkylalkyl, each of which in turn                may carry independently of one another one or more                radicals F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,                N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy,    -   and/or    -   R1 is absent or is one, two or three radicals which are selected        independently of one another from the group of F, Cl, Br, I,        (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, where the alkyl and alkoxy        radical may be substituted one or more times by F, and/or    -   R3 and R4 is independently of one another a radical selected        from the group of H, (C₁-C₅)-alkyl-, phenyl-(C₁-C₄)-alkyl-,        NH₂—(C₁-C₄)-alkyl-, N((C₁-C₄)-alkyl)₂-(C₁-C₄)-alkyl-,        (C₁-C₄)-alkoxy-(C₁-C₄)-alkyl-, (C₃-C₇)-cycloalkyl-(C₁-C₄)-alkyl-        and (C₄-C₅)-cycloheteroalkyl- that comprises an —NH—, —O— or —S—        group, or        -   R3 and R4 form together with the nitrogen to which they are            bonded a 4-8 membered, saturated, unsaturated or partly            unsaturated heterocycle which may additionally comprise one            or more heteroatoms from the list —O—, —S(O)_(n)—, with n=0,            1 or 2, ═N— and —NR8-, where            -   the heterocyclic radicals may be substituted                independently of one another one or more times by                radicals selected from the group of radicals R7 and R9,            -   where the heterocyclic radicals may be bridged by a                bond, (C₁-C₇)-alkyl, (C₁-C₆)-saturated or unsaturated                heteroalkyl chains or by —NH—, N((C₁-C₄)alkyl)-, and                where the alkyl and heteroalkyl chains may also form a                spirocyclic ring system with the ring system formed by                R3 and R4,            -   and where R8 may form with the ring which the radicals                R3 and R4 form a further saturated, unsaturated or                partly unsaturated heterocycle which may additionally                comprise one or two heteroatoms from the list —O—,                —S(O)_(n)—, with n=0, 1 or 2, —NH— and                —N((C₁-C₄)alkyl)-, and/or    -   R7 are H, a (C₁-C₅)-alkyl radical or (C₃-C₆)-cycloalkyl radical,        where the alkyl radical may be substituted independently of one        another one or more times by R9, and/or    -   R8 is an H, a (C₁-C₅)-alkyl radical or (C₁-C₆)-cycloalkyl        radical, where the alkyl radical may be substituted        independently of one another one or more times by F, OH, NH₂,        CN, NO₂, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-alkylthio, —NR13R14,        —NR13COR12, —NR13COOR12, —NR13CONR13R14, —NR13-S(O)₂—R12,        —NR12-S(O)₂—NR13R14, —COOR12, —COR12; —CO(NR13R14), S(O)_(n)R12,        —S(O)₂NR13R14, COR12, —CO(NR13R14), S(O)_(n)R12, —S(O)₂NR13R14        and/or    -   R9 is a radical selected from the group of OH, NH₂, (═O), F, Cl,        Br, I, CN, —NR13R14, —NR13COR12, —NR13COOR12, —NR12CONR13R14,        —NR13-S(O)₂—R12, —NR13-S(O)₂—NR13R14, —COOR12, —COR12;        —CO(NR13R14), S(O)_(n)R12, —S(O)₂NR13R14, (C₃-C₆)-cycloalkyl,        (C₄-C₇)-cycloalkylalkyl, (C₁-C₅)-alkoxy,        (C₂-C₆)-cycloheteroalkyl, (C₃-C₁₀)— cycloheteroalkylalkyl,        phenyl, of the (C₁-C₅)-heteroaryl radicals,    -   where R12, R13 and R14 are independently of one another a        hydrogen radical or a radical selected from the group of        unsubstituted or substituted (C₁-C₄)-alkyl radicals, where the        substituents of the alkyl radicals are selected from F, OH,        (═O), NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN or        (C₁-C₁₀)-alkoxy,

In one embodiment compounds of the formulae I, Ia, Ib, Ic and Id arepreferred, where

-   R3 and R4 form together with the nitrogen to which they are bonded a    4-10 membered, saturated, unsaturated or partly unsaturated    heterocycle which may additionally comprise one or more heteroatoms    from the list —O—, —S(O)_(n)—, ═N— and —NR8-, where    -   the heterocyclic radicals may be substituted independently of        one another one or more times by radicals selected from the        group of R7 and R9, and where    -   the heterocyclic radicals formed by R3 and R4 may be bridged by        a bond, by a saturated or unsaturated (C₁-C₁₀)-alkyl or        (C₁-C₉)-heteroalkyl chain or by —NR15-, —O— or —S—, and where        -   the alkyl and heteroalkyl chains may also form a spirocyclic            ring system with the ring system formed by R3 and R4, where            the alkyl and heteroalkyl bridges may be substituted            independently of one another one or more times by radicals            selected from the group of R7 and R9,    -   and where    -   R8 in the group —NR8- may form with the ring which R3 and R4 may        form a further saturated, unsaturated or partly unsaturated        heterocycle which may be substituted independently of one        another one or more times by radicals selected from the group of        R7 and R9, and may additionally comprise one or more heteroatoms        from the list —O—, —S(O)_(n)—, —N═ and —NR19-;        and where n, R7, R8, R9 and R19 have the meaning indicated        above.

In one embodiment compounds of the formulae I, Ia, Ib, Ic and Id aremore preferred, where

R3 and R4 form together with the nitrogen to which they are bonded a 4-8membered, saturated, unsaturated or partly unsaturated heterocycle whichmay additionally comprise one or more heteroatoms from the list —O—,—S(O)_(n)—, with n=0, 1 or 2, ═N— and —NR8-, where

-   -   the heterocyclic radicals may be substituted independently of        one another one or more times by radicals selected from the        group of radicals R7 and R9,    -   where the heterocyclic radicals may be bridged by a bond,        (C₁-C₇)-alkyl, (C₁-C₆)-saturated or unsaturated heteroalkyl        chains or by —NH—, N((C₁-C₄)alkyl)-, and where the alkyl and        heteroalkyl chains may also form a spirocyclic ring system with        the ring system formed by R3 and R4,    -   and where R8 may form with the ring which the radicals R3 and R4        form a further saturated, unsaturated or partly unsaturated        heterocycle which may additionally comprise one or two        heteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1 or 2,        —NH— and —N((C₁-C₄)alkyl)-;        and where R7, R8 and R9 have the meaning indicated above.

In another embodiment compounds of the formulae I, Ia, Ib, Ic and Id areparticularly preferred, where

-   -   R3 and R4 form together with the nitrogen to which they are        bonded a 4-8 membered, saturated, unsaturated or partly        unsaturated heterocycle which may additionally comprise one or        more heteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1 or        2, ═N— and —NR8-, where        -   the heterocyclic radicals may be substituted independently            of one another one or more times by radicals selected from            the group of radicals R7 and R9,        -   and where R8 may form with the ring which the radicals R3            and R4 form may form together with an adjacent C atom a            fused triazole or pyrrolidine ring;            and where R7, R8 and R9 have the meaning indicated above.

In another embodiment compounds of the formulae I, Ia, Ib, Ic and Id arepreferred, where

-   R3 and R4 are independently of one another a hydrogen radical or a    radical which is selected from the group of (C₁-C₁₀)-alkyl radicals,    of (C₂-C₁₀)-alkenyl radicals, of (C₂-C₁₀)-alkynyl radicals, of    (C₃-C₁₄)-cycloalkyl radicals, of (C₄-C₂₀)-cycloalkylalkyl radicals,    of (C₂-C₁₉)-cycloheteroalkyl radicals, of    (C₃-C₁₉)-cycloheteroalkylalkyl radicals, of (C₆-C₁₀)-aryl radicals,    of (C₇-C₂₀)-arylalkyl radicals, of (C₁-C₉)-heteroaryl radicals, of    (C₂-C₁₉)-heteroarylalkyl radicals, where    -   the radicals R3 and R4 may be substituted independently of one        another one or more times by a radical from the group of OH,        NH₂, (═O), F, Cl, Br, I, CN, NO₂, —NR13R14, —NR13COR12,        —NR13COOR12, —NR12CONR13R14, —NR13-S(O)₂—R12,        —NR13-S(O)₂—NR13R14, —COOR12, —COR12; —CO(NR13R14), S(O)_(n)R12,        —S(O)₂R13R14;        and where R12, R13 and R14 have the meaning indicated above.

In another embodiment compounds of the formulae I, Ia, Ib, Ic and Id areparticularly preferred, where

-   R3 and R4 are independently of one another a radical selected from    the group of H, (C₁-C₅)-alkyl-, phenyl-(C₁-C₄)-alkyl-,    NH₂—(C₁-C₄)-alkyl-, N((C₁-C₄)-alkyl)₂-(C₁-C₄)-alkyl-,    (C₁-C₄)-alkoxy-(C₁-C₄)-alkyl-, (C₃-C₇)-cycloalkyl-(C₁-C₄)-alkyl- and    (C₄-C₆)-cycloheteroalkyl- that comprises an —NH—, —O— or —S— group.

The membership of rings means in the context of the present inventionthe number of ring atoms which form the respective ring system or fusedring system.

6 to 10 membered aryl radicals which may stand for the cyclic radicals Aand B mean in particular phenyl and naphthyl.

Preferred 5 to 10 membered heteroaryl radical which may stand for acyclic radical A are selected from the group of furanyl, thiophenyl,pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl,thiazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl,indolyl, indazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoxalinyl,quinazolinyl and cinnolinyl. A particularly preferred heteroaryl radicalA is thiophenyl.

In one embodiment of the invention, A is phenyl or a 5- or 6-memberedheteroaryl radical, in another embodiment A is phenyl or thiophenyl, inanother embodiment A is phenyl, in another embodiment A is thiophenyl,all of which may be substituted as indicated.

Preferred 5 to 10 membered heteroaryl radical which may stand for acyclic radical B are selected from the group of furanyl, thiophenyl,pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl,isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl,pyridazinyl, indolyl, isoindolyl, quinolyl, isoquinolyl, phthalazinyl,quinoxalinyl, quinazolinyl, cinnolinyl, benzothiophenyl,isobenzothiophenyl, benzofuranyl, isobenzofuranyl, benzoimidazolyl,benzopyrazolyl, benzotriazolyl, benzoxazolyl, isobenzoxazolyl,benzothiazolyl, isobenzothiazolyl.

Preferred 3 to 10 membered cycloalkyl radicals which may stand for acyclic radical B are selected from the group of cyclopropanyl,cyclobutanyl, cylopentanyl, cyclohexanyl, cycloheptanyl, cyclooctanyl,cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl,cyclooctenyl and norbornene.

Preferred 9 to 14 membered cycloalkylaryl radicals which may stand for acyclic radical B are selected from the group of fused ring systemshaving a cycloalkyl ring and an aryl ring. Particularly preferredcycloalkylaryl radicals are indenyl, dihydronaphthyl, tetrahydronaphthyland indanyl.

Preferred 8 to 14 membered cycloalkylheteroaryl radicals which may standfor a cyclic radical B are selected from the group of fused ring systemshaving a cycloalkyl ring and a heteroaryl ring.

Preferred 3 to 10 membered cycloheteroalkyl radicals which may stand fora cyclic radical B are selected from the group of oxiranyl, thiiranyl,aziridinyl, oxetanyl, thietanyl, azetidinyl, pyrrolidinyl,dihydropyrrolyl, dihydroimidazolyl, dihydropyrazolyl,tetrahydropyrazolyl, oxolanyl, dihydrofuranyl, dioxolanyl, thiolanyl,dihydrothiophenyl, oxazolanyl, dihydrooxazolyl, isooxazolanyl,dihydroisooxazolyl, thiazolidinyl, dihydrothiazolyl, isothiazolidinyl,dihydroisothiazolyl, oxathiolanyl, 2H-pyranyl, 4H-pyranyl,tetrahydropyranyl, 2H-thiapyranyl, 4H-thiapyranyl, di-,tetrahydrothiapyranyl, piperidinyl, di-, tetrahydropyridyl, piperazinyl,tetrahydropyrazinyl, di-, tetra-, hexahydropyridazinyl, di-, tetra-,hexahydropyrimidinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl,azepanyl, thiepanyl and oxepinyl, where two of these heterocyclic ringsmay also form a saturated or partly unsaturated fused bicyclic ringsystem.

Examples of such bicyclic ring systems areoctahydropyrrolo[1,2-a]pyrazinyl, octahydropyrrolo[3,4-b]pyrrolyl,hexahydropyrrolo[3,4-c]pyrrolyl and octahydropyrrolo[3,4-c]pyrrolyl.

Preferred 9 to 14 membered cycloheteroalkylaryl radicals which may standfor a cyclic radical B are selected from the group of fused ring systemshaving a cycloheteroalkyl ring and an aryl ring. Particularly preferredcycloheteroalkylaryl radicals are benzodihydrothiophenyl,benzodihydrofuranyl, benzodioxolanyl, benzodihydroimidazolyl,benzodihydroyrazolyl, benzodihydrotriazolyl, benzopiperazinyl,benzodihydrothiazolyl, benzomorpholinyl, benzodihydropyrrolyl,benzodihydrooxazolyl, dihydroquinolinyl, dihydroisoquinolinyl,tetrahydroisoquinolinyl, tetrahydroquinolinyl, benzoxathiolyl,isobenzoxathiolyl and benzodioxolyl

Preferred 8 to 14 membered cycloheteroalkylheteroaryl radicals which maystand for a cyclic radical B are selected from the group of fused ringsystems having a cycloheteroalkyl ring and a heteroaryl ring.

Particularly preferred mono- or bicyclic radicals which may stand forthe group B are selected from the group of phenyl, naphthyl, pyridyl,quinolinyl, isoquinolinyl, indolyl, benzodihydropyrrolyl,benzdihydroisopyrrolyl, benzothiophenyl, benzodihydrothiophenyl,benzofuranyl, benzoisofuranyl, benzodihydrofuranyl, benzoimidazolyl,benzopyrazolyl, benzotriazolyl, thiazolyl, benzothiazolyl,benzoxathiolanyl, benzodioxolanyl, tetrahydroisoquinolinyl ortetrahydroquinolinyl. In this connection, the radicals B can be bondedto the group -LX— as pyrid-2, 3 or 4-yl, quinol-1, 2, 3, 4, 5, 6, 7 or8-yl, isoquinol-1, 2, 3, 4, 5, 6, 7 or 8-yl, indol-1, 2, 3, 4, 5, 6 or7-yl, isoindol-1, 2, 3, 4, 5, 6, or 7-yl, benzo[b]thiophen-2, 3, 4, 5, 6or 7-yl, benzo[c]thiophen-1, 3, 4, 5, 6 or 7-yl,benzo[b]dihydrothiophen-2, 3, 4, 5, 6 or 7-yl,benzo[c]dihydrothiophen-1, 3, 4, 5, 6 or 7-yl, benzo[b]furan-2, 3, 4, 5,6, or 7-yl, benzo[c]furan-1, 3, 4, 5, 6, or 7-yl,benzo[b]dihydrofuran-2, 3, 4, 5, 6, or 7-yl, benzo[c]dihydrofuran-1, 3,4, 5, 6, or 7-yl, benzo[b]pyrrolidin-1, 2, 3, 4, 5, 6 or 7-yl,benzo[c]pyrrolidin-1, 2, 3, 4, 5, 6 or 7-yl, benzoimidazol-1, 2, 3, 4,5, 6 or 7-yl, benzopyrazol-1, 2, 3, 4, 5, 6 or 7-yl, benzotriazol-1, 2,4, 5, 6 or 7-yl, thiazo-2, 4 or 5-yl, benzothiazol-2, 3, 4, 5, 6 or7-yl, benzoxathiolan-2, 4, 5, 6 or 7-yl, benzodioxolan-2, 4, 5, 6 or7-yl, tetrahydroisoquinol-1, 2, 3, 4, 5, 6, 7 or 8-yl ortetrahydroquinol-1, 2, 3, 4, 5, 6, 7 or 8-yl.

One, two, three or four hydrogen atoms in group B can preferably bereplaced by radicals which are selected independently of one anotherfrom the group of R5. In one embodiment of the invention, one, two orthree hydrogen atoms, and in another embodiment one or two hydrogenatoms, can be replaced by radicals which are selected independently ofone another from the group R5.

Particularly preferred for B are the following groups:

where the substituents R5 in the bicyclic ring systems B may be locatedon both rings.

In one embodiment of the invention, B is selected from the group ofphenyl, naphthyl, pyridyl, quinolinyl or isoquinolinyl, in anotherembodiment from the group of phenyl and pyridyl, and in anotherembodiment B is phenyl, in another embodiment pyridyl, all of which maybe substituted as indicated.

L is preferably a covalent single bond, a —C(O)— bridge or a methylenebridge.

In one embodiment of the invention, L is a covalent single bond, inanother embodiment is a —C(O)— bridge, in another embodiment is amethylene bridge.

X is preferably a group —N(R6)-, —O— or —S(O)_(n)—.

In one embodiment of the invention, X is a group —N(R6)-, in anotherembodiment is —O—, in another embodiment is —S(O)n-.

In one embodiment of the invention, one, two or three H atoms, inanother embodiment one or two H atoms, in the aryl or heteroarylradicals standing for A may be replaced by substituents R1.

Preferred R1 radicals are selected from the group of F, Cl, Br, I,(C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, where the alkyl and alkoxy radicals maybe substituted one or more times by F. Particularly preferred R1radicals are selected from the group of F, Cl, methyl, ethyl, propyl,butyl, methoxy, ethoxy, trifluoromethyl, pentafluoroethyl,trifluoroethyl, especially —CH₂—CF₃, difluoroethyl, especially—CH₂—CHF₂, monofluoroethyl, especially —CH₂—CH₂F, methoxy, ethoxy,trifluoromethoxy, pentafluoroethoxy, trifluoroethoxy, especially—O—CF₂—CF₃, difluoroethoxy, especially —O—CH₂—CHF₂, monofluoroethoxy,especially —O—CH₂—CH₂F.

Preferred R2 radicals are selected from the group of F, (C₁-C₆)-alkyl,where the alkyl radicals may be substituted independently of one anotherone or more times by F, and particularly preferred radicals are F,methyl, ethyl, propyl, butyl, trifluoromethyl, trifluoroethyl, e.g.—CF₂—CF₃, —CH₂—CHF₂, —CH₂—CH₂F.

Preferred R3 and R4 radicals are selected independently of one anotherfrom the group of

hydrogen, (C₁-C₄)-alkyl, such as, for example, methyl, ethyl, n-propyl,isopropyl, n-butyl, tertiary butyl,

-   -   where the alkyl radical may be substituted by one or two        radicals from the group of —N(C₁-C₄-alkyl)₂ and        —O—(C₁-C₄-alkyl), especially by —N(CH₃)₂, —N(C₂CH₅)₂, resulting        for example in —CH₂—N(CH₃)₂, —CH₂—CH₂—N(CH₃)₂,        —CH₂—CH₂—CH₂—N(CH₃)₂, —CH₂—OCH₃, or —CH₂—CH₂—OCH₃ radicals,

-   (C₃-C₇)-cycloalkyl, such as, for example, cyclopropanyl,    cyclobutanyl, cyclopentanyl, cyclohexanyl or cycloheptanyl,

-   (C₃-C₇)-cycloalkyl-(C₁-C₄)-alkyl, such as, for example,    cyclopropanylmethyl, cyclopropanylethyl, cyclobutanylmethyl,    cyclobutanylethyl, cyclopentanylmethyl, cyclopentanylethyl,    cyclohexanylmethyl or cylohexanylethyl,

-   (C₃-C₆)-cycloheteroalkyl, such as, for example, piperidinyl,    piperazinyl, hexahydropyrimidinyl, hexahydropyridazolyl,    morpholinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl or    tetrahydrothiophenyl,

-   phenyl, phenyl-(C₁-C₄)-alkyl, such as, for example, phenylmethyl,    phenylethyl, phenylpropyl or phenylbutyl,

-   (C₁-C₅)-heteroaryl, such as, for example, furanyl, thiophenyl,    pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl,    isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl    or pyridazinyl.

The R3 and R4 radicals preferably form together with the nitrogen atomto which they are bonded the following groups:

The R3 and R4 radicals particularly preferably form a 4-8 membered,saturated, unsaturated or partly unsaturated heterocycle. The 4-8membered, saturated, unsaturated or partly unsaturated heterocycle mayadditionally comprise one or more heteroatomic groups selected from thelist —O—, —S(O)_(n)—, with n=0, 1 or 2, ═N— and —NR8-. —NR8- may formtogether with an adjacent C atom a fused triazole or pyrrolidine ring,e.g. octahydropyrrolo[1,2-a]pyrazinyl andtetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl.

Preferred heterocycles formed by R3 and R4 are selected from the groupof azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,thiomorpholinyl, oxothiomorpholinyl, dioxothiomorpholinyl, azepanyl,1,4-diazepanyl, pyrrolyl, pyrazolyl and imidazolyl. The heterocyclicrings may be bridged by a covalent bond, a (C₁-C₇)-alkylene bridge or a(C₁-C₆)-heteroalkylene bridge or an —NH— bridge or an —N(C₁-C₄)-alkylenebridge, thus forming a fused or bridged bicyclic ring system. The(C₁-C₇)-alkylene bridge or the (C₁-C₆)-heteroalkylene bridge may alsoform a spirocyclic ring system with the ring system formed by R3 and R4.Examples of such fused, bridged or spirocyclic ring systems formed by R3and R4 are diazabicyclo[3.2.1]octanyl, especially a3,8-diazabicyclo[3.2.1]octanyl, a diazabicyclo[2.2.1]heptanyl,especially a 2,5-diazabicyclo[2.2.1]heptanyl,octahydropyrrolo[3,4-b]pyrrolyl, hexahydropyrrolo[3,4-c]pyrrolyl,octahydropyrrolo[3,4-c]pyrrolyl and diazaspirononanyl, especially2,7-diazaspiro[4.4]nonanyl.

In one embodiment of the invention, R3 and R4 form together with thenitrogen atom to which they are bonded a heterocyclic radical selectedfrom the group of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl,morpholinyl, thiomorpholinyl, azepanyl and 1,4-diazepanyl, in anotherembodiment a heterocyclic radical selected from the group of azetidinyl,pyrrolidinyl, piperidinyl and morpholinyl, in another embodiment aheterocyclic radical selected from the group of azetidinyl,pyrrolidinyl, piperidinyl, in another embodiment an azetidinyl radical,in another embodiment a pyrrolidinyl radical, in another embodiment apiperidinyl radical, in another embodiment a morpholinyl radical, all ofwhich may be substituted as indicated.

The heterocyclic groups formed by R3 and R4 may carry furthersubstituents independently of one another selected from the group of R7and R9. Preferred substituents of this group are

F, Cl, Br, I,

-   (C₁-C₄)-alkyl, where the alkyl radicals may be substituted one or    more times by F, such as, for example, methyl, ethyl, n-propyl,    isopropyl, n-butyl, tert-butyl, —CF₃, —CH₂—CF₃, —CH₂—CH₂—CF₃,    —CH₂—CH₂—CH₂—CF₃, —CH₂F, —CH₂—CH₂F, —CH₂—CH₂—CH₂—CH₂F,-   (C₃-C₇)-cycloalkyl, such as, for example, cyclopropyl, cyclopentyl,-   —OH, hydroxy-(C₁-C₄)-alkyl, such as, for example, —CH₂—OH,    —CH₂—CH₂—OH, —CH₂—CH₂—CH₂—OH,-   (C₁-C₄)-alkyl-O—, such as, for example, —OCH₃,-   (C₁-C₄)-alkoxy-(C₁-C₄)-alkyl, such as, for example, —CH₂—OCH₃,    —CH₂—CH₂—OCH₃, —CH₂—CH₂—CH₂—OCH₃,-   —SO₂—(C₁-C₄)-alkyl, such as, for example, —SO₂—CH₃,-   —NH₂, N((C₁-C₄)-alkyl)₂-, such as, for example: —N(CH₃)₂, —N(C₂H₅)₂,-   NH₂(C₁-C₄)-alkyl-, N((C₁-C₄)-alkyl)₂-(C₁-C₄)-alkyl, such as, for    example, —CH₂—NH₂, —CH₂—CH₂—NH₂, —CH₂—CH₂—CH₂—NH₂,-   —CN, NC—(C₁-C₄)-alkyl-, such as, for example, —CH₂—CN, —CH₂—CH₂—CN,    —CH₂—CH₂—CH₂—CN-   —NH—(C₁-C₄)-alkyl, where the alkyl group may be substituted one or    more times by F, such as, for example, —NH—CH₂—F, —NH—CH₂—CH₂—F,    —NH—CH₂—CF₃, —NH—CH₂—CH₂—CF₃,-   —NH—(C₁-C₄)-alkyl-OH, —NH—(C₁-C₄)-alkyl-O—(C₁-C₄)-alkyl, such as,    for example, —NH—CH₂—OH, —NH—CH₂—CH₂—OH,-   —NH—(C₁-C₄)-alkyl-CN, such as, for example, —NH—CH₂—CN,    —NH—CH₂—CH₂—CN,-   —NH—(C₁-C₄)-alkyl-O—(C₁-C₄)-alkyl-OH, such as, for example,    —NH—CH₂—CH₂—O—CH₂—CH₂—OH,-   —NH—C(O)—(C₁-C₄)-alkyl, where the alkyl group may be substituted one    or more times by F, such as, for example, —NH—C(O)—CH₃,    —NH—C(O)—CF₃,    pyrrolidinyl, pyrrolidinyl-(C₁-C₄)-alkyl, such as, for example,    N-pyrrolidinyl-CH₂—, pyrimidinyl, such as, for example,    pyrimidin-2-yl.

In one embodiment of the invention, the heterocyclic groups formed by R3and R4 together with the nitrogen atom to which they are bonded maycarry substituents R7 and R9 which are selected independently of oneanother from the group of methyl, ethyl, CF₃, F, Cl, CN, NH₂, N(CH₃)₂,OH, OCH₃, SO₂CH₃, in another embodiment substituents R9 which areselected independently of one another from the group of F, Cl, CN, NH₂,N(CH₃)₂, OH, OCH₃, SO₂CH₃. In one embodiment of the invention, theheterocyclic groups formed by R3 and R4 together with the nitrogen atomto which they are bonded may carry one, two or three substituents R7 andR9, in another embodiment one or two substituents, in another embodimentone substituent.

The R3 and R4 radicals particularly preferably form together with thenitrogen to which they are bonded one of the following heterocyclic ringsystems:

Preferred R5 radicals are selected independently of one another from thegroup of F, Cl, Br, I, ═O, —CN, —OH, —NH₂, —NO₂,

-   (C₁-C₄)-alkyl, such as, for example, methyl, ethyl, n-propyl,    isopropyl, n-butyl, tert-butyl, where the alkyl radical may be    substituted one or more times by F, such as, for example, in —CF₃,    —CF₂H;-   (C₁-C₄)-alkoxy, such as, for example, —OCH₃, —OC₂H₅, where the alkyl    radical may be substituted one or more times by F, such as, for    example, in —OCF₃, —OCHF₂, —OCH₂F,-   —S—(C₁-C₄)-alkyl, such as, for example, —SCH₃, where the alkyl    radical may be substituted one or more times by F, such as, for    example, in —SCF₃,-   (C₁-C₄)-alkoxy-(C₁-C₄)-alkyl, such as, for example, in —CH₂—OCH₃,    —CH₂—CH₂—OCH₃-   —NC—(C₁-C₄)-alkyl-, such as, for example, in —CH₂—CN,-   NH₂—(C₁-C₄)-alkyl-, such as, for example, in —CH₂—NH₂,-   N((C₁-C₄)-alkyl)₂-(C₁-C₄)-alkyl-, such as, for example, in    —CH₂—N(CH₃)₂,-   (C₁-C₄)-alkyl-C(O)—NH—(C₁-C₄)-alkyl-, such as, for example,    —CH₂—NH—C(O)CH₃,-   N((C₁-C₄)-alkyl)₂-C(O)—(C₁-C₄)-alkyl-, such as, for example,    —CH₂—C(O)—N(CH₃)₂,-   —SO₂—(C₁-C₄)-alkyl, such as, for example, —SO₂CH₃, where the alkyl    group may be substituted one or more times by F, such as, for    example, in —SO₂CF₃,-   —SO₂NH₂, —SO₂N((C₁-C₄)-alkyl)₂, such as, for example, —SO₂N(CH₃)₂,    —SO₂N(C₂H₅)₂,-   —SO₂—NH—(C₁-C₄)-alkyl, such as, for example, —SO₂—NH—CH₃,    —SO₂—NH—CH₂—CH₃, —SO₂—NH—CH₂—CH₂—CH₃, where the alkyl radical may be    substituted one or more times by F, such as, for example, in    —SO₂—NH—CH₂—CF₃, —SO₂—NH—CH₂—CH₂—CF₃,-   —NH—C(O)—(C₁-C₄)-alkyl, such as, for example, —NH—C(O)—CH₃,-   —NH—C(O)—NH₂, —NH—C(O)—N((C₁-C₄)-alkyl)₂, such as, for example,    —NH—C(O)—N(CH₃)₂,-   —NH—C(O)—O—(C₁-C₄)-alkylphenyl, such as, for example,    —NH—C(O)—O—CH₂—C₆H₆,-   —NH—C(O)—O—(C₁-C₄)-alkyl-COOH, such as, for example,    —NH—C(O)—O—CH₂—COOH,-   —NH—C(O)—O—(C₁-C₄)-alkyl-COO(C₁-C₄)-alkyl, such as, for example,    —NH—C(O)—O—CH₂—COOCH₃,-   —NH—SO₂—(C₁-C₄)-alkyl, such as, for example, —NH—SO₂CH₃,-   —N((C₁-C₄)-alkyl)-SO₂—(C₁-C₄)-alkyl, such as, for example,    —N(CH₃)—SO₂CH₃,-   —C(O)—(C₁-C₄)-alkyl), such as, for example, —C(O)—CH₃,    —C(O)—CH₂—CH₃,-   —C(O)—NH₂, —C(O)—N((C₁-C₄)-alkyl)₂, such as, for example,    —C(O)—N(CH₃)₂, —C(O)—N(C₂H₅)₂,-   —C(O)—O(C₁-C₄)-alkyl, such as, for example, —C(O)—OCH₃,-   —C(O)phenyl,-   —O-phenyl,-   —COOH, —COO(C₁-C₄)-alkyl, such as, for example, —COOCH₃, —COOC₂H₅,-   (C₁-C₄)-alkyl-(C₃-C₇)-cycloheteroalkyl-C(O)—, such as, for example,    (C₁-C₄)-alkyl-piperazinyl- or -pyrimdinyl- or -piperidinyl- or    -tetrahydropyridazinyl-C(O)—, in particular    4-methylpiperazin-1-yl-C(O)—,-   (C₃-C₇)-cycloheteroalkyl-(C₁-C₄)-alkyl-, such as, for example,    piperidinyl- or piperazinyl- or pyrimidinyl- or    tetrahydropyridazinyl-(C₁-C₄)-alkyl-, in particular    piperidin-1-yl-methyl-.

The preferred aryl radical R5 is phenyl.

Further preferred R5 radicals are heteroaryl radicals, especially thoseselected from the group of pyrrol-1, 2, or 3-yl, pyrazol-1, 3, 4 or5-yl, imidazol-1, 2, 4 or 5-yl, 1,2,3-triazol-1, 2, 4 or 5-yl,1,2,4-triazol-1, 3 or 4-yl, tetrazol-1, 2 or 5-yl, 1,3,4-oxadiazol-3 or4-yl, 1,2-isoxazoly-2, 3, 4 or 5-yl, oxazol-2, 3, 4 or 5-yl, thiazol-2,3, 4 or 5-yl, isothiazol-2, 3, 4 or 5-yl, thiadiazol-2, 3, 4 or 5-ylpyrid-2, 3 or 4-yl, benzo[b]furan-2, 3, 4, 5, 6 or 7-yl,benzo[b]thiophen-2, 3, 4, 5, 6 or 7-yl, indol-1, 2, 3, 4, 5, 6 or 7-yl,isoindol-1, 2, 3, 4, 5, 6 or 7-yl, benzothiazol-2, 4, 5, 6 or 7-yl,benzoisothiazol-3, 4, 5, 6 or 7-yl, benzoxazol-2, 4, 5, 6 or 7-yl,benzoisoxazol-3, 4, 5, 6 or 7-yl, benzodiazol-1, 2, 4, 5, 6 or 7-yl andbenzoisodiazol-1, 2, 3, 4, 5, 6 or 7-yl.

Preferred cycloheteroalkyl radicals R5 are selected from the group ofpiperidin-1, 2, 3 or 4-yl, piperazin-1, 2 or 3-yl, pyrimidin-1, 2, 4 or5-yl, tetrahydropyridazin-1, 3 or 4-yl, 2H-pyridin-1, 2, 3, 4, 5 or6-yl, 4H-pyridin-1, 2, 3 or 4-yl, morpholin-2, 3 or 4-yl,thiomorpholin-2, 3 or 4-yl, pyrrolidin-1, 2 or 3-yl,dihydropyrrolidin-1, 2 or 3-yl, imidazolidin-1, 2 or 4-yl,dihydroimidazol-1, 2 or 4-yl, thiazolidin-2, 3, 4 or 5-yl,isothiazolidin-2, 3, 4 or 5-yl and oxazolan-2, 3, 4 or 5-yl.

Preferred cycloheteroalkylaryl radicals R5 are selected from the groupof benzo[b]dihydrofuran-2, 3, 4, 5, 6 or 7-yl, benzo[c]dihydrofuran-1,3, 4, 5, 6 or 7-yl, benzo[b]dihydrofuran-2, 3, 4, 5, 6 or 7-yl,benzo[c]dihydrothiophen-1, 3, 4, 5, 6 or 7-yl,benzo[b]dihydrothiophen-1, 2, 3, 4, 5, 6 or 7-yl,benzo[c]dihydropyrrol-1, 2, 3, 4, 5, 6 or 7-yl, benzodioxolan-2, 4, 5, 6or 7-yl and benzoxathiolan-2, 4, 5, 6 or 7-yl, tetrahydroquinol-2, 3, 4,5, 6, 7 or 8-yl and isoquinol-1, 3, 4, 5, 6, 7 or 8-yl.

The preferred aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkylaryland cycloheteroalkylheteroaryl radicals may carry one or more,preferably one, two, three or four, further substituents which areselected independently of one another from the group of R11 radicals.Particularly preferred R11 radicals are selected from the group of

F, Cl, Br, I, —CN, NH₂, OH, ═O,

(C₁-C₄)-alkyl-, such as, for example, methyl, ethyl, n-propyl,isopropyl, n-butyl, tert-butyl and(C₁-C₄)-alkyloxy-, such as, for example, —OCH₃, —OC₂H₅, where the alkyland alkoxy radicals may be substituted one or more times by F,—SO₂CH₃, —SO₂NH₂, —NH—C(O)—CH₃, —C(O)—NH₂ and —NH—C(O)—NH₂, —COOCH₃,—COOC₂H₅.

Particularly preferred aryl, heteroaryl, cycloheteroalkyl,cycloheteroalkylaryl and cycloheteroalkylheteroaryl radicals R5 are:

In one embodiment of the invention, the R5 radicals can be selectedindependently of one another from the group of F, Cl, Br, CN, methyl,ethyl, propyl, tertiary butyl, NH₂, OCH₃, SO₂CH₃, SO₂NH₂, C(O)NH₂,—NH—C(O)—CH₃, pyrazol-1, 2 or 3-yl, imidazol-1, 2 or 3-yl,1,2,3-triazol-1 or 2-yl, 1,2,4-triazol-1, 3 or 4-yl, tetrazol-1, 2 or5-yl, thiazol-2, 3 or 4-yl, 1,3,4-oxadiazol-3 or 4-yl, oxazol-2 or 3-yl,isooxazol-2, or 3-yl, triazol-1 or 2-yl, piperidin-1-yl, piperazin-1-yl,pyrrolidin-1-yl, oxazolidin-3-yl, isoxazolidin-2-yl,tetrahydroimidazol-1-yl, dihydroimidazol-1-yl, isothiazol-1-yl andmorpholin-4-yl, where the cyclic radicals R5 may carry furthersubstituents R11. In another embodiment, one of the R5 radicals isselected from the group of F, Cl, CN, methyl, ethyl, tertiary butyl,OCH₃, SO₂CH₃, SO₂NH₂, C(O)NH₂ and —NH—C(O)—CH₃. In another embodiment,one of the R5 radicals is selected from pyrazol-1, 2 or 3-yl,imidazol-1-yl, 1,2,3-triazol-1 or 2-yl, 1,2,4-triazol-1, 3 or 4-yl,thiazol-2 or 4-yl, oxazol-2 or 3-yl, isooxazol-2, or 3-yl, triazol-1 or2-yl, tetrazol-1-yl, all of which may carry further substituents fromthe group of methyl, ethyl, cyclopropyl, methoxy, CN, OH, NH₂, N(CH₃)₂,or selected from the group of piperidin-1-yl, piperazin-1-yl,pyrrolidin-1-yl, oxazolidin-3-yl, isoxazolidin-2-yl,tetrahydroimidazol-1-yl, all of which may carry further substituents R11selected from the group of methyl, ethyl, cyclopropyl, methoxy, CN,(═O), OH, NH₂ and N(CH₃)₂.

In one embodiment of the invention, one of the R5 radicals is selectedfrom the group of F, Cl, Br, CN, methyl, ethyl, propyl, tertiary butyl,NH₂, OCH₃, SO₂CH₃, SO₂NH₂, C(O)NH₂, —NH—C(O)—CH₃ and one of the R5radicals is selected from the group of pyrazol-1, 2 or 3-yl, imidazol-1,2 or 3-yl, 1,2,3-triazol-1 or 2-yl, 1,2,4-triazol-1, 3 or 4-yl,thiazol-2, 3 or 4-yl, 1,3,4-oxadiazol-3 or 4-yl, oxazol-2 or 3-yl,isooxazol-2, or 3-yl, triazol-1 or 2-yl, tetrazol-1-yl, all of which maycarry substituents R11 selected from the group of methyl, ethyl,cyclopropyl, methoxy, CN, OH, NH₂, N(CH₃)₂, or selected from the groupof piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, oxazolidin-3-yl,isoxazolidin-2-yl, tetrahydroimidazol-1-yl, dihydroimidazol-1-yl,isothiazol-1-yl and morpholin-4-yl, all of which may carry substituentsR11 selected from the group of methyl, ethyl, cyclopropyl, methoxy, CN,(═O), OH, NH₂ and N(CH₃)₂.

In one embodiment of the invention, the substituents R11 are selectedfrom the group of methyl, ethyl, cyclopropyl, methoxy, CN, (═O), OH,NH₂, N(CH₃)₂, SO₂Me and CO₂Me.

(C₁-C₁₀)-Alkyl radicals may in the context of the present invention bestraight-chain or branched. This also applies when they carrysubstituents or occur as substituents of other radicals, for example influoroalkyl radicals or alkoxy radicals. Examples of alkyl radicals aremethyl, ethyl, n-propyl, isopropyl (=1-methylethyl), n-butyl, isobutyl(=2-methylpropyl), sec-butyl (=1-methylpropyl), tert-butyl(=1,1-dimethylethyl), n-pentyl, isopentyl, tert-pentyl, neopentyl andhexyl. Preferred alkyl radicals are methyl, ethyl, n-propyl, isopropyl,n-butyl and tert-butyl.

(C₂-C₁₀)-Alkenyl radicals in the context of the present invention maylikewise be straight-chain or branched. This also applies when theycarry substituents or occur as substituents of other radicals. Examplesof alkenyl radicals are ethenyl, propenyl and butenyl.

(C₂-C₁₀)-Alkynyl radicals in the context of the present invention maylikewise be straight-chain or branched. This also applies when theycarry substituents or occur as substituents of other radicals. Examplesof alkynyl radicals are ethynyl, propynyl and butynyl.

(C₃-C₁₄)-Cycloalkyl radicals in the context of the present invention maybe saturated or partly unsaturated. This also applies when they carrysubstituents or occur as substituents of other radicals. Cycloalkylradicals having 3, 4, 5, 6, 7 or 8 carbon atoms are preferred. Examplesof cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl and cyclooctyl.

(C₂-C₁₉)-Cycloheteroalkyl radicals in the context of the presentinvention may be saturated or partly unsaturated. This also applies whenthey carry substituents or occur as substituents of other radicals. Thecycloheteroalkyl radicals preferably have heteroatoms selected from thegroup of nitrogen, oxygen and sulfur. Cycloheteroalkyl radicals having2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms are preferred, it being possiblefor 1 or 2 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, 1nitrogen and 1 oxygen atom or 1 sulfur atom or 1 oxygen and 1 sulfuratom to be present as heteroatoms. The cycloheteroalkyl radicals can beattached by any position. Examples of such heterocycles are selectedfrom the group of oxiranyl, thiiranyl, aziridinyl, oxetanyl, thietanyl,azetidinyl, diazetidinyl, pyrrolidinyl, dihydropyrrolyl,dihydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, oxolanyl,dihydrofuranyl, dioxolanyl, thiolanyl, dihydrothiophenyl, oxazolanyl,dihydrooxazolyl, isooxazolanyl, dihydroisooxazolyl, thiazolidinyl,dihydrothiazolyl, isothiazolidinyl, dihydroisothiazolyl, oxathiolidinyl,2H-pyranyl, 4H-pyranyl, tetrahydropyranyl, 2H-thiopyranyl,4H-thiapyranyl, tetrahydrothiopyranyl, piperidinyl, di-,tetrahydropyridyl, piperazinyl, di-, tetrahydropyrazinyl, di-, tetra-,hexahydropyridazinyl, di-, tetra-, hexahydropyrimidinyl, morpholinyl,thiomorpholinyl, azepanyl, thiepanyl and oxepinyl, it also beingpossible for two of these heterocyclic rings to form a saturated orpartly unsaturated fused bicyclic ring system. Examples of such bicyclicring systems are octahydropyrrolo[1,2a]pyrazinyl,octahydropyrrolo[3,4b]pyrrolyl, hexahydropyrrolo[3,4-c]pyrrolyl- andoctahydropyrrolo[3,4-c]pyrrolyl.

Examples of preferred (C₆-C₁₀)-aryl radicals are phenyl and naphthyl.This also applies when they carry substituents or occur as substituentsof other radicals.

(C₁-C₉)-Heteroaryl radicals are aromatic ring compounds in which one ormore ring atoms are oxygen atoms, sulfur atoms or nitrogen atoms, e.g.1, 2 or 3 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms or acombination of various heteroatoms. This also applies when they carrysubstituents or occur as substituents of other radicals. The heteroarylradicals may be attached by all positions. Heteroaryl means for examplefuranyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl,tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl,pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, quinolyl,isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl and cinnolinyl.

Particularly preferred heteroaryl radicals are 2- or 3-thiophenyl, 2- or3-furyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or5-pyrazolyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or-5-yl, 1- or 5-tetrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl,1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl,1,3,4-oxadiazol-2-yl or -5-yl, 2-, 4- or 5-thiazolyl, 3-, 4- or5-isothiazolyl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or-5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or6-pyrimidinyl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or7-indazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-,7- or 8-isoquinolyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 3-, 4-, 5-,6-, 7- or 8-cinnolinyl, 2-, 3-, 5-, 6-, 7- or 8-quinoxalinyl, 1-, 4-,5-, 6-, 7- or 8-phthalazinyl.

(C₉-C₁₄)-Cycloalkylaryl radicals are preferably selected from the groupof fused ring systems having a cycloalkyl ring and an aryl ring, inparticular a phenyl ring. Particularly preferred cycloalkylaryl radicalsare indenyl, dihydronaphthyl, tetrahydronaphthyl and indanyl.

(C₅-C₁₃)-Cycloalkylheteroaryl radicals are preferably selected from thegroup of fused ring systems having a cycloalkyl ring and a heteroarylring.

(C₇-C₁₃)-Cycloheteroalkylaryl radicals are preferably fused ring systemshaving a cycloheteroalkyl ring and an aryl ring, in particular a phenylring. Particularly preferred cycloheteroalkylaryl radicals arebenzodihydrothiophenyl, benzothiolanyl, benzodihydrofuranyl,benzooxolanyl, benzodioxolanyl, benzodihydropyrrolyl,benzodihydroimidazolyl, benzodihydropyrazolyl, benzodihydrotriazolyl,benzopiperazinyl, benzodihydrothiazolyl, benzomorpholinylbenzodihydrooxazolyl, dihydroquinolinyl, dihydroisoquinolinyl,tetrahydroisoquinolinyl and tetrahydroquinolinyl.

(C₄-C₁₂)-Cycloheteroalkylheteroaryl radicals are preferably selectedfrom the group of fused ring systems having a cycloheteroalkyl ring anda heteroaryl ring.

In one embodiment of the invention, p is 1, and in another embodiment, pis 2. In one embodiment of the invention, q is 0, and in anotherembodiment, q is 1.

If the compounds of the formula I comprise one or more centers ofasymmetry, these may have independently of one another either the S orthe R configuration. The compounds may be in the form of opticalisomers, diastereomers, racemates or mixtures in all ratios thereof. Thecompounds of the formula I may furthermore be in the form of rotationalisomers.

Particular preference is given to stereoisomers of the formula I inwhich the radical XLBR5 bonded at position 1 is directed downwards andthe radical —(CH₂)_(q)NR3R4 bonded at position 2 is directed upwards,the direction being defined starting from a plane which is spanned bythe three carbon atoms in positions 1, 2 and 3, and the moleculeassuming the following orientation (formula Ie):

Compounds of formula I with trans-1S,2S configuration at position 1 and2 are preferred.

The present invention includes all possible tautomeric forms of thecompounds of the formulae I.

Particularly preferred compounds of formula I are selected from thegroup of

Example Configuration Name 1 trans-1S,2S-((R)-1-{trans-(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4- 3′R-yl)phenoxy]indan-2-yl}piperidin-3-yl)-(3,3,3- trifluoropropyl)amine 2trans-1S,2S 3-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]-3,8-diazabicyclo[3.2.1]octane 3 trans-1S,2S-2-[trans-(1S,2S)-4,6-dichloro-1-(4- methanesulfonylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 4 rac-trans-1,2-2-[rac-trans-(1,2)-1-(2,4-dichloro-3-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 5 rac-trans-1,2-2-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 6 rac-trans-1,2-2-[rac-trans-(1,2)-1-(3-chloro-2-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 7 rac-trans-1,2-2-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 8 trans-1S,2S2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-5-methyloctahydropyrrolo[3,4-c]pyrrole 9 rac-trans-1,2-2-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 10 rac-trans-1,2-2-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 11 rac-trans-1,2-2-[rac-trans-(1,2)-1-(2-bromophenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 12 rac-trans-1,2-2-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 13 rac-trans-1,2-2-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 14 rac-trans-1,2-2-[rac-trans-(1,2)-1-(3-piperidin-1-ylmethylphenoxy)indan-2-yl]octahydropyrrolo[3,4- c]pyrrole 15rac-trans-1,2- 2-[rac-trans-(1,2)-1-(3-piperidin-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 16 rac-trans-1,2-2-[rac-trans-(1,2)-1-(4-fluoro-2-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 17 rac-trans-1,2-2-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 18 rac-trans-1,2-2-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 19 rac-trans-1,2-2-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}octahydropyrrolo[3,4-c]pyrrole 20 rac-trans-1,2-2-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}octahydropyrrolo[3,4-c]pyrrole 21 trans-1S,2S-cis-(3R,5S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′-5′-methanesulfonylphenoxy)indan-2-yl]-3,5- dimethylpiperazine 22rac-trans-1,2-(4-methylpiperazin-1-yl)-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]methanone 23 trans-1S,2S-(R)-1-(trans-(1R,2R)-4,6-dichloro-1-phenoxyindan-2- 3′R-yl)piperidin-3-ylamine 24 trans-1S,2S-(R)-1-[(1S,2S)-4,6-dichloro-1-(2-chloro-4- 3′R-methanesulfonylbenzyloxy)indan-2-yl]pyrrolidin-3-ol 25 trans-1S,2S-3′R(R)-1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine 26 trans-1S,2S-(R)-1-[(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenylamino)indan-2-yl]pyrrolidin-3-ol 27 trans-1S,2S-3′R(R)-1-[(1S,2S)-4,6-dichloro-1-(5-fluoroquinolin-8-yloxy)indan-2-yl]piperidin-3-ylamine 28 trans-1S,2S-(R)-1-[(1S,2S)-4,6-difluoro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol 29 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(1H-benzotriazol-4-yloxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 30 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(1H-indol-4-yloxy)indan-2- 3′R-yl]piperidin-3-ylamine 31 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2,3-dichloro-4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine 32 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 33 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)indan-2- 3′R-yl]piperidin-3-ylamine 34 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2,6-dimethoxyphenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 35 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 36 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-bromophenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 37 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-chloro-4- 3′Rmethanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine 38 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-chloro-4-methylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 39 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-chloro-6-methylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 40 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-chloropyridin-4-yloxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 41 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-chloroquinolin-8-yloxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 42 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-fluoro-4-methoxyphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 43 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-fluoro-5-methylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 44 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 45 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-methanesulfonylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 46 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 47 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-methylbenzothiazol-5- 3′R-yloxy)indan-2-yl]piperidin-3-ylamine 48 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-morpholin-4-ylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 49 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-tert-butyl-4- 3′R-ethylphenoxy)indan-2-yl]piperidin-3-ylamine 50 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(2-trifluoromethoxyphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 51 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3,4-difluorophenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 52 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3-chloro-4-fluorophenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 53 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3-chloro-4-methylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 54 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 55 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3-chlorophenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 56 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3-difluoromethoxyphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 57 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3-fluorophenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 58 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3-piperidin-1- 3′R-ylmethylphenoxy)indan-2-yl]piperidin-3-ylamine 59 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3-piperidin-1-ylphenoxy)indan-2- 3′R-yl]piperidin-3-ylamine 60 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(3-tetrazol-1-ylphenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 61 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 62 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1- 3′R-ylphenoxy)indan-2-yl]piperidin-3-ylamine 63 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-bromo-3-methoxyphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 64 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-chloro-2-methoxyphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 65 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-chloro-3-methylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 66 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-chlorophenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 67 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4- 3′R- dimethylaminomethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 68 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-fluoro-2-isoxazol-5- 3′R-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3- ylamine 69rac-trans-1,2- (R)-1-[rac-trans-(1,2)-1-(4-fluoro-3- 3′R-trifluoromethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 70 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-fluorophenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 71 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 72 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)indan-2- 3′R-yl]piperidin-3-ylamine 73 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 74 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-methylsulfanylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 75 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 76 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan- 3′R-2-yl]piperidin-3-ylamine 77 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(4-trifluoromethylphenoxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 78 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(5,7-dimethylquinolin-8-yloxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 79 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(5-fluoroquinolin-8-yloxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 80 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(6-aminonaphthalen-1-yloxy)- 3′R-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 81 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 82 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)indan-2- 3′R-yl]piperidin-3-ylamine 83 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(benzo[1,3]dioxol-5-yloxy)indan- 3′R-2-yl]piperidin-3-ylamine 84 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(isoquinolin-7-yloxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 85 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(isoquinolin-7-yloxy)indan-2- 3′R-yl]piperidin-3-ylamine 86 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(pyridin-4-yloxy)indan-2- 3′R-yl]piperidin-3-ylamine 87 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(quinolin-3-yloxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 88 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(quinolin-4-yloxy)indan-2- 3′R-yl]piperidin-3-ylamine 89 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-1-(quinolin-5-yloxy)-1,2,3,4- 3′R-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 90 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(3-methyl-4- 3′R-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3- ylamine 91rac-trans-1,2- (R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine 92 rac-trans-1,2-(R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(3-methyl-4- 3′R-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3- ylamine 93rac-trans-1,2- (R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine 94 trans-1S,2S-(R)-1-[trans-(1R,2R)-4,6-dichloro-1-(2-fluoro-6- 3′R-methoxyphenoxy)indan-2-yl]piperidin-3-ylamine 95 trans-1S,2S-(R)-1-[trans-(1S,2S)-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine 96 trans-1S,2S-(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(2- 3′R-methylbenzothiazol-5-yloxy)indan-2-yl]pyrrolidin-3-ol 97 trans-1S,2S-(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1- 3′R-ylphenoxy)indan-2-yl]piperidin-3-ylamine 98 trans-1S,2S-(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-imidazol-1- 3′R-ylphenoxy)indan-2-yl]piperidin-3-ylamine 99 trans-1S,2S-(R)-1′-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]-[1,3′]bipyrrolidinyl 100 trans-1S,2S-(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]-3-fluoropyrrolidine 101 trans-1S,2S-(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]-3-methylpiperazine 102 trans-1S,2S-(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine 103 trans-1S,2S-(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol 104 trans-1S,2S-(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ylamine 105 trans-1S,2S-(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]pyrrolidine-3- carbonitrile 106trans-1S,2S- (R)-1-[trans-(1S,2S)-6-chloro-1-(2-chloro-4- 3′R-methanesulfonylphenoxy)-4-fluoroindan-2-yl]pyrrolidin-3- ol 107trans-1S,2S- (R)-1-[trans-(1S,2S)-6-chloro-1-(2-chloro-4- 3′R-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol 108 trans-1S,2S-(R)-1-[trans-(1S,2S)-6-chloro-4-fluoro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol 109 trans-1S,2S-(R)-1-{(1S,2S)-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol- 3′R-4-yl)phenoxy]-4,6-difluoroindan-2-yl}pyrrolidin-3-ol 110 trans-1S,2S-(R)-1-{(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2- 3′R-fluorophenoxy]-4,6-difluoroindan-2-yl}pyrrolidin-3-ol 111 trans-1S,2S-(R)-1-{(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- rac-3′-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-3-methylpyrrolidin- 3-ol 112trans-1S,2S- (R)-1-{(1S,2S)-4,6-dichloro-1-[4-(5-methyltetrazol-1- 3′R-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol 113 trans-1S,2S-3′R(R)-1-{(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-3-ylamine 114 trans-1S,2S-(R)-1-{(1S,2S)-4,6-dichloro-1-[5-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin- 3-ol 115rac-trans-1,2- (R)-1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]-3′R- 1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine 116rac-trans-1,2- (R)-1-{rac-trans-(1,2)-1-[4-(2- 3′R-methoxyethyl)phenoxy]indan-2-yl}piperidin-3-ylamine 117 rac-trans-1,2-(R)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3- 3′R-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin- 3-ylamine 118rac-trans-1,2- (R)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3- 3′R-yl)phenoxy]indan-2-yl}piperidin-3-ylamine 119 rac-trans-1,2-(R)-1-{rac-trans-(1,2)-1-[4-chloro-2-(1H-pyrazol-3- 3′R-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin- 3-ylamine 120rac-trans-1,2- (R)-1-{rac-trans-(1,2)-1-[4-fluoro-2-(1H-pyrazol-3- 3′R-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin- 3-ylamine 121trans-1S,2S- (R)-1-{trans-(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-3′R- yl)phenoxy]indan-2-yl}piperidin-3-ylamine 122 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5- 3′R-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin- 3-ol 123trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[3-(1,1-dioxo- 3′R-1lambda6-isothiazolidin-2-yl)phenoxy]indan-2- yl}pyrrolidin-3-ol 124trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(1,3,5-trimethyl-3′R- 1H-pyrazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol 125 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(2,4-dimethyl- 3′R-thiazol-5-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol 126 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)-2,3-difluorophenoxy]indan-2- yl}pyrrolidin-3-ol 127trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]indan-2- yl}pyrrolidin-3-ol 128trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]indan-2- yl}pyrrolidin-3-ol 130trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin- 3-ol 131trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)-2-methylphenoxy]indan-2-yl}pyrrolidin- 3-ol 132trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}piperidin-3-ol 133 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol 134 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidine-3- carbonitrile 135trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5- 3′R-dimethylisoxazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol 136trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5- 3′R-dimethylpyrazol-1-yl)-2-fluorophenoxy]indan-2- yl}pyrrolidin-3-ol 137trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(2H- 3′R-pyrazol-3-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol 138 trans-1S,2S-(R)-1-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5- 3′R-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol 139 trans-1S,2S-(R)-1-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5- 3′R-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin- 3-ol 140trans-1S,2S- (R)-1-{trans-(1S,2S)-6-chloro-1-[4-(1,3,5-trimethyl-1H-3′R- pyrazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol 141 trans-1S,2S-(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol 142 trans-1S,2S-(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)-2-fluorophenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol 143 trans-1S,2S-(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin- 3-ol 144trans-1S,2S- (R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)phenoxy]-4-fluoroindan-2-yl}pyrrolidin- 3-ol 145trans-1S,2S- (R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl- 3′R-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol 146 trans-1S,2S-(S)-1-[(1S,2S)-4,6-dichloro-1-(4- rac-3′-methanesulfonylphenoxy)indan-2-yl]-3-methylpyrrolidin- 3-ol 147rac-trans-1,2- (S)-1-[rac-trans-(1,2)-1-(1H-benzotriazol-4-yloxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 148 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(1H-indol-6-yloxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 149 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 150 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 151 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-bromophenoxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 152 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-chloro-4-methylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 153 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-chloropyridin-4-yloxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 154 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-chloroquinolin-8-yloxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 155 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-fluoro-5-methylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 156 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-methanesulfonylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 157 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 158 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-morpholin-4-ylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 159 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(2-trifluoromethoxyphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 160 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3-chloro-2-methylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 161 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3-chloro-4-methylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 162 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3-chloro-5-fluorophenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 163 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 164 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3-chloro-5- 3′S-methoxyphenoxy)indan-2-yl]piperidin-3-ylamine 165 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3-chlorophenoxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 166 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3-difluoromethoxyphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 167 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3- 3′S-dimethylaminomethylphenoxy)indan-2-yl]piperidin-3- ylamine 168rac-trans-1,2- (S)-1-[rac-trans-(1,2)-1-(3-fluorophenoxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 169 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan- 3′S-2-yl]piperidin-3-ylamine 170 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(3-piperidin-1- 3′S-ylmethylphenoxy)indan-2-yl]piperidin-3-ylamine 171 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 172 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1- 3′S-ylphenoxy)indan-2-yl]piperidin-3-ylamine 173 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-bromo-3-methoxyphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 174 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-chloro-2-methoxyphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 175 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-chlorophenoxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 176 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-difluoromethoxyphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 177 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4- 3′S- dimethylaminomethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 178 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-fluoro-2-isoxazol-5- 3′S-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3- ylamine 179rac-trans-1,2- (S)-1-[rac-trans-(1,2)-1-(4-fluorophenoxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 180 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 181 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)indan-2- 3′S-yl]piperidin-3-ylamine 182 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 183 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-methylsulfanylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 184 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 185 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan- 3′S-2-yl]piperidin-3-ylamine 186 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(4-trifluoromethylphenoxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 187 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(5,7-dimethylquinolin-8-yloxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 188 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(5-fluoroquinolin-8-yloxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 189 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(6-aminonaphthalen-1-yloxy)- 3′S-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 190 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 191 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(pyridin-4-yloxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 192 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(quinolin-3-yloxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 193 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(quinolin-5-yloxy)-1,2,3,4- 3′S-tetrahydronaphthalen-2-yl]piperidin-3-ylamine 194 rac-trans-1,2-(S)-1-[rac-trans-(1,2)-1-(quinolin-5-yloxy)indan-2- 3′S-yl]piperidin-3-ylamine 195 trans-1S,2S-(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 2′S-methanesulfonylphenoxy)indan-2-yl]-2-pyrrolidin-1- ylmethylpyrrolidine196 trans-1S,2S- (S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′S-methanesulfonylphenoxy)indan-2-yl]-3-fluoropyrrolidine 197 trans-1S,2S-(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′S-methanesulfonylphenoxy)indan-2-yl]-3-methylpiperazine 198 trans-1S,2S-(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′S-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol 199 trans-1S,2S-(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′S-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ylamine 200 trans-1S,2S-(S)-1-{(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′S-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin- 3-ol 201rac-trans-1,2- (S)-1-{rac-trans-(1,2)-1-[3-(2-aminoethyl)-1H-indol-5-3′S- yloxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3- ylamine 202rac-trans-1,2- (S)-1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]-3′S- 1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine 203rac-trans-1,2- (S)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3- 3′S-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin- 3-ylamine 204rac-trans-1,2- (S)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3- 3′S-yl)phenoxy]indan-2-yl}piperidin-3-ylamine 205 rac-trans-1,2-(S)-1-{rac-trans-(1,2)-1-[4-fluoro-2-(1H-pyrazol-3- 3′S-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin- 3-ylamine 206trans-1S,2S- (S)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′S-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol 207 trans-1S,2S-(S)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl- 3′S-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ylamine 208trans-1S,2S- (S)-2-[(S)-4-(S)-chloro-6-chloro-1-(4- 3′S-methanesulfonylphenoxy)indan-2- yl]octahydropyrrolo[1,2-a]pyrazine 209trans-1S,2S- (S)-2-[trans-(1S,2S)-4,6-dichloro-1-(4- 2′R-5′Smethanesulfonylphenoxy)indan-2-yl]-2,5- diazabicyclo[2.2.1]heptane 210trans-1S,2S- (S)-3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-4-isopropyloxazolidin-2-one 211 trans-1S,2S-(S)-3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-4-isopropyloxazolidin-2-one 212 rac-trans-1,2-[3-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)phenyl]- urea 213rac-trans-1,2- [3-methoxy-2-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)phenyl]acetonitrile 214 rac-trans-1,2-[rac-trans-(1,2)-1-(1H-indol-4-yloxy)indan-2- rac-3′-yl]methylpiperidin-3-ylamine 215 rac-trans-1,2-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]methylpiperidin-4-ylamine 216 rac-trans-1,2-[rac-trans-(1,2)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]dimethylamine 217 rac-trans-1,2[rac-trans-(1,2)-4,6-dichloro-1-(4- methanesulfonylphenoxy)indan-2-ylmethyl]dimethylamine 218 trans-1S,2S [trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-(2-methoxyethyl)- methylamine 219trans-1S,2S- {(R)-1-[trans-(1S,2S)-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(2,2,2-trifluoroethyl)amine 220 trans-1S,2S- {(R)-1-[trans-(1S,2S)-1-(4-3′R- methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine 221 trans-1S,2S-{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1- 3′R-ylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3- trifluoropropyl)amine 222trans-1S,2S- {(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(2- fluoroethyl)amine223 trans-1S,2S- {(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine 224 trans-1S,2S-{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}- dimethylamine 225trans-1S,2S- {(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3- ylamino}acetonitrile 226trans-1S,2S- {(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-yl}-(2- fluoroethyl)amine227 trans-1S,2S- {(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3- yl}methanol 228trans-1S,2S-2′S {(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-2- yl}methanol 229rac-trans-1,2-{2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]-3- methoxyphenyl}acetonitrile 230rac-trans-1,2-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]phenyl}acetonitrile 231 rac-trans-1,2-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]phenyl}urea 232 rac-trans-1,2-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1- 3′S-yloxy]phenyl}urea 233 rac-trans-1,2-{3-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan- rac-3′-1-yloxy]phenyl}urea 234 rac-trans-1,2-{3-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1- rac-3′-yloxy]phenyl}urea 235 rac-trans-1,2-{3-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]phenyl}urea 236 trans-1S,2S-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1- yloxy]phenylcarbamoyloxy}acetic acid 237rac-trans-1,2-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]phenyl}carbamic acid benzyl ester 238rac-trans-1,2- {4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-3′R- yloxy]phenyl}carbamic acid benzyl ester 239 rac-trans-1,2-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4- 3′S-tetrahydronaphthalen-1-yloxy]phenyl}carbamic acid benzyl ester 240rac-trans-1,2-{4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan- rac-3′-1-yloxy]phenyl}carbamic acid benzyl ester 241 rac-trans-1,2-{4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1- rac-3′-yloxy]phenyl}carbamic acid benzyl ester 242 rac-trans-1,2-{4-[rac-trans-(1,2)-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazin-1- yl}acetonitrile 243trans-1S,2S {trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-(2-methoxyethyl)- methylamine244 rac-trans-1,2- 1-(4-methanesulfonylphenoxy)indan-2-ylmethyl]-dimethylamine 245 trans-1S,2S- 1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]azetidine 246 trans-1S,2S-1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]piperazine 247 trans-1S,2S-1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]pyrrolidine 248 trans-1S,2S-1-[(1S,2S)-4,6-dichloro-1-(3-tetrazol-1-ylphenoxy)indan- 2-yl]piperazine249 trans-1S,2S- 1-[(1S,2S)-4,6-dichloro-1-(4- rac-3′-methanesulfonylphenoxy)indan-2-yl]-3- methanesulfonylpyrrolidine 250trans-1S,2S- 1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4,4- difluoropiperidine 251rac-trans-1,2- 1-[1-(2-chloro-4-nitrophenoxy)indan-2-yl]pyrrolidine 252rac-trans-1,2- 1-[1-(4-methanesulfonylphenoxy)-2-methylindan-2-yl]pyrrolidine 253 rac-trans-4,5-1-[1,3-dichloro-4-(4-methanesulfonylphenoxy)-4,5,6,7-tetrahydrobenzo[c]thiophen-5-yl]pyrrolidine 254 rac-trans-1,2-1-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-1,3-dihydroimidazol-2-one 255 rac-trans-1,2-1-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidin-2-one 256 rac-trans-1,2-1-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidine-2,5-dione 257 rac-trans-1,2-1-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]-3-methyl-1,3-dihydroimidazol-2-one 258 rac-trans-1,2-1-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]-3-methylimidazolidin-2-one 259 trans-1S,2S-1-[4-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)phenyl]pyrrolidin-2-one 260 trans-1S,2S-1-[4-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidin-2-one 261 rac-cis-1,21-[rac-cis-(1,2)-1-(4-methanesulfonylphenoxy)indan-2- yl]-1H-imidazole262 rac-trans-1,2- 1-[rac-trans-(1,2)-1-(1H-indol-6-yloxy)indan-2-rac-3′- yl]pyrrolidin-3-ylamine 263 rac-trans-1,21-[rac-trans-(1,2)-1-(2,3-dichloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine 264 rac-trans-1,2-1-[rac-trans-(1,2)-1-(2,6-dichloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine 265 rac-trans-1,21-[rac-trans-(1,2)-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine 266 rac-trans-1,2-1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2- rac-3′-yl]pyrrolidin-3-ylamine 267 rac-trans-1,2-1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2- rac-3′-yl]pyrrolidin-3-ylamine 268 rac-trans-1,21-[rac-trans-(1,2)-1-(3-chloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine 269 rac-trans-1,2-1-[rac-trans-(1,2)-1-(3-methanesulfonylphenoxy)indan-2- yl]pyrrolidine270 rac-trans-1,2-1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2- rac-3′-yl]pyrrolidin-3-ylamine 271 rac-trans-1,2-1-[rac-trans-(1,2)-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine 272 rac-trans-1,2-1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2- yl]piperazine273 rac-trans-1,2-1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2- yl]pyrrolidine274 rac-trans-1,21-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-ylmethyl]pyrrolidine 275 rac-trans-1,2-1-[rac-trans-(1,2)-1-(quinolin-4-yloxy)indan-2- rac-3′-yl]pyrrolidin-3-ylamine 276 rac-trans-1,2-1-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperazine 277 rac-trans-1,2-1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane 278 rac-trans-1,21-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1H-imidazole 279 rac-trans-1,2-1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methyl- [1,4]diazepane 280rac-trans-1,2 1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-ylmethyl]pyrrolidine 281 rac-trans-1,2-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]piperazine 282 rac-trans-1,2-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine 283 rac-trans-1,2-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine 284 rac-trans-1,2-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine 285 rac-trans-1,2-1-[rac-trans-(1,2)-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine 286 rac-trans-1,2-1-[rac-trans-(1,2)-5,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane 287 rac-trans-1,2-1-[rac-trans-(1,2)-5,7-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine 288 rac-trans-1,2-1-[rac-trans-(1,2)-6,7-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane 289 rac-trans-1,2-1-[rac-trans-(1,2)-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine 290 rac-trans-1,2-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperazine 291 rac-trans-1,2-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine 292 rac-trans-1,2-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine 293 rac-trans-1,2-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine 294 rac-trans-1,2-1-[rac-trans-(1,2)-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine 295 trans-1S,2S1-[trans-(1S,2S)-4,6-dichloro-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane 296 trans-1S,2S1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]-4-methylpiperazine 297 trans-1S,2S1-[trans-(1S,2S)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]-4-methylpiperazine 298 trans-1S,2S-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane 299 trans-1S,2S-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′epimer1-methanesulfonylphenoxy)indan-2-yl]-3-propylpiperidin-3- ylamine 300trans-1S,2S- 1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′epimer2-methanesulfonylphenoxy)indan-2-yl]-3-propylpiperidin-3- ylamine 301trans-1S,2S- 1-[trans-(1S,2S)-4,6-dichloro-1-(4- rac-3′-methanesulfonylphenoxy)indan-2-yl]-3- trifluoromethylpiperazine 302trans-1S,2S- 1-[trans-(1S,2S)-4,6-dichloro-1-(4- rac-3′-methanesulfonylphenoxy)indan-2-yl]-3-trifluoromethylpyrrolidin-3-ylamine 303 trans-1S,2S1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-(2-fluoroethyl)- [1,4]diazepane 304trans-1S,2S 1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-(2-methoxyethyl)- [1,4]diazepane305 trans-1S,2S 1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methyl- [1,4]diazepane 306trans-1S,2S 1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methylpiperazine 307 trans-1S,2S1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]azetidin-3-ol 308 trans-1S,2S1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine 309 trans-1S,2S-1-{(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperazine 310 trans-1S,2S-1-{2-chloro-5-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one 311 trans-1S,2S-1-{2-chloro-5-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3- methylimidazolidin-2-one312 trans-1S,2S-1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]-2-methylphenyl}-3-methyl-1,3- dihydroimidazol-2-one313 trans-1S,2S-1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3- dihydroimidazol-2-one314 trans-1S,2S-1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]-4-fluorophenyl}-3-methylimidazolidin-2- one 315trans-1S,2S- 1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-3′R- yl)indan-1-yloxy]phenyl}pyrrolidin-2-one 316 trans-1S,2S-1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione 317 trans-1S,2S-1-{3-[(1S,2S)-4,6-difluoro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3- dihydroimidazol-2-one318 trans-1S,2S- 1-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one 319 trans-1S,2S-1-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3- methylimidazolidin-2-one320 trans-1S,2S- 1-{3-[trans-(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3- methylimidazolidin-2-one321 trans-1S,2S- 1-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2- one 322trans-1S,2S- 1-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine- 2,5-dione 323trans-1S,2S- 1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-3′R- yl)indan-1-yloxy]-3-fluorophenyl}-1,3-dihydroimidazol-2- one 324trans-1S,2S- 1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-3′R- yl)indan-1-yloxy]-3-fluorophenyl}-2,6-dimethyl-1H- pyridin-4-one325 trans-1S,2S-1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]phenyl}-1,3-dihydroimidazol-2-one 326 rac-trans-1,2-1-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)- 3′R-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}pyrrolidine- 2,5-dione 327rac-trans-1,2- 1-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)- 3′S-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3,5- difluorophenyl}propan-1-one328 rac-trans-1,2- 1-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-3′S- 1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}pyrrolidine- 2,5-dione329 trans-1S,2S- 1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one 330 trans-1S,2S-1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3-methylimidazolidin-2-one 331 trans-1S,2S-1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one 332 trans-1S,2S-1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3- methylimidazolidin-2-one333 trans-1S,2S- 1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2- one 334trans-1S,2S- 1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine- 2,5-dione 335trans-1S,2S- 1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one 336 trans-1S,2S-1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2- one 337trans-1S,2S- 1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine- 2,5-dione 338trans-1S,2S- 1-{4-chloro-3-[(1S,2S)-4,6-difluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one 339 trans-1S,2S-1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one 340 trans-1S,2S-1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3- methylimidazolidin-2-one341 trans-1S,2S- 1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2- one 342rac-trans-1,2- 1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-rac-3′- yl}pyrrolidin-3-ylamine 343 rac-trans-1,2-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-4-ylamine 344 trans-1S,2S-1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-[1,4]diazepane 345 trans-1S,2S1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-methyl- [1,4]diazepane 346trans-1S,2S 1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}-4-methyl-[1,4]diazepane 347 trans-1S,2S1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-[1,4]diazepane 348 trans-1S,2S-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-(2-methoxyethyl)-[1,4]diazepane 349 trans-1S,2S-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-methyl- [1,4]diazepane 350trans-1S,2S- 1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylisoxazol-4-yl)phenoxy]indan-2-yl}-4-(2-methoxyethyl)- [1,4]diazepane 351trans-1S,2S- 1-Cyclopropyl-4-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine 352 rac-trans-1,2-1-methyl-3-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-1,3-dihydroimidazol-2-one 353 trans-1S,2S-2-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-5- chlorobenzamide354 trans-1S,2S- 2,2,2-trifluoro-N-{(R)-1-[trans-(1S,2S)-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3- yl}acetamide 355rac-trans-1,2- 2,3-dichloro-4-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)benzenesulfonamide 356 rac-trans-1,2-2,3-dichloro-4-(rac-trans-(1,2)-2-dimethylaminoindan-1-yloxy)benzenesulfonamide 357 rac-trans-1,2-2,3-dichloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 358 rac-trans-1,2-2,3-dichloro-4-(rac-trans-(1,2)-4,6-dichloro-2-morpholin-4-ylindan-1-yloxy)benzenesulfonamide 359 rac-trans-1,2-2,3-dichloro-4-[rac-trans-(1,2)-2-((R)-3- 3′R-methoxypyrrolidin-1-yl)indan-1- yloxy]benzenesulfonamide 360rac-trans-1,2- 2,3-dichloro-4-[rac-trans-(1,2)-2-(methylpiperidin-3-rac-3′- ylamino)indan-1-yloxy]benzenesulfonamide 361 trans-1S,2S-2,3-dichloro-4-[trans-(1S,2S)-2-(3-hydroxy-piperidin-1- rac-3′-yl)indan-1-yloxy]benzenesulfonamide 362 rac-trans-1,2-2,3-dichloro-N,N-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 363 rac-trans-1,2-2-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]isothiazolidine 1,1-dioxide 364 rac-trans-1,2-2-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1- yloxy)phenyl]thiazole365 rac-trans-1,2-2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]-5-chlorobenzamide 366 rac-trans-1,2-2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]-5-chlorobenzonitrile 367 rac-trans-1,2-2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]-6-fluorobenzonitrile 368 rac-trans-1,2-2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]benzamide 369 rac-trans-1,2-2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4- 3′S-tetrahydronaphthalen-1-yloxy]-5-bromobenzonitrile 370 rac-trans-1,2-2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4- 3′S-tetrahydronaphthalen-1-yloxy]-5-chlorobenzamide 371 rac-trans-1,2-2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4- 3′S-tetrahydronaphthalen-1-yloxy]-5-chlorobenzonitrile 372 rac-trans-1,2-2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4- 3′S-tetrahydronaphthalen-1-yloxy]-6-fluorobenzonitrile 373 rac-trans-1,2-2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4- 3′S-tetrahydronaphthalen-1-yloxy]benzamide 374 rac-trans-1,2-2-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan- rac-3′-1-yloxy]-6-fluorobenzonitrile 375 rac-trans-1,2-2-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1- rac-3′-yloxy]-5-chlorobenzonitrile 376 rac-trans-1,2-2-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-5-chlorobenzonitrile 377 rac-trans-1,2-2-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole 378 trans-1S,2S-2-[trans-(1S,2S)-4,6-dichloro-1-(4- rac-3′-methanesulfonylphenoxy)indan-2-yl]-2,7-diaza- spiro[4.4]nonane 379trans-1S,2S- 2-{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4- 3′R-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamino}- ethanol 380rac-trans-1,2- 2-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)- 3′R-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}-N,N- dimethylacetamide 381rac-trans-1,2- 2-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-3′R- 1-yloxy]phenyl}thiazole-4-carbonitrile 382 rac-trans-1,2-2-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)- 3′S-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}-N,N- dimethylacetamide 383rac-trans-1,2- 2-{4-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepan-1-yl}- ethanol 384rac-trans-1,2- 2-{4-[rac-trans-(1,2)-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazin-1-yl}- ethanol 385trans-1S,2S 2-{4-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepan-1-yl}- ethanol 386rac-trans-1,2- 2-{5-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-rac-3′- yl)indan-1-yloxy]-1H-indol-3-yl}acetamide 387 rac-trans-1,2-2-{5-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1- rac-3′-yloxy]-1H-indol-3-yl}acetamide 388 rac-trans-1,2-2-{5-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-1H-indol-3-yl}acetamide 389 rac-trans-1,2-2-chloro-4-(2-pyrrolidin-1-ylmethylindan-1- yloxy)benzenesulfonamide 390rac-trans-1,2- 2-chloro-4-(2-pyrrolidin-1-ylmethylindan-1-yloxy)benzoicacid 391 rac-trans-1,2- 2-chloro-4-(2-pyrrolidin-1-ylmethylindan-1-yloxy)benzonitrile 392 rac-trans-1,22-chloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1- yloxy)benzonitrile393 rac-trans-1,2- 2-chloro-4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile 394 trans-1S,2S-2-chloro-4-methanesulfonylaminobenzoic acid (1S,2S)-2-pyrrolidin-1-ylindan-1-yl ester 395 rac-trans-1,2-2-chloro-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline 396 rac-trans-1,2-2-fluoro-4-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)benzonitrile 397 rac-trans-1,2-2-fluoro-4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile 398 rac-trans-1,2-2-fluoro-6-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile 399 rac-trans-1,2-2-methyl-4-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)-1H-indole 400 rac-trans-1,2-3-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline 401 rac-trans-1,2-3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1- yloxy)phenylamine 402rac-trans-1,2 3,5-dichloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 403 rac-trans-1,23,5-dichloro-N,N-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 404 rac-trans-1,2-3,5-dimethyl-4-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole 405 rac-trans-1,2-3,5-dimethyl-4-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole 406 trans-1S,2S-3,5-dimethyl-4-[4-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)-3-trifluoromethylphenyl]-4H-[1,2,4]triazole 407 trans-1S,2S3,5-dimethyl-4-[4-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-isoxazole 408 trans-1S,2S-3,5-dimethyl-4-[5-methyl-2-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]isoxazole 409 rac-trans-1,2-3-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]oxazolidin-2-one 410 rac-trans-1,2-3-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzamide 411 rac-trans-1,2-3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]benzamide 412 rac-trans-1,2-3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4- 3′S-tetrahydronaphthalen-1-yloxy]benzamide 413 rac-trans-1,2-3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1- 3′S-yloxy]benzamide 414 rac-trans-1,2-3-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan- rac-3′-1-yloxy]benzamide 415 rac-trans-1,2-3-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1- rac-3′-yloxy]benzamide 416 trans-1S,2S-3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]-4-fluorophenyl}-5,5- dimethylimidazolidine-2,4-dione417 trans-1S,2S-3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]-4-fluorophenyl}imidazolidine-2,4-dione 418trans-1S,2S- 3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-3′R- yl)indan-1-yloxy]-4-fluorophenyl}oxazolidine-2,4-dione 419trans-1S,2S- 3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-3′R- yl)indan-1-yloxy]phenyl}oxazolidin-2-one 420 trans-1S,2S-3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-5,5-dimethylimidazolidine-2,4-dione 421 trans-1S,2S-3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}imidazolidine-2,4-dione 422 trans-1S,2S-3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione 423 trans-1S,2S-3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione 424 trans-1S,2S-3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidine- 2,4-dione 425trans-1S,2S- 3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-3′R- yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4- dione 426trans-1S,2S- 3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-3′R- yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione 427 trans-1S,2S-3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]phenyl}oxazolidine-2,4-dione 428 trans-1S,2S-3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]phenyl}thiazolidine-2,4-dione 429 trans-1S,2S-3-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2- one 430trans-1S,2S- 3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione 431 trans-1S,2S-3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione 432 trans-1S,2S-3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethyloxazolidine-2,4-dione 433 trans-1S,2S-3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1- yloxy]phenyl}imidazolidine-2,4-dione 434trans-1S,2S- 3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2- one 435trans-1S,2S- 3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione 436 trans-1S,2S-3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione 437 trans-1S,2S-3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethyloxazolidine-2,4-dione 438 trans-1S,2S-3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1- yloxy]phenyl}imidazolidine-2,4-dione 439trans-1S,2S- 3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2- one 440rac-trans-1,2- 3-chloro-4-(2-piperidin-1-ylmethylindan-1-yloxy)benzenesulfonamide 441 rac-trans-1,2-3-chloro-4-(2-pyrrolidin-1-ylindan-1-yloxy)pyridine 442 rac-trans-1,2-3-chloro-4-(2-pyrrolidin-1-ylmethylindan-1- yloxy)benzenesulfonamide 443rac-trans-1,2- 3-chloro-4-(2-pyrrolidin-1-ylmethylindan-1-yloxy)pyridine444 rac-trans-1,2 3-chloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 445 rac-trans-1,2-3-chloro-4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile 446 trans-1S,2S-3-chloro-4-[trans-(1S,2S)-6-chloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]benzoic acid methyl ester 447rac-trans-1,2 3-chloro-N,N-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 448 rac-trans-1,2-3-Cyclopropyl-5-methyl-4-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole 449 rac-trans-1,2-3-fluoro-4-(2-morpholin-4-ylmethylindan-1- yloxy)benzenesulfonamide 450rac-trans-1,2- 3-fluoro-4-(2-piperidin-1-ylmethylindan-1-yloxy)benzenesulfonamide 451 rac-trans-1,2-3-fluoro-4-(2-pyrrolidin-1-ylindan-1- yloxy)benzenesulfonamide 452rac-trans-1,2- 3-fluoro-4-(2-pyrrolidin-1-ylmethylindan-1-yloxy)benzenesulfonamide 453 rac-trans-1,2-3-methyl-4-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole 454 trans-1S,2S-4-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-3-fluorobenzonitrile 455 trans-1S,2S-4-((1S,2S)-2-pyrrolidin-1-ylindan-1-ylsulfanyl)benzonitrile 456trans-1S,2S- 4-((1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-3-fluorobenzonitrile 457 trans-1S,2S-4-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 458 trans-1S,2S-4-(2,5-dioxopyrrolidin-1-yl)benzoic acid (1S,2S)-2-pyrrolidin-1-ylindan-1-yl ester 459 rac-trans-1,2-4-(2-benzylaminoindan-1-yloxy)-3- fluorobenzenesulfonamide 460rac-trans-1,2- 4-(2-cyclopentylaminoindan-1-yloxy)-3-fluorobenzenesulfonamide 461 trans-1S,2S-4-(2-Oxopyrrolidin-1-yl)benzoic acid (1S,2S)-2-pyrrolidin-1-ylindan-1-yl ester 462 rac-trans-1,2-4-(2-pyrrolidin-1-ylmethylindan-1-yloxy)-3- trifluoromethylpyridine 463rac-trans-1,2-4-(rac-trans-(1,2)-(R)-2-[1,3′]Bipyrrolidinyl-1′-ylindan-1- 3′R-yloxy)benzenesulfonamide 464 rac-trans-1,2-4-(rac-trans-(1,2)-2-azepan-1-ylindan-1- yloxy)benzenesulfonamide 465rac-trans-1,2- 4-(rac-trans-(1,2)-2-piperidin-1-ylindan-1-yloxy)benzenesulfonamide 466 rac-trans-1,2-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1- yloxy)benzenesulfonamide467 rac-trans-1,2-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzoic acid methylester 468 rac-trans-1,2 4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzonitrile 469 rac-trans-1,2-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-N-(2,2,2-trifluoroethyl)benzenesulfonamide 470 rac-trans-1,2-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-N-(3,3,3-trifluoropropyl)benzenesulfonamide 471 rac-trans-1,2-4-(rac-trans-(1,2)-4-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 472 rac-trans-1,2-4-(rac-trans-(1,2)-4-methyl-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 473 rac-trans-1,2-4-(rac-trans-(1,2)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 474 rac-trans-1,2-4-(rac-trans-(1,2)-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 475 rac-trans-1,2-4-(rac-trans-(1,2)-6-methyl-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 476 rac-trans-1,2-4-(rac-trans-(1,2)-7-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 477 trans-1S,2S-4-(trans-(1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-3-fluorobenzonitrile 478 rac-cis-1,2-4-[(1R,2S)-1-(2-chloro-4-nitrophenoxy)indan-2- yl]morpholine 479trans-1S,2S-3′R 4-[(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]-3-fluorobenzonitrile 480 trans-1S,2S-3′R4-[(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]benzenesulfonamide 481 trans-1S,2S-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-ylamino]-N,N-dimethylbenzenesulfonamide 482 trans-1S,2S-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxymethyl]-3-fluorobenzonitrile 483 trans-1S,2S-4-[(1S,2S)-4,6-dichloro-2-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)indan-1-yloxy]benzenesulfonamide 484 trans-1S,2S-4-[(1S,2S)-4,6-dichloro-2-(4,4-difluoropiperidin-1-yl)indan-1-yloxy]benzenesulfonamide 485 trans-1S,2S-4-[(1S,2S)-4,6-dichloro-2-(4-methylpiperazin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile 486 rac-trans-1,2-4-[1-(3-chloropyridin-4-yloxy)indan-2- ylmethyl]morpholine 487rac-trans-1,2- 4-[1-(4-methanesulfonylphenoxy)indan-2-ylmethyl]morpholine 488 rac-trans-1,2-4-[2,3-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 489 trans-1S,2S-4-[2-fluoro-5-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethylisoxazole 490 rac-trans-1,2-4-[3-chloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 491 trans-1S,2S-4-[3-chloro-4-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 492 trans-1S,2S-4-[3-chloro-4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 493 trans-1S,2S4-[3-chloro-4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 494rac-trans-1,2- 4-[3-fluoro-4-(-2-methyl-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 495 rac-trans-1,2-4-[4-((4S,5S)-1,3-dichloro-5-pyrrolidin-1-yl-4,5,6,7-tetrahydrobenzo[c]thiophen-4-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole 496 rac-trans-4,5-4-[4-(1,3-dichloro-5-pyrrolidin-1-yl-4,5,6,7-tetrahydrobenzo[c]thiophen-4-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 497 rac-trans-1,2-4-[4-(rac-trans-(1,2)-3,3-dimethyl-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 498 rac-trans-1,2-4-[4-(rac-trans-(1,2)-5,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 499 trans-1S,2S4-[4-(trans-(1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole 500 trans-1S,2S4-[4-(trans-(1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 501 trans-1S,2S4-[4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole 502 trans-1S,2S4-[4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole 503 trans-1S,2S-4-[5-fluoro-2-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethylisoxazole 504 rac-trans-1,2-4-[rac-trans-(1,2)-2-(Hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-1H-indole 505 rac-trans-1,2-4-[rac-trans-(1,2)-2-(Hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-2,6-dimethylbenzonitrile 506 rac-trans-1,2-4-[rac-trans-(1,2)-1-(2-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]morpholine 507 rac-trans-1,2-4-[rac-trans-(1,2)-1-(4-fluoro-2-isoxazol-5-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]morpholine 508 rac-trans-1,2-4-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]morpholine 509 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]-2,3-difluorobenzonitrile 510rac-trans-1,2- 4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-3′R- tetrahydronaphthalen-1-yloxy]-2-fluorobenzonitrile 511rac-trans-1,2- 4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-3′R- tetrahydronaphthalen-1-yloxy]-3,5-dimethylbenzonitrile 512rac-trans-1,2- 4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-3′R- tetrahydronaphthalen-1-yloxy]-3-chloro-5-methoxy- benzonitrile 513rac-trans-1,2- 4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-3′R- tetrahydronaphthalen-1-yloxy]-3-chlorobenzoic acid methyl ester 514rac-trans-1,2- 4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-3′R- tetrahydronaphthalen-1-yloxy]-3-chlorobenzonitrile 515rac-trans-1,2- 4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-3′R- tetrahydronaphthalen-1-yloxy]-3-fluorobenzonitrile 516rac-trans-1,2- 4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-3′R- tetrahydronaphthalen-1-yloxy]benzonitrile 517 rac-trans-1,2-4′-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]-biphenyl-4-carbonitrile 518 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]-2,3-dichlorobenzenesulfonamide 519 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]-2,3-dichlorobenzenesulfonamide 520 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′Ryloxy]-2,3-dichloro-N,N-dimethylbenzenesulfonamide 521 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]-2-chlorobenzonitrile 522 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]-2-fluorobenzonitrile 523 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]-3-chlorobenzonitrile 524 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]benzamide 525 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]benzamide 526 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-Hydroxymethylpyrrolidin-1- 3′R-yl)indan-1-yloxy]benzenesulfonamide 527 rac-trans-1,2-4-[rac-trans-(1,2)-2-((R)-3-Hydroxypyrrolidin-1-yl)indan- 3′R-1-yloxy]benzenesulfonamide 528 rac-trans-1,2-4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4- 3′S-tetrahydronaphthalen-1-yloxy]-2,3-difluorobenzonitrile 529rac-trans-1,2- 4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-3′S- tetrahydronaphthalen-1-yloxy]-2-chlorobenzonitrile 530rac-trans-1,2- 4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-3′S- tetrahydronaphthalen-1-yloxy]-2-fluorobenzonitrile 531rac-trans-1,2- 4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-3′S- tetrahydronaphthalen-1-yloxy]-3-chlorobenzoic acid methyl ester 532rac-trans-1,2- 4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-3′S- tetrahydronaphthalen-1-yloxy]-3-chlorobenzonitrile 533rac-trans-1,2- 4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-3′S- tetrahydronaphthalen-1-yloxy]-3-fluorobenzonitrile 534rac-trans-1,2- 4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-3′S- tetrahydronaphthalen-1-yloxy]-3-nitrobenzonitrile 535rac-trans-1,2- 4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-3′S- tetrahydronaphthalen-1-yloxy]benzonitrile 536 rac-trans-1,2-4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1- 3′S-yloxy]-2,3-dichlorobenzenesulfonamide 537 rac-trans-1,2-4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1- 3′S-yloxy]benzamide 538 rac-trans-1,2-4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan- rac-3′-1-yloxy]-2,3-dichlorobenzenesulfonamide 539 rac-trans-1,2-4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan- rac-3′-1-yloxy]-2,6-dimethylbenzonitrile 540 rac-trans-1,2-4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan- rac-3′-1-yloxy]-2-chlorobenzonitrile 541 rac-trans-1,2-4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan- rac-3′-1-yloxy]-3-chlorobenzonitrile 542 rac-trans-1,2-4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1- rac-3′-yloxy]-2,3-dichlorobenzenesulfonamide 543 rac-trans-1,2-4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1- rac-3′-yloxy]-3-chlorobenzonitrile 544 rac-trans-1,2-4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1- rac-3′-yloxy]benzamide 545 rac-trans-1,2-4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide 546 rac-trans-1,2-4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-2-chlorobenzonitrile 547 rac-trans-1,2-4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-3-chlorobenzonitrile 548 rac-trans-1,2-4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]benzamide 549 rac-trans-1,2-4-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]morpholine 550 trans-1S,2S-4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6- 3′R-dichloroindan-1-yloxy]-2,3-dichlorobenzenesulfonamide 551 trans-1S,2S-4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6- 3′R-dichloroindan-1-yloxy]-3-fluorobenzonitrile 552 trans-1S,2S-4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]benzenesulfonamide 553 trans-1S,2S-4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin- 3′R-1-yl)indan-1-yloxy]-3-fluorobenzoic acid methyl ester 554 trans-1S,2S-4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin- 3′R-1-yl)indan-1-yloxy]-3-fluorobenzonitrile 555 trans-1S,2S-4-[trans-(1S,2S)-4,6-dichloro-2-((S)-3-hydroxypyrrolidin- 3′S-1-yl)indan-1-yloxy]-3-fluorobenzonitrile 556 trans-1S,2S4-[trans-(1S,2S)-4,6-dichloro-2-(4-methyl-[1,4]diazepan-1-yl)indan-1-yloxy]-3-fluorobenzonitrile 557 trans-1S,2S-4-[trans-(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile 558trans-1S,2S- 4-{3-chloro-4-[trans-(1S,2S)-6-chloro-2-((R)-3- 3′R-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole 559 trans-1S,2S-4-{3-chloro-4-[trans-(1S,2S)-6-chloro-2-((S)-3- 3′S-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole 560 trans-1S,2S-4-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]-3-fluorophenyl}morpholine-3,5-dione 561 trans-1S,2S-4-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-fluoropyrrolidin- 3′R-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole 562trans-1S,2S- 4-{4-[trans-(1S,2S)-4,6-dichloro-2-((S)-2- 2′S-methoxymethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole 563 trans-1S,2S-4-{4-[trans-(1S,2S)-6-chloro-2-((R)-3-fluoropyrrolidin-1- 3′R-yl)indan-1-yloxy]-3-fluorophenyl}-3,5-dimethyl-4H- [1,2,4]triazole 564trans-1S,2S 4-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}morpholine 565trans-1S,2S 4-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2- yl}thiomorpholine1,1-dioxide 566 trans-1S,2S-4-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}morpholine 567 trans-1S,2S-4-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}thiomorpholine 1,1- dioxide 568rac-trans-1,2- 5-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)-1,3-dimethyl-1,3-dihydroindol-2-one 569 rac-trans-1,2-5-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)naphthalen-2-ylamine 570 rac-trans-1,2-5-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline 571 rac-trans-1,2-5-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-3H-isobenzofuran-1-one 572 rac-trans-1,2-5-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-2-methylbenzothiazole 573 rac-trans-1,2-5,7-dimethyl-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline 574 trans-1S,2S-5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]-3,4-dihydro-1H-quinolin-2-one 575 trans-1S,2S-5-[5-fluoro-2-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-1H-pyrazole 576 rac-trans-1,2-5-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-2-methylbenzothiazole 577 rac-trans-1,2-5-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzo[1,3]oxathiol-2-one 578 rac-trans-1,2-5-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4- 3′R-tetrahydronaphthalen-1-yloxy]benzo[1,3]oxathiol-2-one 579 rac-trans-1,2-5-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]benzo[1,3]oxathiol-2-one 580 rac-trans-1,2-5-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4- 3′S-tetrahydronaphthalen-1-yloxy]benzo[1,3]oxathiol-2-one 581 trans-1S,2S-5-[trans-(1S,2S)-4,6-dichloro-1-(4- diastereomer1methanesulfonylphenoxy)indan-2-yl]-1-methyloctahydropyrrolo[3,4-b]pyrrole 582 trans-1S,2S-5-[trans-(1S,2S)-4,6-dichloro-1-(4- diastereomer2methanesulfonylphenoxy)indan-2-yl]-1-methyloctahydropyrrolo[3,4-b]pyrrole 583 rac-trans-1,2-5-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)- 3′R-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}oxazole-4- carboxylic acidethyl ester 584 rac-trans-1,2-5-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)- 3′S-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}oxazole-4- carboxylic acidethyl ester 585 rac-trans-1,2-5-chloro-2-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)benzonitrile 586 rac-trans-1,2-5-fluoro-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline 587 rac-trans-1,2-6-[rac-trans-(1,2)-2-(Hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-1H-indole 588 rac-trans-1,2-7-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)isoquinoline 589 rac-trans-1,2-7-[rac-trans-(1,2)-2-(Hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]isoquinoline 590 rac-trans-1,2-7-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine 591 trans-1S,2S-8-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-5- fluoroquinoline592 trans-1S,2S-8-((1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-5-fluoroquinoline 593 trans-1S,2S-8-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)-5-fluoroquinoline 594 rac-trans-1,2-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline-2-carbonitrile 595 rac-trans-1,2-8-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)quinoline 596rac-trans-1,2- 8-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-3′S- tetrahydronaphthalen-1-yloxy]quinoline-2-carbonitrile 597rac-trans-1,2- benzyl[1-(4-methanesulfonylphenoxy)indan-2-yl]amine 598rac-trans-1,2- C-(1-{rac-trans-(1,2)-1-[4-(2- rac-3′-methoxyethyl)phenoxy]indan-2-yl}pyrrolidin-3- yl)methylamine 599rac-trans-1,2- C-(1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-4-yl)methylamine 600 rac-trans-1,2-C-(1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3- rac-3′-yl)phenoxy]indan-2-yl}pyrrolidin-3-yl)methylamine 601 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(1H-indol-4-yloxy)indan-2- rac-3′-yl]pyrrolidin-3-yl}methylamine 602 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)indan-2- rac-3′-yl]pyrrolidin-3-yl}methylamine 603 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)indan-2-yl]piperidin-4-yl}methylamine 604 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]piperidin-4-yl}methylamine 605 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(2-fluoro-6- rac-3′-methoxyphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine 606 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)indan-2-yl]piperidin-4-yl}methylamine 607 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(2-methoxy-5- rac-3′-methylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine 608 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(2-methylbenzothiazol-5- rac-3′-yloxy)indan-2-yl]pyrrolidin-3-yl}methylamine 609 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]piperidin-4-yl}methylamine 610 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(2-tert-butyl-4- rac-3′-ethylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine 611 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(3-chloro-2-methylphenoxy)indan- rac-3′-2-yl]pyrrolidin-3-yl}methylamine 612 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)indan-2-yl]piperidin-4-yl}methylamine 613 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(3-chloro-5- rac-3′-methoxyphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine 614 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(3-ethoxyphenoxy)indan-2-yl]piperidin-4-yl}methylamine 615 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(3-ethoxyphenoxy)indan-2- rac-3′-yl]pyrrolidin-3-yl}methylamine 616 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-yl}methylamine 617 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2- rac-3′-yl]pyrrolidin-3-yl}methylamine 618 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1- rac-3′-ylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine 619 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-yl}methylamine 620 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(benzo[1,3]dioxol-5-yloxy)indan-2-yl]piperidin-4-yl}methylamine 621 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(benzo[1,3]dioxol-5-yloxy)indan-2- rac-3′-yl]pyrrolidin-3-yl}methylamine 622 rac-trans-1,2-C-{1-[rac-trans-(1,2)-1-(quinolin-4-yloxy)indan-2-yl]piperidin-4-yl}methylamine 623 rac-trans-1,2-Cyclopentyl-[1-(4-methanesulfonylphenoxy)indan-2- yl]amine 624rac-trans-1,2- Cyclopropylmethyl-[1-(4-methanesulfonylphenoxy)indan-2-yl]amine 625 rac-trans-1,2-Diethyl-[rac-trans-(1,2)-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]amine 626 rac-trans-1,2-Diethyl-[rac-trans-(1,2)-1-(3-piperazin-1- ylphenoxy)indan-2-yl]amine627 rac-trans-1,2- Diethyl-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]amine 628 rac-trans-1,2-Diethyl-{rac-trans-(1,2)-1-[4-(2- methoxyethyl)phenoxy]indan-2-yl}amine629 rac-trans-1,2-methyl-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-ylamine 630 rac-trans-1,2-methyl-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-ylamine 631 trans-1S,2S-N-(3-{trans-(1S,2S)-2-[(R)-3-(2- 3′R-fluoroethylamino)piperidin-1-yl]indan-1-yloxy}phenyl)- acetamide 632trans-1S,2S- N-(3-{trans-(1S,2S)-2-[(R)-3-(3,3,3- 3′R-trifluoropropylamino)piperidin-1-yl]indan-1-yloxy}- phenyl)acetamide 633rac-trans-1,2- N,N-diethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzamide 634 rac-trans-1,2-N,N-dimethyl-2-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 635 rac-trans-1,2-N-[2-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1- yloxy)phenyl]acetamide636 rac-trans-1,2- N-[3-(rac-trans-(1,2)-2-azepan-1-ylindan-1-yloxy)phenyl]acetamide 637 rac-trans-1,2-N-[3-(rac-trans-(1,2)-2-diethylaminoindan-1- yloxy)phenyl]acetamide 638rac-trans-1,2- N-[3-(rac-trans-(1,2)-2-dimethylaminoindan-1-yloxy)phenyl]acetamide 639 rac-trans-1,2-N-[3-(rac-trans-(1,2)-2-piperazin-1-ylindan-1- yloxy)phenyl]acetamide640 rac-trans-1,2- N-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzyl]acetamide 641 rac-trans-1,2-N-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1- yloxy)phenyl]acetamide642 rac-trans-1,2- N-[3-(rac-trans-(1,2)-2-thiomorpholin-4-ylindan-1-yloxy)phenyl]acetamide 643 rac-trans-1,2-N-[3-(rac-trans-(1,2)-2-thiomorpholin-4-ylindan-1-yloxy)phenyl]acetamide 644 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4,6-dichloro-2-[1,4]diazepan-1-ylindan-1-yloxy)phenyl]acetamide 645 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4,6-dichloro-2-dimethylaminoindan-1-yloxy)phenyl]acetamide 646 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4,6-dichloro-2-morpholin-4-ylindan-1-yloxy)phenyl]acetamide 647 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide 648 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 649 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 650 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4-chloro-6-fluoro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide 651 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4-chloro-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 652 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 653 rac-trans-1,2-N-[3-(rac-trans-(1,2)-4-methyl-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 654 rac-trans-1,2-N-[3-(rac-trans-(1,2)-5,7-dichloro-2-dimethylaminoindan-1-yloxy)phenyl]acetamide 655 rac-trans-1,2-N-[3-(rac-trans-(1,2)-5-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 656 rac-trans-1,2-N-[3-(rac-trans-(1,2)-5-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 657 rac-trans-1,2-N-[3-(rac-trans-(1,2)-6-chloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide 658 rac-trans-1,2-N-[3-(rac-trans-(1,2)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 659 rac-trans-1,2-N-[3-(rac-trans-(1,2)-6-chloro-4-fluoro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide 660 rac-trans-1,2-N-[3-(rac-trans-(1,2)-6-chloro-4-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 661 rac-trans-1,2-N-[3-(rac-trans-(1,2)-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 662 rac-trans-1,2-N-[3-(rac-trans-(1,2)-7-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide 663 trans-1S,2SN-[3-(trans-(1S,2S)-2-piperidin-1-ylindan-1- yloxy)phenyl]acetamide 664trans-1S,2S N-[3-(trans-(1S,2S)-4,6-dichloro-2-3,8-diazabicyclo[3.2.1]oct-3-ylindan-1- yloxy)phenyl]acetamide 665trans-1S,2S N-[3-(trans-(1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide 666 rac-trans-1,2-N-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1- yloxy)phenyl]acetamide667 rac-trans-1,2-N-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-pyridin-2-yl]acetamide 668 rac-trans-1,2-N-[6-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-pyridin-2-yl]acetamide 669 rac-trans-1,2-N-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]-N,N′,N′-trimethylpropane-1,3-diamine 670 rac-trans-1,2-N-[rac-trans-(1,2)-3-((R)-2-[1,3′]bipyrrolidinyl-1′-ylindan- 3′R-1-yloxy)phenyl]acetamide 671 trans-1S,2S-N-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-N,N′,N′-trimethyl- ethane-1,2-diamine672 trans-1S,2S- N-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-N,N′,N′- trimethylpropane-1,3-diamine673 trans-1S,2S- N-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-N-methyl-methanesulfonamide 674 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]phenyl}acetamide 675 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)- 3′R-1,2,3,4-tetrahydronaphthalen-1-yloxy]-4- propylphenyl}acetamide 676rac-trans-1,2- N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)- 3′R-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}acetamide 677 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-4- 3′R-chloro-6-fluoroindan-1-yloxy]phenyl}acetamide 678 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-6- 3′R-chloro-4-fluoroindan-1-yloxy]phenyl}acetamide 679 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan- 3′R-1-yloxy]phenyl}acetamide 680 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-((R)-3-hydroxymethylpyrrolidin-1- 3′R-yl)indan-1-yloxy]phenyl}acetamide 681 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]phenyl}acetamide 682 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-((R)-3-methoxypyrrolidin-1- 3′R-yl)indan-1-yloxy]phenyl}acetamide 683 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)- 3′S-1,2,3,4-tetrahydronaphthalen-1-yloxy]-4- propylphenyl}acetamide 684rac-trans-1,2- N-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)- 3′S-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}acetamide 685 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan- 3′S-1-yloxy]phenyl}acetamide 686 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1- rac-3′-yl)indan-1-yloxy]phenyl}acetamide 687 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1- rac-3′-yloxy]phenyl}acetamide 688 rac-trans-1,2-N-{3-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]phenyl}acetamide 689 rac-trans-1,2-N-{3-[rac-trans-(1,2)-4,6-dichloro-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1- yloxy]phenyl}acetamide 690trans-1S,2S- N-{3-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6- 3′R-dichloroindan-1-yloxy]phenyl}acetamide 691 trans-1S,2S-N-{3-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)indan-1- 3′R-yloxy]phenyl}acetamide 692 trans-1S,2S-N-{3-[trans-(1S,2S)-2-((R)-3-dimethylaminopiperidin-1- 3′R-yl)indan-1-yloxy]phenyl}acetamide 693 trans-1S,2S-racN-{3-[trans-(1S,2S)-2-(3-amino-3-propylpiperidin-1-yl)- 3′-4,6-dichloroindan-1-yloxy]phenyl}acetamide 694 trans-1S,2S-N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-dimethylaminopiperidin-1-yl)indan-1- yloxy]phenyl}acetamide 695trans-1S,2S- N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxymethylpyrrolidin-1-yl)indan-1- yloxy]phenyl}acetamide 696trans-1S,2S- N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3- 3′R-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide 697 trans-1S,2SN-{3-[trans-(1S,2S)-4,6-dichloro-2-(4-methylpiperazin-1-yl)indan-1-yloxy]phenyl}acetamide 698 trans-1S,2S-N-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-yloxy]phenyl}-N-methylmethanesulfonamide 699 trans-1S,2S-N-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1- 3′R-yl)indan-1-ylsulfanyl]phenyl}acetamide 700 rac-trans-1,2-N-ethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide 701 rac-trans-1,2-tert-butyl-[1-(4-methanesulfonylphenoxy)indan-2- yl]amine 702trans-1S,2S- 2-{[trans-(1S,2S)-4,6-Dichloro-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-methyl-amino}-ethanol 703 rac-trans-1,2-4-(rac-trans-(1,2)-2-Cyclopropylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide 704 trans-1S,2S-2-({trans-(1S,2S)-4,6-Dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}-methyl-amino)-ethanol 705 rac-trans-1,2-Cyclopentylmethyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine 706 rac-cis-1,2-Cyclobutyl-[rac-cis-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine 707 trans-1S,2S-(4-Methanesulfonyl-phenyl)-((1S,2S)-2-pyrrolidin-1-yl- indan-1-yl)-amine708 rac-trans-1,2- Cyclobutyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine 709 rac-trans-1,2-4-(rac-trans-(1,2)-2-Cyclobutylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide 710 trans-1S,2S-2-Chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-benzoic acid 3′R-trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxy-pyrrolidin-1- yl)-indan-1-ylester 711 rac-trans-1,2-Cycloheptyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine 712 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-ethyl-4-methyl- 3′R-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol 713 rac-trans-1,2-4-(rac-trans-(1,2)-2-Cycloheptylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide 714 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-isopropyl-4- 3′R-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol 715trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3-isopropyl-5- 3′R-methyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin- 3-ol 716trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3-ethyl-5- 3′R-isopropyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}- pyrrolidin-3-ol 717rac-trans-1,2- Cyclobutylmethyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine 718 rac-trans-1,2-4-[rac-trans-(1,2)-2-(Cyclobutylmethyl-amino)-indan-1-yloxy]-3-fluoro-benzenesulfonamide 719 trans-1S,2S-(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(2-ethyl-4-methyl- 3′R-imidazol-1-yl)-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3- ol 720trans-1S,2S- (R)-1-{trans-(1S,2S)-6-Chloro-4-fluoro-1-[4-(2-isopropyl-3′R- 4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3- ol 721trans-1S,2S- (R)-1-{trans-(1S,2S)-6-Chloro-4-fluoro-1-[4-(3-isopropyl-3′R- 5-methyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}- pyrrolidin-3-ol722 trans-1S,2S-(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(3-ethyl-5-isopropyl- 3′R-[1,2,4]triazol-4-yl)-phenoxy]-4-fluoro-indan-2-yl}- pyrrolidin-3-ol 723rac-trans-1,2- (1-Ethyl-propyl)-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine 724 trans-1S,2S-(R)-1-{trans-(1S,2S)-1-[4-(4-tert-Butyl-2-isopropyl- 3′R-imidazol-1-yl)-phenoxy]-6-chloro-4-fluoro-indan-2-yl}- pyrrolidin-3-ol725 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[5-(2-ethyl-4-methyl- 3′R-imidazol-1-yl)-2-fluoro-phenoxy]-indan-2-yl}-pyrrolidin-3- ol 726trans-1S,2S- N-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}-N,N′,N′-trimethyl-ethane-1,2-diamine 727 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2,4-dimethyl- 3′R-imidazol-1-yl)-2-fluoro-phenoxy]-indan-2-yl}-pyrrolidin-3- ol 728trans-1S,2S- (R)-1-[trans-(1S,2S)-4,6-Dichloro-1-(4-imidazol-1-yl- 3′R-phenoxy)-indan-2-yl]-pyrrolidin-3-ol 729 trans-1S,2S-(R)-1-{trans-(1S,2S)-1-[4-(4-tert-Butyl-2-methyl-imidazol- 3′R-1-yl)-2-fluoro-phenoxy]-4,6-dichloro-indan-2-yl}-pyrrolidin- 3-ol 730rac-trans-1,2- Cyclopentyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-methyl-amine 731 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2- 3′R-methanesulfonyl-imidazol-1-yl)-phenoxy]-indan-2-yl}- pyrrolidin-3-ol 732trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-isopropyl- 3′R-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol 733 trans-1S,2S-3-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy- 3′R-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-5-methyl-3H-[1,3,4]oxadiazol-2-one 734 rac-trans-1,2-Cyclobutyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-methyl-amine 735 trans-1S,2S-3-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy- 3′R-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-3H- [1,3,4]oxadiazol-2-one 736trans-1S,2S- 2-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy- 3′R-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-4-ethyl-2,4-dihydro-[1,2,4]triazol-3-one 737 trans-1S,2S-2-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy- 3′R-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-4-ethyl-5-methyl-2,4-dihydro-[1,2,4]triazol-3-one 738 trans-1S,2S-(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(2,4-dimethyl- 3′R-imidazol-1-yl)-2-fluoro-phenoxy]-4-fluoro-indan-2-yl}- pyrrolidin-3-ol739 trans-1S,2S- (R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[2-fluoro-4-(2-3′R- methanesulfonyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol 740 trans-1S,2S-1-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy- 3′R-pyrrolidin-1-yl)-indan-1-yloxy]-3-fluoro-phenyl}-1H-imidazole-2-carboxylic acid methyl ester 741 trans-1S,2S-4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin- 3′R-1-yl)-indan-1-yloxy]-3-fluoro-benzenesulfonamide 742 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(4-methyl- 3′R-piperazine-1-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol 743trans-1S,2S- 4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-3′R- 1-yl)-indan-1-yloxy]-benzenesulfonamide 744 trans-1S,2S-(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(morpholine-4- 3′R-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol 745 trans-1S,2S-1-{5-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy- 3′R-pyrrolidin-1-yl)-indan-1-yloxy]-2-fluoro-phenyl}-3-methyl-1,3-dihydro-imidazol-2-one 746 trans-1S,2S-Cyclopentyl-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}- amine 747trans-1S,2S- Cyclopentyl-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine 748 trans-1S,2S-4-(trans-(1S,2S)-4,6-Dichloro-2-cyclopentylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide 749 trans-1S,2S-{trans-(1S,2S)-6-Chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-4-fluoro-indan-2-yl}-cyclopentyl- amine 750trans-1S,2S- 4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-benzenesulfonamide 751 trans-1S,2S-[trans-(1S,2S)-6-Chloro-4-fluoro-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-cyclopentyl-amine 752 trans-1S,2S-1-[4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-phenyl]-pyrrolidine-2,5- dione 753trans-1S,2S- 3-[4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-phenyl]-imidazolidine-2,4- dione 754trans-1S,2S- {trans-(1S,2S)-6-Chloro-4-fluoro-1-[2-fluoro-4-(2-methanesulfonyl-imidazol-1-yl)-phenoxy]-indan-2-yl}- cyclopentyl-amine755 trans-1S,2S- 1-[4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-phenyl]-3-methyl-1,3-dihydro-imidazol-2-one 756 trans-1S,2S-1-[3-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-4-fluoro-phenyl]-3-methyl-1,3-dihydro-imidazol-2-oneand the pharmaceutically acceptable salts thereof.

Because of their NHE-inhibitory properties, the compounds of the formulaI are suitable for the prevention and treatment of diseases which arecaused by activation of or by an activated NHE, and of diseases whichare caused secondarily by the NHE-related damage. The compounds of theformula I can also be employed for the treatment and prevention ofdiseases where NHE is only partially inhibited, for example by use of alower dosage. Where mention is made hereinafter of compounds of theformula I or of compounds of the invention, the pharmaceuticallyacceptable salts thereof are always included even if this is notexplicitly mentioned.

Accordingly, the present invention further relates to the use of thecompounds of the formula I for the prevention and treatment of acute orchronic diseases in veterinary and human medicine.

As a consequence of their pharmacological effects, the compounds of theformula I are particularly suitable for leading to an improvement inrespiratory drive. They can therefore be used for the treatment ofimpaired respiratory conditions like those which may occur for examplein the following clinical conditions and diseases: impaired centralrespiratory drive (e.g. central sleep apneas, sudden infant death,postoperative hypoxia), muscle-related respiratory impairments,respiratory impairments following long-term ventilation, respiratoryimpairments associated with adaptation to high altitude, obstructive andmixed form of sleep apneas, sleep-related respiratory impairments, sleephypoventilation syndrome, upper airway resistance syndrome, acute andchronic pulmonary diseases with hypoxia and hypercapnia.

In addition, the compounds increase the tone of the muscles of the upperairways, so that snoring is suppressed. Said compounds are thereforeused in particular for the prevention and treatment of sleep apneas, ofthe upper airway resistance syndrome, of muscle-related respiratoryimpairments and for the prevention and treatment of snoring.

Combination of an NHE inhibitor of the formula I with a carbonicanhydrase inhibitor (e.g. acetazolamide) is in this connection alsoadvantageous, the latter bringing about a metabolic acidosis and thusitself increasing respiratory activity, so that an enhanced effect andreduced use of active ingredient can be achieved.

The compounds of the invention preserve, as a result of theirNHE3-inhibitory effect, the cellular energy reserves which are rapidlyexhausted during toxic and pathogenic events and thus lead to celldamage or cell death. In this connection, the energy-costlyATP-consuming sodium absorption in the proximal tubule temporarilyceases under the influence of NHE3 inhibitors, and the cell is thus ableto survive an acute pathogenic, ischemic or toxic situation. Thecompounds are therefore suitable for example as pharmaceuticals for thetreatment of ischemic situations, especially ischemic noxae, for exampleof acute renal failure.

The compounds are further suitable also for the treatment of chronicrenal disorders and types of nephritis which lead, as a consequence ofincreased protein excretion, to chronic renal failure. Accordingly, thecompounds of the formula I are suitable for the manufacture of amedicament for the treatment of late damage from diabetes, of diabeticnephropathy and of chronic renal disorders, in particular of all renalinflammations (nephritides) which are associated with an increasedprotein/albumin excretion.

It has emerged that the compounds of the invention have an inhibitingand delaying effect on glucose absorption and thereby are able to reducethe blood glucose and have a beneficial influence on further metabolicparameters such as triglycerides. Because of these effects, thecompounds of the invention can advantageously be used for the preventionand therapy of the metabolic syndrome, diabetes mellitus andhyperlipidemias.

It has emerged that the compounds of the invention have a mild laxativeeffect and accordingly can also be used advantageously as laxatives orif there is a risk of constipation and for the prophylaxis and treatmentof constipation.

The compounds of the invention can further be used advantageously forthe prevention and therapy of acute and chronic disorders of theintestinal tract which are induced for example by ischemic states in theintestinal region and/or by subsequent reperfusion or by inflammatorystates and events. Such complications may arise for example throughdeficient intestinal peristalsis as are frequently to be observed forexample following surgical interventions, associated with constipationor greatly reduced intestinal activity.

It is possible with the compounds of the invention to prevent theformation of gallstones.

In general, the NHE inhibitors described herein can beneficially becombined with other compounds which likewise regulate the intracellularpH, those suitable being inhibitors of the enzyme group of carbonicanhydratases, inhibitors of systems which transport bicarbonate ions,such as the sodium-bicarbonate cotransporter (NBC) or thesodium-dependent chloride-bicarbonate exchanger (NCBE), and with otherNHE inhibitors having an inhibitory effect on other NHE subtypes, ascombination partners, because they may enhance or modulate thepharmacologically relevant pH-regulating effects of the NHE inhibitorsdescribed herein.

Since sodium ion/proton exchange is significantly elevated in essentialhypertensives, the compounds of the formula I are suitable for theprevention and treatment of high blood pressure and of cardiovasculardisorders. They can be used in this connection alone or with a suitablecombination partner for the treatment of high blood pressure and for thetreatment of cardiovascular disorders. Thus, for example, one or morediuretics having a thiazide-like action, loop diuretics, aldosterone andpseudoaldosterone antagonists such as hydrochlorothiazide, indapamide,polythiazide, furosemide, piretanide, torasemide, bumetanide, amiloride,triamterene, spironolactone or eplerone, can be combined with compoundsof the formula I. The NHE inhibitors of the present invention canmoreover be used in combination with calcium antagonists such asverapamil, diltiazem, amlodipine or nifedipine, and with ACE inhibitorssuch as, for example, ramipril, enalapril, lisinopril, fosinopril orcaptopril. Further beneficial combination partners are also β blockerssuch as metoprolol, albuterol etc., antagonists of the angiotensinreceptor and its receptor subtypes such as losartan, irbesartan,valsartan, omapatrilat, gernopatrilat, endothelin antagonists, renininhibitors, adenosine receptor agonists, inhibitors and activators ofpotassium channels such as glibenclamide, glimepiride, diazoxide,cromokalim, minoxidil and derivatives thereof, activators of themitochondrial ATP-sensitive potassium channel (mitoK(ATP) channel),inhibitors of further potassium channels such as of Kv1.5 etc.

NHE inhibitors are additionally suitable for the treatment ofnon-insulin-dependent diabetes (NIDDM), in which case for exampleinsulin resistance is restrained. It may in this connection bebeneficial, for enhancing the antidiabetic efficacy and quality of theeffect of the compounds of the invention, to combine them with abiguanide such as metformin, with an antidiabetic sulfonylurea such asglyburide, glimepiride, tolbutamide etc., with a glucosidase inhibitor,with a PPAR agonist such as rosiglitazone, pioglitazone etc., with aninsulin product of different administration form, with a DB4 inhibitor,with an insulin sensitizer or with meglitinide.

Said compounds are therefore advantageously used alone or in combinationwith other pharmaceuticals or active ingredients for the manufacture ofa medicament for the treatment or prophylaxis of impairments ofrespiratory drive, of respiratory disorders, sleep-related respiratorydisorders, sleep apneas, of snoring, of acute and chronic renaldisorders, of acute renal failure and of chronic renal failure, ofimpairments of bowel function, of high blood pressure, of essentialhypertension.

The compounds of the invention are further suited for treating cysticfibrosis (mucoviscidosis). Lack of the CFTR protein in cystic fibrosishas been shown to activate the NHE3 leading to an excessive absorptionof salt and water in the intestine (gut, gall system, pancreas), seminalfluid, the upper airway and the lung. This leads to a drying of thefeces (obstipation), of the intestinal secretions and of the lung fluidwith the consequence of a viscoelastic mucus in the lung that gives riseto frequent airway infections and finally to a deterioration of lungfunction which is an important cause for mortality. Moreover, anexcessive activation of the NHE3 leads to a more acidic environment inthe gut impairing digestion (maldigestion) and a more acidic pH of thelung fluid favouring bacterial infections (particularly Pseudomonasaeruginosa infections). Compounds can be administered systemically (peros, i.m., i.v., s.c.) or given as an inhalation for a treatment of theairway and lung symptoms.

Compounds have a potential in acute and chronic airway diseases andinfections as mucolytics by inhibiting salt and water absorption in theupper airway and in the lungs leading to a liquidification of the mucus.This effect is of therapeutic utility in acute and chronic viral,bacterial and fungal infections of the upper airways and the lungs andin chronic inflammatory lung diseases such as asthma and COPD.

The invention further relates to the use of the compounds of the formulaI and the pharmaceutically acceptable salts thereof for the use asmedicaments and to a medicament comprising compounds of the formula I orpharmaceutically acceptable salts thereof.

The invention further relates to the use of these compounds or thepharmaceutically acceptable salts for the treatment or prophylaxis ofdisorders by complete or partial inhibition of the Na⁺/H⁺ exchange byNHE3.

Therefore, a further aspect of the invention is the use of a compound ofthe formula I and/or its pharmaceutically acceptable salts as claimed inone or more of claims 1 to 15 alone or in combination with otherpharmaceuticals or active ingredients for the manufacture of amedicament for the treatment or prophylaxis of impairments ofrespiratory drive, of respiratory disorders, of sleep-relatedrespiratory disorders, sleep apneas, of snoring, of cystic fibrosis,upper and lower airway diseases that are associated with viscous mucus,of acute and chronic renal disorders, of acute renal failure and ofchronic renal failure, of impairments of bowel function, ofconstipation, of high blood pressure, of essential hypertension, ofcardiovascular disorders, of central nervous system disorders, ofdisorders resulting from CNS overexcitability, epilepsy and centrallyinduced spasms or of anxiety states, depressions and psychoses, ofischemic states of the peripheral or central nervous system or ofstroke, degenerative CNS disorders, reduced memory capacity, dementiaand Alzheimer's disease, and of acute and chronic damage and disordersof peripheral organs or limbs caused by ischemic or reperfusion events,of atherosclerosis, of impairments of lipid metabolism, ofhyperlipidemias, of thromboses, of diabetes mellitus, of impairments ofbiliary function, of infestation by ectoparasites, of disordersresulting from endothelial dysfunction, of protozoal diseases, ofmalaria, of states of shock or of diabetes and late damage from diabetesor of diseases in which cell proliferation represents a primary orsecondary cause, for the preservation and storage of transplants forsurgical procedures, for use in surgical operations and organtransplantations and for maintaining health and prolonging life.

The invention also relates to medicines for human, veterinary orphytoprotective use comprising an effective amount of a compound of theformula I and/or of a pharmaceutically acceptable salt thereof, as wellas medicines for human, veterinary or phytoprotective use comprising aneffective amount of a compound of the formula I and/or of apharmaceutically acceptable salt thereof alone or in combination withone or more other pharmacological active ingredients or pharmaceuticals.

Pharmaceuticals which comprise a compound of the formula I or thepharmaceutically acceptable salts thereof can be administered forexample orally, parenterally, intramuscularly, intravenously, rectally,nasally, pharyngeally, by inhalation, subcutaneously or by a suitabletranscutaneous dosage form, the preferred administration depending onthe respective manifestation of the disorder. The compounds of theformula I can moreover be used alone or together with pharmaceuticalexcipients, specifically both in veterinary and in human medicine and incrop protection. The pharmaceuticals comprise active ingredients of theformula I and/or pharmaceutically acceptable salts thereof generally inan amount of from 0.01 mg to 1 g per dose unit.

The skilled worker is familiar on the basis of his expert knowledge withthe excipients suitable for the desired pharmaceutical formulation.Besides solvents, gel formers, suppository bases, tablet excipients andother active ingredient carriers it is possible to use for exampleantioxidants, dispersants, emulsifiers, antifoams, masking flavors,preservatives, solubilizers or colorants.

For a form for oral administration, the active compounds are mixed withadditives suitable for this purpose, such as carriers, stabilizers orinert diluents, and converted by conventional methods into suitabledosage forms such as tablets, coated tablets, hard gelatin capsules,aqueous, alcoholic or oily solutions. Examples of inert carriers whichcan be used are gum arabic, magnesia, magnesium carbonate, potassiumphosphate, lactose, glucose or starch, especially corn starch. It ismoreover possible for the preparation to take place both as dry and aswet granules. Examples of suitable oily carriers or solvents arevegetable or animal oils, such as sunflower oil or fish liver oil.

For subcutaneous, percutaneous or intravenous administration, the activecompounds used are converted, if desired with the substances usual forthis purpose, such as solubilizers, emulsifiers or further excipients,into solution, suspension or emulsion. Examples of suitable solubilizersare: water, physiological saline or alcohols, e.g. ethanol, propanol,glycerol, as well as sugar solutions such as glucose or mannitolsolutions, or also a mixture of the various solvents mentioned.

Suitable as pharmaceutical formulation for administration in the form ofaerosols or sprays are for example solutions, suspensions or emulsionsof the active ingredient of the formula I in a pharmaceuticallyacceptable solvent such as, in particular, ethanol or water, or amixture of such solvents. The formulation may, if required, alsocomprise other pharmaceutical excipients such as surfactants,emulsifiers and stabilizers, and a propellant gas. Such a preparationnormally comprises the active ingredient in a concentration of about 0.1to 10, in particular of about 0.3 to 3% by weight.

The dosage of the active ingredient of the formula I to be administeredand the frequency of administration depend on the potency and durationof action of the compounds used; additionally also on the nature andseverity of the disease to be treated and on the gender, age, weight andindividual response of the mammal to be treated.

On average, the daily dose of a compound of the formula I for a patientweighing about 75 kg is at least 0.001 mg/kg, preferably 0.1 mg/kg, to amaximum of 30 mg/kg, preferably 1 mg/kg, of body weight. In acutesituations, for example immediately after suffering apneic states athigh altitude, higher doses may also be necessary. Up to 300 mg/kg perday may be necessary in particular on i.v. administration, for examplefor an infarct patient in intensive care. The daily dose can be dividedinto one or more, for example up to 4, single doses.

If the compounds of the formula I comprise one or more acidic or basicgroups or one or more basic heterocycles, the correspondingphysiologically or toxicologically acceptable salts are also included inthe invention, especially the pharmaceutically acceptable salts. Thecompounds of the formula I may thus be deprotonated on an acidic groupand be used for example as alkali metal salts, preferably sodium orpotassium salts, or as ammonium salts, for example as salts with ammoniaor organic amines or amino acids. Compounds of the formula I comprisingat least one basic group can also be prepared in the form of theirphysiologically tolerated acid addition salts, e.g. with the followingacids: from inorganic acids such as hydrochloric acid, sulfuric acid orphosphoric acid or from organic acids such as acetic acid, citric acid,tartaric acid, lactic acid, malonic acid, methanesulfonic acid, fumaricacid. Suitable acid addition salts in this connection are salts of allpharmacologically acceptable acids, for example halides, in particularhydrochlorides, lactates, sulfates, citrates, tartrates, acetates,phosphates, methylsulfonates, p-toluenesulfonates, adipates, fumarates,gluconates, glutamates, glycerolphosphates, maleates and pamoates (thisgroup also corresponds to the physiologically acceptable anions); butalso trifluoroacetates.

The present invention further comprises derivatives of the compounds ofthe formula I, for example solvates, such as hydrates and alcoholadducts, esters, prodrugs and other physiologically acceptablederivatives of the compounds of the formula I, and active metabolites ofthe compounds of the formula I. The invention likewise comprises allcrystal modifications of the compounds of the formula I.

Processes for Preparing Compounds of the Formula I:

General processes suitable for preparing compounds of the generalformula I are described below. The compounds of the formula I can inthis connection be prepared by different chemical processes. The groupsand radicals A, B, L, X, R1, R2, R3, R4 and R5 and index p mentioned inthe following methods have the abovementioned meaning unless they areexplicitly defined otherwise.

ABBREVIATIONS

HPLC high performance liquid chromatographyLC liquid chromatographyRt retention timeTHF tetrahydrofuranTFA trifluoroacetic acidFA formic acidDMSO dimethyl sulfoxideabs. absoluteDMF dimethylformamideAcN acetonitrilert room temperaturemin. minutesh hour(s)CI chemical ionizationES=ESI electrospray ionizationdba dibenzylideneacetone

Method A:

For example as shown in scheme A that starting from epoxides of theformula II which initially, after epoxide ring opening with an amine ofthe formula HNR3R4, afford a corresponding 1-amino 2-ol intermediate ofthe formula III, which is subsequently subjected to a Mitsunobu reactionwith an aryl or heteroaryl compounds B—OH which may be substituted oneor more times by R5. Phenols are preferably employed in this reaction.It is also possible alternatively to employ aryl or heteroaryl thiolsB—SH or aryl- or heteroarylcarboxylic acids B—CO₂H which may besubstituted one or more times by R5 in order to obtain the corresponding—S— or —CO₂H— bridged derivatives. Mitsunobu reactions are, as is known,carried out in the presence of a phosphine, e.g. such astriphenylphosphine and of azodicarboxylic esters such as, for example,diisopropyl azodicarboxylate in inert solvents such as acetonitrile,CH₂Cl₂ or tetrahydrofuran. In the case of 1-amino 2-ols of the formulaIII, this entails migration of the amine residue NR3R4 into position 2of the basic structure (J. Org. Chem. 1991, 56, 670-672).

in which L is a covalent bond, —C(═O)— and X is O,or L is a covalent bond and X is S.

It is possible in this way to prepare a large number of compounds I,preferably those in which the two substituents are in a transconfiguration relative to one another. If one of the radicals R3 and R4of the amine substituent is to be replaced by a further functional groupsuch as, for example, a hydroxy group or an amino group, care must betaken where appropriate to protect such groups during the Mitsunobureaction. This can take place for example by trialkyl or triarylsilylgroups in the case of OH groups or by the BOC protective groups in thecase of amino groups. After the Mitsunobu reaction, the protective groupis then removed again, for example by treatment with hydrochloric acidor trifluoroacetic acid, to obtain the compounds of the formula I. Afterdeprotection, these functional groups can be further modified whereappropriate, for example by alkylation with an alkylating agent or byacylation and subsequent reduction in order to obtain further compoundsI.

The starting materials employed in scheme A, such as the epoxides of theformula II, the amine NHR3R4, and the hydroxyaryls or hydroxyheteroarylsor the thiol derivatives thereof are either commercially available,known from the literature or can be synthesized easily in analogy tocompounds known from the literature. A few suitable synthetic schemesfor such starting materials are reproduced by way of example in theexperimental section.

Method B:

A further method for preparing compounds of the formula I is depicted inscheme B.

In this process, 2-bromo 1-one compounds of the formula IV are reactedwith amines of the formula R3-NH—R4 to give the corresponding aminoketones V. The keto group is then reduced to the 1-hydroxy group,resulting in the intermediates of the formula VI. It is possible in thisconnection for products VI with both the cis and the trans configurationwith regard to centers 1 and 2 to be produced. The resultingintermediates of the formula VI are then arylated by nucleophilicaromatic substitution on aryl or heteroaryl compounds B—Y, where B maybe substituted one or more times by R5, using a strong base such as, forexample, sodium hydride or powdered NaOH in an inert solvent such asDMSO. Y is in this connection a suitable leaving group such as, forexample, fluorine, chlorine or trifluoromesyloxy. If the radicals R3 andR4 are substituted for example by amino or hydroxy groups, these shouldbe protected where appropriate by base-stable protective groups such as,for instance, alkyl- or aryl-substituted silyl groups.

It is also possible with this process to have recourse to a large extentto known or commercially available bromo ketones IV or can easily beobtained for example by bromination under standard conditions from theappropriate ketones.

Method C:

A further process relates to those compounds of the formula I in whichthe amine group NR3R4 is linked via a carbon-containing bridge toposition 2, that is q is 1 in general formula I.

In this case, ketones of the formula VII are reacted with formamideacetals, preferably N,N-dimethylformamide dimethyl acetal, in order toobtain the corresponding dimethylaminomethylene compounds of the formulaVIII. The dimethylamino group can be replaced in the next stage by otheramino groups to give aminomethylene compounds of the formula IX. Thiscan take place for example by heating compounds of the formula VIII inDMF in the presence of excess amine HNR3R4. Subsequent reduction, forexample by sodium borohydride in methanol, ordinarily affords mixturesof stereoisomeric amine alcohols of the formula X which can, whereappropriate after separation into the individual components, be arylatedin analogy to the illustration in scheme B to give the compounds I ofthe invention.

Method D

A further process for preparing compounds of the formula I isrepresented in scheme D. 1-Amino-2-indanol III and analogs thereof arereacted in an inert solvent such as, for example, THF in the presence ofa suitable azide source such as, for example, diphenylphosphoryl azide(DPPA) under Mitsunobu conditions. In this case too, the amine residuemigrates from position 1 to position 2 as described in scheme A. Thereis preferential formation of 1-azido-2-indanamines with thetransconfiguration, which are reacted in situ after addition of suitablereducing agents such as, for example, LiAlH₄ directly to give diaminesof the general formula XI with the trans configuration. In order obtaincompounds of the formula I, compounds of the formula XI are arylatedwith palladium catalysis for example under Buchwald conditions knownfrom the literature (J. Am. Chem. Soc. 1997, 8451-8458).

Method E

A further process for preparing compounds of the formula I is depictedin scheme E. Benzoic esters I which are synthesized as in scheme A arehydrolyzed in a known manner to give compounds of the general formulaVI. This takes place for example in solvents such as acetone/watermixtures and using suitable bases such as sodium hydroxide. Compounds ofthe formula VI are then reacted with suitable alkylating agents such as,for example, benzyl bromides in solvents such as, for example, THF inthe presence of suitable bases such as sodium hydride. The compound Iobtained in this way is available where appropriate for furthermanipulations.

in which L is an alkylene bridge.

If the compounds I contain further functional groups such as, forexample, alcohols or amines, these can be reacted further in a knownmanner as in scheme F. Suitable examples are acylations, alkylations oracylation/reduction sequences. The procedure is described in theexperimental section by means of exemplary embodiments.

Method G:

A further process relates to those compounds of the formula I in whichone or two substituents R3 or R4 at the amine group NR3R4 equalshydrogen, that is R3=H or R3=R4=H in general formula I.

In this process allyl amines XI, which for example can be synthesizedfollowing method A, are deprotected using nucleophiles, e.g. such asthiosalicylic acid or dimethylbarbituric acid, in inert solvents such asCH₂Cl₂ or THF. The reaction is catalyzed by Pd. Suitable Pd sources arefor example Pd(PPh₃)₄ or Pd(dba)₂ in the presents of stabilizing ligandssuch as bis(diphenylphosphino)butane. In case of bisallyl amines(R3=R4=allyl) both allyl groups can be cleaved using at least 2equivalents of a suitable nucleophile and prolonged reaction times.Compounds of the general formula I, which are synthesized followingmethod G, are available for further manipulations e.g. acylation oralkylation.

EXEMPLARY EMBODIMENTS

Reference in the following procedures to equivalents refers to theindication of the amount of substance unless explicitly mentionedotherwise.

The following LC methods were used to analyze the exemplary embodiments.

Method Conditions LC method 1: YMC Jsphere H80, 33 * 2, 4μ, H2O + 0.05%TFA:AcN + 0.05% TFA 2:98 (1 min) to 95:5 (5.0 min) to 95:5 (6.25 min);1.0 ml/min, rt LC method 2: YMC Jsphere H80, 33 * 2, 4μ, H2O + 0.05%TFA:AcN + 0.05% TFA 95:5 (0 min) to 95:5 (0.5 min) to 5:95 (3.5 min) to5:95 (4 min); 1.3 ml/min, rt LC method 3: YMC Jsphere H80, 33 * 2, 4μ,H2O + 0.1% FA:AcN + 0.08% FA 95:5 (0 min) to 5:95 (2.5 min) to 5:95 (3min); 1.3 ml/min, rt LC method 4: YMC Jsphere H80, 33 * 2, 4μ, H2O +0.05% TFA:AcN + 0.05% TFA 95:5 (0 min) to 5:95 (2.5 min) to 5:95 (3min); 1.3 ml/min, rt LC method 5: YMC Jsphere H80, 33 * 2, 4μ, H2O +0.05% FA:AcN + 0.05% FA 95:5 (0 min) to 5:95 (2.5 min); 1.0 ml/min, rtLC method 6: YMC Jsphere H80, 33 * 2, 4μ, H2O + 0.05% TFA:AcN + 0.05%TFA 5:95 (0 min) to 95:5 (3.4 min) to 95:5 (4.4 min); 1.0 ml/min, rt LCmethod 7: YMC Jsphere H80, 33 * 2, 4μ, H2O + 0.05% TFA:AcN + 0.05% TFA95:5 (0 min) to 5:95 (2.5 min); 1.3 ml/min, rt LC method 8: WatersXBridge C18 4.6 * 50 mm; 2.5μ, H2O + 0.1% FA:AcN + 0.08% FA 97:3 (0 min)to 40:60 (3.5 min) to 2:98 (4 min) to 2:98 (5 min) to 97:3 (5.2 min) to97:3 (6.5 min); 1.3 ml/min, rt LC method 9: WatersXBridge C18, 4, 6 *50, 2, 5μ, H2O + 0.05% TFA:AcN + 0.05% TFA 95:5 (0 min) to 95:5 (0.3min) to 5:95 (3.5 min) to 5:95 (4 min); 1.7 ml/min, 40° C. LC method 10:YMC Jsphere H80, 33 * 2, 4μ, H2O + 0.05% TFA:AcN + 0.05% TFA 95:5 (0min) to 5:95 (2.5 min) to 95:5; 1.3 ml/min, rt LC method 11: YMC JsphereH80, 33 * 2, 4μ, H2O + 0.05% TFA:AcN + 0.05% TFA 95:5 (0 min) to 5:95(2.5 min) to 95:5 (3.2 min); 1.3 ml/min, rt LC method 12: YMC JsphereH80, 33 * 2, 4μ, H2O + 0.05% TFA:AcN + 0.05% TFA 95:5 (0 min) to 5:95(3.7 min); 1.0 ml/min, rt LC method 13: YMC Jsphere H80, 33 * 2, 4μ,H2O + 0.1% FA:AcN + 0.08% FA 95:5 (0 min) to 5:95 (2.5 min); 1.3 ml/min,rt LC method 14: YMC Jsphere H80, 33 * 2, 4μ, H2O + 0.05% TFA:AcN +0.05% TFA 95:5 (0 min) to 95:5 (0.5 min) to 5:95 (3.5 min) to 5:95 (4min); 1.3 ml/min, rt LC method 15: WatersXBridge C18, 4, 6 * 50, 2, 5μ,H2O + 0.05% TFA:AcN + 0.05% TFA 95:5 (0 min) to 95:5 (0.2 min) to 5:95(2.4 min) to 5:95 (3.2 min), to 95:5 (3.3 min) to 95:5 (4.0 min); 1.7ml/min, 40° C. LC method 16: WatersXBridge C18, 4, 6 * 50, 2, 5μ, H2O +0.05% TFA:AcN + 0.05% TFA 95:5 (0 min) to 5:95 (3.3 min) to 5:95 (3.85min) to 95:5 (4 min); 1.7 ml/min, 40° C. LC method 17: YMC Jsphere H8033 * 2, 4μ, H2O + 0.05% TFA:AcN + 0.05% TFA 98:2 (1 min) to 5:95 (5.0min) to 5:95 (6.25 min); 1.0 ml/min, rt LC method 18: YMC Jsphere H80,33 * 2, 4μ, H2O + 0.05% TFA:AcN + 0.05% TFA 5:95 (0 min) to 95:5 (2.5min) to 95:5 (3 min); 1.3 ml/min, rt LC method 19: WatersXBridge C18, 4,6 * 50, 2, 5μ, H2O + 0.05% TFA:AcN + 0.05% TFA 95:5 (0 min) to 95:5 (0.2min) to 5:95 (2.4 min) to 5:95 (3.2 min), to 95:5 (3.3 min), to 95:5(3.8 min), to 95:5 (4.0 min) 1.7 ml/min, 40° C. LC method 20: MerckChromolith FastGrad. RP-18e, 50 × 2 mm, 0.05% TFA:AcN + 0.05% TFA 98:2(0.2 min) to 2:98 (2.4 min) to 2:98 (3.2 min) to 98:2 (3.3 min) to 98:2(4 min); 2.0 ml/min, 50° C. LC method 21: Merck Chromolith FastGrad.RP-18e, 50 × 2 mm, 0.05% TFA:AcN + 0.05% TFA 98:2 (0.2 min) to 2:98 (2.4min) to 2:98 (3.2 min) to 98:2 (3.3 min) to 98:2 (4 min); 2.4 ml/min,50° C. LC method 22: Waters UPLC BEH C18XBridge C18 2.1 * 50 mm; 1.7u,H2O + 0.1% FA:AcN + 0.08% FA 95:5 (0 min) to to 5:95 (1.1 min) to 5:95(1.7 min) to 95:5 (1.8 min) to 95:5 (2 min); 0.9 ml/min, 55° C. LCmethod 23: Waters XBridge C18 4.6 * 50 mm; 2, 5u, H2O + 0.1% FA:AcN +0.1% FA 97:3 (0 min) to 40:60 (3.5 min) to 2:98 (4 min) to 2:98 (5 min)to 97:3 (5.2 min) to 97:3 (6.5 min); 1.3 ml/min, 45° C. LC method 24:WatersXBridge C18, 4, 6 * 50, 2, 5μ, H2O + 0.05% TFA:AcN + 0.05% TFA95:5 (0 min) to 95:5 (0.2 min) to 5:95 (2.4 min) to 5:95 (3.5 min), to95:5 (3.6 min) to t 95:5 (4.5 min); 1.7 ml/min, 50° C. LC method 25:YMC-Pack Jsphere H80 33 * 2.1, 4u, H2O + 0.05% TFA:CH3OH + 0.05% TFA98:2 (1 min) to 5:95 (5.0 min) to 5:95 (6.25 min); 1 ml/min, rt

General Synthetic Methods:

Step 1/2: Cinnamic acid (1 equivalent) and PtO₂ (2.2 mol %) weresuspended in ethanol (EtOH) (8 ml/mmol of cinnamic acid) and vigorouslystirred under an H₂ atmosphere (1 bar) until the reaction mixture nolonger absorbs H₂. The suspension was filtered and the residue waswashed with EtOH. The solvent of the filtrate was removed in vacuo, andthe resulting crude mixture of propionic acid and propionic ester wasemployed without further purification in the next reaction.

The mixture from reaction step 1 was dissolved in EtOH (2 ml/mmol ofintermediate from step 1), and an aqueous NaOH solution (2.5 equivalentsbased on the intermediate from step 1) was added. The solution wasstirred for 16 h, and the volume of the mixture was reduced by applyinga vacuum. The resulting solution was diluted with water and acidifiedwith aqueous 2 N HCl. The suspension was filtered and the residue waswashed with water. The desired propionic acids resulted as solid.

Step 3/4: Oxalyl chloride (3.40 equivalents) was cautiously added to asolution of the propionic acid (1 equivalent) in CH₂Cl₂ (1.4 ml/mmol ofpropionic acid) and DMF (0.01 ml/mmol of propionic acid) so that thesolution foams. The resulting clear solution was stirred for a further 6h and then volatile constituents were removed in vacuo. The appropriateacid chloride was employed without further workup in the next reactionstep.

A solution of the acid chloride in CH₂Cl₂ (1.2 ml/mmol of propionic acidfrom step 3) was added dropwise to a solution of AlCl₃ (1.30equivalents) in CH₂Cl₂ (0.75 ml/mmol AlCl₃) at 0° C. After the additionwas complete, the ice bath was removed and heated under reflux for afurther 3 h. The mixture was poured into ice-water, and the aqueousphase was extracted with CH₂Cl₂. The combined organic phases were driedwith Na₂SO₄ and filtered, and the solvent was removed in vacuo. Thecrude products were purified by column chromatography. If the ringclosure did not take place regioselectively, the regioisomers wereseparated by column chromatography.

Step 5: NaBH₄ (1 mmol/mmol of indanone) was cautiously added in portionsto a solution of the indanone (1 equivalent) in EtOH (4 ml/mmol ofindanones) at 10° C. After addition was complete, the solution wasstirred at room temperature (rt) for 3-16 h and then the volume of thereaction solution was reduced in vacuo. The suspension was added toice-water, and the aqueous phase was extracted with ethyl acetate. Thecombined organic phases were dried with Na₂SO₄ and filtered, and thesolvent was removed in vacuo. The crude products were purified by columnchromatography.

Step 6: Dowex® (Marathon® MSC (H) ion-exchange resin; 0.02 g/mmol ofindanol) was added to a solution of the indanol (1 equivalent) intoluene (3 ml/mmol of indanol) and the suspension was heated to refluxwith a water trap for 1 h. The cooled suspension was filtered, theresidue was washed with toluene, and the solvent of the combined organicphases was removed in vacuo. The crude product was purified by columnchromatography.

Alternatively, in step 6 a solution of the indanol (1 equivalent) andp-toluenesulfonic acid monohydrate (0.1 equivalent) in toluene (4ml/mmol of indanol) was heated under reflux with a water trap for 1-2 h.The solution was cooled to room temperature (rt) and washed withsaturated aqueous NaHCO₃ solution. The organic phase was dried withNa₂SO₄ and filtered, and the solvent was removed in vacuo. The crudeproducts were purified by column chromatography.

Step 7: 4-(3-Phenylpropyl)pyridine N-oxide (0.04 equivalents) was addedto a solution of the indene (1 equivalent) in CH₂Cl₂ (1.2 ml/mmol ofindene) and(S,S)-(+)-N,N′-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminomanganese(III)chloride (0.01 equivalent). The reaction solution was stirred for 10 minand cooled to −2° C. Half-saturated aqueous K₂CO₃ solution (0.5 ml/mmolof indene) was added and, while stirring this suspension vigorously,aqueous NaOCl solution (1.25 ml/mmol of indene; 13% free chlorine) wasslowly added dropwise. Immediately thereafter the pH was adjusted to pH11-12 with 0.1 M phosphate buffer (pH=7.5). The 2 phase system wasstirred vigorously for 4 h, during which the temperature slowly rose to5° C. The phases were separated and the aqueous phase was extracted withCH₂Cl₂. The combined organic phases were washed with saturated aqueousNa₂S₂O₃ solution and water, dried with Na₂SO₄ and filtered, and thesolvent was removed in vacuo. The crude products were purified by columnchromatography. The resulting product was additionally recrystallizedfrom heptane.

Step 8: NBS (2 equivalents) was added in small portions to a solution ofthe indene (1 equivalent) in DMSO (1 ml/mmol of indene) and water (0.025ml/mmol of indene) at 25° C. in such a way that the temperature did notrise above 35° C. The solution was stirred at room temperature (rt) for2 h and poured onto ice. The aqueous phase was extracted with ethylacetate, and the combined organic phases were washed with brine and thendried with Na₂SO₄ and filtered, and the solvent was removed in vacuo.The crude products were purified by column chromatography.

Step 9: Powdered NaOH (6.6 equivalents) was added to a solution of thebromohydrin (1 equivalent) in THF (7 ml/mmol of bromohydrin). Thesuspension was stirred at room temperature (rt) until the precursor wascompletely reacted, and the reaction was monitored by thin-layerchromatography (TLC). The suspension was filtered and the residue waswashed with ethyl acetate. The combined organic phases were dried withNa₂SO₄ and again filtered, and the solvent was removed in vacuo. Thecrude products were purified by column chromatography.

Step 10: mCPBA (1.1 equivalents) was added in small portions to asolution of the indene (1 equivalent) in CH₂Cl₂ (2.5 ml/mmol of indene).The suspension was vigorously stirred for 2 days and then filtered. Theresidue was washed with CH₂Cl₂, and the combined organic phases werewashed successively with saturated aqueous Na₂SO₃ solution and saturatedaqueous NaHCO₃ solution, dried with Na₂SO₄ and filtered, and the solventwas removed in vacuo. The crude products were purified by columnchromatography.

General Synthetic Methods:

Step 1: A solution of 2,5-dichlorothiophene (1.0 equivalents) in CH₂Cl₂(0.75 ml/mmol of thiophene) was slowly added dropwise to a suspension ofAlCl₃ (1.25 equivalents) and succinic anhydride (1.0 equivalents) inCH₂Cl₂ (1.00 ml/mmol AlCl₃) at 0° C. After the addition was complete,the ice bath was removed and stirred at room temperature (rt) for afurther 4 h. The mixture was poured into ice-water, and the aqueousphase was extracted with CH₂Cl₂. The combined organic phases wereextracted with 2N aqueous NaOH solution, and the combined aqueous phaseswere then acidified with conc. HCl. The acidic aqueous solution wasextracted with CH₂Cl₂, and the combined organic phases were dried withNa₂SO₄ and filtered, and the solvent was removed in vacuo. The resultingcrude product was purified by column chromatography.

Step 2: A solution of the precursor (1.0 equivalents) and N(C₂H₅)₃ (1.10equivalents) in THF (0.80 ml/mmol of precursor) was slowly addeddropwise to a solution of ClSi(CH₃)₃ (1.10 equivalents) in THF (1.70ml/mmol ClSi(CH₃)₃) at 0° C. After the addition was complete, stirringwas continued at 0° C. for 15 min and the resulting suspension wasfiltered. The solvent of the filtrate was removed in vacuo, and theresidue was dissolved in CH₂Cl₂ (2.00 ml/mmol of precursor). HSi(C₂H₅)₃(3.0 equivalents) and TiCl₄ (3.0 equivalents, 1M in CH₂Cl₂) was added tothe solution at room temperature (rt). The solution was stirred at roomtemperature (rt) for 20 h and then poured into ice-water. The aqueousphase was extracted with CH₂Cl₂. The combined organic phases wereextracted with aqueous saturated NaHCO₃ solution, and the combinedaqueous phases were then cautiously acidified with conc. HCl. The acidicaqueous solution was extracted with ethyl acetate, and the combinedorganic phases were dried with Na₂SO₄ and filtered, and the solvent wasremoved in vacuo. The crude product was purified by columnchromatography.

Step 3: The carboxylic acid (1.00 equivalents) was dissolved at 0° C. inconc. H₂SO₄ (6.30 ml/mmol of carboxylic acid) and then stirred at roomtemperature (rt) for 4 h. The solution was poured into ice-water, andthe aqueous phase was extracted with ethyl acetate. The combined organicphases were dried with Na₂SO₄ and filtered, and the solvent was removedin vacuo. The crude product was purified by column chromatography.

The further reactions to give the epoxide took place in analogy toscheme 1/route B.

General Synthetic Methods:

Step 1: At 0° C., 1,2-dihydronaphthalene (1.00 equivalents) and1,1,1-trifluoroacetone (0.15 equivalents) were added to 1.5 M aqueouspotassium carbonate solution (4×10⁻⁴ M in EDTA, 1.55 ml/mmol of1,2-dihydronaphthalene) and acetonitrile (1.55 ml/mmol of1,2-dihydronaphthalene) and stirred for 5 min. This was followed bycautious addition of 30% strength hydrogen peroxide (4.00 equivalents).The reaction mixture was stirred at 0° C. for 4.5 h (reaction monitoredby TLC) and then ethyl acetate was added. After separation of thephases, the aqueous phase was extracted twice with ethyl acetate, thecombined organic phases were washed with saturated aqueous NaClsolution, dried with MgSO₄ and filtered, and the solvent was removed invacuo. The crude product was purified by column chromatography.

General Synthetic Methods:

Step 1: mCPBA (meta-chloroperbenzoic acid, 2.2 equivalents) was added insmall portions to a solution of the indanone (1 equivalent) in CH₂Cl₂(4.0 ml/mmol of indanone) at room temperature (rt). The suspension wasvigorously stirred overnight and then, at 0° C., an aqueous Na₂S₂O₅solution was added. The two-phase mixture was stirred for 10 min andfiltered, the phases were separated, and the aqueous phase was extractedwith CH₂Cl₂. The combined organic phases were washed with saturatedaqueous saturated NaHCO₃ solution, dried with Na₂SO₄ and filtered, andthe solvent was removed in vacuo. The crude product was purified bycolumn chromatography.

The following indane oxides and analogs were synthesized by the methodsdescribed:

Epoxide

rac-cis-6-chloroindane oxide 1S,2R-4,6-difluoroindane oxide1S,2R-4,6-dichloroindane oxide rac-cis-4,6-dichloroindane oxide Route AA A C Epoxide

rac-cis-5,6-dichloroindane oxide rac-cis-6,7-dichloroindane oxiderac-cis-4-chloroindane oxide rac-cis-4-fluoroindane oxide Route B B B BEpoxide

rac-cis-7-chloroindane oxide rac-cis-6-fluoroindane oxiderac-cis-4-methylindane oxide rac-cis-7-methylindane oxide Route B B B BEpoxide

rac-cis-5-fluoroindane oxide rac-cis-6-chloroindane oxide1S,2R-6-chloro-4-fluorindane rac-cis-6-trifluoro- oxide methoxyindaneoxide Route B B A B Epoxide

rac-cis-6-chloro-4- 4,6-dichloro-1a,2,3,6b-tetrahydro-rac-cis-6-methoxyindane oxide rac-cis-3,3-dimethylindane oxidefluorindane oxide 1-oxa-5-thiacyclo-propa[e]indene Route C B B B Epoxide

rac-cis-6-methylindane oxide rac-cis-4-chloro-6-fluorindane oxiderac-cis-6- rac-cis-1,2-Tetralin oxide methylsulfonylindane oxide Route BC C D

General Synthesis of Phenols:

General Synthetic Methods:

Step 1/2: At −10° C., BBr₃ (1M solution in CH₂Cl₂; 2.5 equivalents) wasadded dropwise to a solution of the methyl ether (1 equivalent) inCH₂Cl₂ (7 ml/mmol ether) and the cooling bath was removed. Thesuspension was stirred for a total of 4 h, checking the progress of thereaction by TLC monitoring and, after the reaction was complete, thesuspension was added to ice-water. The resulting aqueous suspension wasneutralized with NaHCO₃ and extracted with ethyl acetate. The combinedorganic phases were dried with Na₂SO₄ and filtered, and the solvent wasremoved in vacuo. The crude products were purified by columnchromatography.

At −78° C., BCl₃ (1M solution in hexane; 2.0 equivalents) was addeddropwise to a solution of the isopropyl ether (1 equivalent) in CH₂Cl₂(6 ml/mmol ether) and the cooling bath was removed. The suspension wasstirred for a total of 3 h (TLC monitoring) and added to ice-water. Theresulting aqueous suspension was neutralized with NaHCO₃ and extractedwith ethyl acetate. The combined organic phases were dried with Na₂SO₄and filtered, and the solvent was removed in vacuo. The crude productswere purified by column chromatography.

General Synthetic Methods:

Step 1: SnCl₂2H₂O (5 equivalents) was added in small portions to asolution of the nitrophenol (1 equivalent) in ethyl acetate (6 ml/mmolof precursor). The suspension was heated under reflux for 1-6 h (TLCmonitoring). The reaction was stopped with water and basified withaqueous 2 N NaOH solution. The resulting suspension was filtered and thefiltrate was extracted with ethyl acetate. The combined organic phaseswere dried with Na₂SO₄ and filtered, and the solvent was removed invacuo. The crude products were purified by column chromatography.

Step 2/3: At 0° C., a solution of the appropriate aniline (1.0equivalents) and Hünig's base (1.1 equivalents) in CH₂Cl₂ (1.3 ml/mmolof aniline) was added dropwise to a solution of 4-nitrophenylchloroformate (1.5 equivalents) in CH₂Cl₂ (0.4 ml/mmol of formate) sothat the temperature did not rise above 5° C. The solution was stirredat room temperature (rt) for a further 2 h and then cooled to 0° C. Theappropriate amino acetal (2.3 equivalents) was added, and the suspensionwas stirred at room temperature (rt) for a further 4 h. The reaction wasdiluted with CH₂Cl₂ and washed successively with water, aqueous 2 N NaOHsolution and aqueous saturated NH₄Cl solution. The combined organicphases were dried with Na₂SO₄ and filtered, and the solvent was removedin vacuo. The crude product was employed without further purification inthe next reaction step.

The crude product from the preceding step (1 equivalent) was dissolvedat 0° C. in formic acid (1.5 ml/mmol of precursor) and stirred at roomtemperature (rt) for 2-16 h (with TLC monitoring). The volume of thereaction solution was reduced by a factor of 2 in vacuo, and theresulting solution was diluted with water. The aqueous phase wasextracted with ethyl acetate, and the combined organic phases werecautiously washed with saturated aqueous NaHCO₃ solution. The combinedorganic phases were dried with Na₂SO₄ and filtered, and the solvent wasremoved in vacuo. The crude products were purified by columnchromatography.

Step 4: PtO₂ (5 mol %) was added to a solution of the precursor (1equivalent) in an EtOH/ethyl acetate mixture (1:1 5 ml/mmol ofprecursor). The suspension was vigorously stirred under an H₂ atmosphere(1.5 bar) for 5 h (TLC monitoring). The suspension was filtered and theresidue was washed with EtOH. The solvent of the organic phases wasremoved in vacuo, and the resulting crude product was employed in thenext reaction step.

Step 5/6: At 0° C., a solution of the appropriate aniline (1.0equivalents) and Hünig's base (3.5 equivalents) in CH₂Cl₂ (1.3 ml/mmolof aniline) was added dropwise to a solution of 4-nitrophenylchloroformate (1.5 equivalents) in CH₂Cl₂ (0.4 ml/mmol of formate) sothat the temperature did not rise above 5° C. The solution was stirredat room temperature (rt) for a further 2 h and then cooled to 0° C. Theappropriate ammonium salt of the amino acid (1.6 equivalents) was addedand the suspension was stirred at room temperature (rt) for a further 16h. The reaction mixture was diluted with CH₂Cl₂ and washed successivelywith water, aqueous 2N NaOH solution and aqueous saturated NH₄Clsolution. The combined organic phases were dried with Na₂SO₄ andfiltered, and the solvent was removed in vacuo. The crude product wasemployed without further purification in the next reaction step.

The crude product from the preceding step (1 equivalent) was suspendedat 0° C. in 10% strength aqueous HCl (3.0 ml/mmol of precursor) andheated under reflux for 2-16 h (TLC monitoring). The pH of the solutionwas adjusted to pH 8 with aqueous 2 N NaOH solution and extracted withethyl acetate. The combined organic phases were dried with Na₂SO₄ andfiltered, and the solvent was removed in vacuo. The crude products werepurified by column chromatography. The phenol ethers obtained in thisway were cleaved as described in scheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: A thoroughly blended mixture of the appropriate aniline (1equivalent) and succinic acid (1 equivalent) was stirred at 180° C. for2 h, during which a melt formed. The melt was cooled to room temperature(rt) (solidification of the melt) and dissolved in EtOH. The resultingsolution was mixed with activated carbon and filtered, and the solventwas removed in vacuo. The residue was dissolved in ethyl acetate andwashed with saturated aqueous NaHCO₃. The organic phase was dried withNa₂SO₄ and again filtered, and the solvent was removed in vacuo. Thecrude products were purified by column chromatography.

Step 2: A thoroughly blended mixture of the appropriate aniline (1equivalent) and gamma-butyrolactone (1 equivalent) was stirred at 180°C. for 2 h, during which a melt formed. The melt was cooled to roomtemperature (rt) (solidification of the melt) and dissolved in EtOH. Theresulting solution was mixed with activated carbon and filtered, and thesolvent was removed in vacuo. The crude product was purified by columnchromatography.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: Boronic acid (1 equivalent), aryl iodide (1 equivalent) andNa₂CO₃ (3.0 equivalents) were suspended in a water/DME mixture ((1:1; 3ml/mmol of boronic acid). PdCl₂(PPh₃)₂ (2 mol %) was added and thesuspension was stirred at 80° C. for 20 h (TLC monitoring). Thesuspension was subsequently diluted with ethyl acetate and water, thephases were separated, and the aqueous phase was extracted with ethylacetate. The combined organic phases were dried with Na₂SO₄ andfiltered, and the solvent was removed in vacuo. The crude products werepurified by column chromatography.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: Aryl bromide (1 equivalent), oxazolidone (1 equivalent), K₂CO₃(2.0 equivalents), trans-diaminocyclohexane (10 mol %) and CuI (5 mol %)were suspended in dioxane (0.5 ml/mmol of aryl bromide). The suspensionwas heated under reflux for 16 h (TLC monitoring) and diluted with ethylacetate and filtered through a little Celite. The organic phase wasdried with Na₂SO₄ and filtered, and the solvent was removed in vacuo.The crude products were purified by column chromatography.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: Aryl bromide (1 equivalent), boronic acid (1 equivalent), K₂CO₃(2.0 equivalents) and Pd(PPh₃)₄ (10 mol %) were suspended in DME (1.0ml/mmol of aryl bromide). The suspension was heated to reflux for 48 h,and the reaction was monitored by TLC. The reaction mixture was dilutedwith ethyl acetate and water, the phases were separated, and the aqueousphase was extracted with ethyl acetate. The combined organic phases weredried with Na₂SO₄ and filtered, and the solvent was removed in vacuo.The crude products were purified by column chromatography.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenol was synthesized by the method described:

General Synthetic Method:

Step 1/2: The appropriate hydroxy ester (2 equivalents) was added to asolution of the isocyanate (1 equivalent) in toluene (1.0 ml/mmol ofisocyanate). The solution was heated at 110° C. in a closed vessel for 4h, and the reaction was monitored by TLC. The solvent was removed invacuo, and the crude products were purified by column chromatography.The product from the preceding reaction was heated without solvent at180° C. for 4 h. After the reaction solution had cooled to roomtemperature (rt), the crude product was purified by columnchromatography.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: At 0° C., the appropriate ammonium hydrochloride (3 equivalents)was added to a solution of the sulfonyl chloride (1 equivalent) in ethylacetate (2 ml/mmol) and pyridine (6 equivalents). The suspension wasstirred at room temperature (rt) for 16 h and the reaction was monitoredby TLC. The reaction mixture was diluted with ethyl acetate and water,the phases were separated, and the aqueous phase was extracted withethyl acetate. The combined organic phases were washed with saturatedaqueous NH₄Cl solution, dried with Na₂SO₄ and filtered, and the solventwas removed in vacuo. The crude products were purified by columnchromatography.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: A suspension of periodic acid (2.1 equivalents) in CH₃CN (3ml/mmol of periodic acid) was stirred at room temperature (rt) until aclear solution had formed (about 50 min). Chromium trioxide (10 mol %relative to the sulfide) was added and stirred for a further 10 min.This orange-colored solution was slowly added at −35° C. to a solutionof the appropriate sulfide (1 equivalent) in ethyl acetate (10 ml/mmolof sulfide). The temperature did not rise above −35° C. during this. Thesuspension which formed was stirred at this temperature for a further 60min and stopped with 5 ml of saturated aqueous Na₂SO₃ solution. Thesuspension was filtered and the residue was washed with ethyl acetate.The filtrate was washed with saturated aqueous Na₂SO₃ solution, driedwith Na₂SO₄ and filtered, and the solvent was removed in vacuo. Thecrude product was purified by column chromatography.

The following phenol was synthesized by the method described:

General Synthetic Method:

Step 0 (optional): 4.5 equivalents of SnCl2 are added to a solution ofthe aniline F (1 equivalent) in concentrated aqueous hydrochloric acid(0.36 ml/mmol of precursor) and the solution is heated to 60° C. Afterstirring overnight, the mixture was poured onto ice, adjusted to pH>10with 10 M KOH and extracted 4 times with dichloromethane, and thecollected organic phases were washed with saturated NaCl solution anddried over Na₂SO₄. The solvent was removed in vacuo.

Step 1: 1.1 equivalents of the dimethylamide dimethyl acetal or orthoester C were added to a solution of the hydrazide B (1.1 equivalents) inacetonitrile (6 ml/mmol of precursor), and the solution was stirred at50° C. for 30 min. After addition of a solution of the aniline (A) inacetonitrile (3 ml/mmol of precursor) and acetic acid (9 ml/mmol ofprecursor), the mixture was heated in an open flask at 120° C. for 16 h.The solvent was removed in vacuo. The crude products were purified bycolumn chromatography, using a dichloromethane/methanol gradient forelution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: Argon was passed through a mixture of the boric acid A (1equivalent), the heteroaryl iodide/bromide B (1 equivalent) in water/DME1/1 (3 ml/mmol of precursor) for 15 min. After addition of palladiumdichlorobistriphenylphosphine (0.02 equivalents) and Na₂CO₃ (3.0equivalents), the mixture was heated at 80° C. under argon (20 h). Afterthe reaction was complete (LC-MS monitoring), the mixture was mixed withethyl acetate and with saturated aqueous NaHCO₃ solution and extractedtwice with ethyl acetate. The collected organic phases were washed withsaturated NaCl solution and dried over Na₂SO₄. The solvent was removedin vacuo. The crude products were purified by column chromatography,using a heptane/ethyl acetate gradient for elution.

Variant A: After stirring for 1 hour, the resulting mixture wasextracted three times with dichloromethane, and the collected organicphases were washed with saturated NaCl solution and dried over Na₂SO₄.The solvent was removed in vacuo.

Variant B: After stirring for 1 hour, the resulting mixture wasneutralized with NaOH, and the product was either filtered off withsuction or extracted 3 times with dichloromethane, and the collectedorganic phases were washed with saturated NaCl solution and dried overNa₂SO₄. The solvent was removed in vacuo.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: Triethylamine (2 equivalents) and, dropwise,3-chloropropanesulfonyl chloride (1.3 equivalents) are successivelyadded to a solution of the aniline A (1 equivalent) in dichloromethane(1.5 ml/mmol of precursor), and the mixture is stirred at roomtemperature for 16 h. After addition of dichloromethane (1 ml/mmol ofprecursor), the mixture is washed successively with aqueous 1 N HCl andsat. NaHCO₃ solution. The solvent was removed in vacuo. The product wasdissolved in DMF (1.3 ml/mmol of precursor), and1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (1.1 equivalents) was added.After stirring at 25° C. for 3 h and after addition of ethylacetate/heptane 2/1, the organic phase was washed twice with 0.1 N HCl,and the organic phase was washed with saturated NaCl solution and driedover Na₂SO₄. The solvent was removed in vacuo.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: A mixture of the bromide A (1 equivalent),N-methylmethanesulfonamide (1.2 equivalents), copper(I) iodide (0.2equivalents), sarcosine (0.2 equivalents), K3PO4 (2.5 equivalents) inDMF (6 ml/mmol of precursor) was stirred at 150° C. for 24 h. Thesolvent was removed in vacuo. After addition of dichloromethane, theorganic phase was washed with saturated NaHCO₃ solution and dried overNa₂SO₄. The solvent was removed in vacuo. The crude product was purifiedby flash chromatography on silica gel, using a dichloromethane/methanolgradient for elution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenol was synthesized by the method described:

General Synthetic Method:

Step 1: A mixture of the amine (1 equivalent), 2,6-dimethyl-gamma-pyrone(2.5 equivalents) in 2 N aqueous HCl was heated at 160° C. in amicrowave for 30 minutes. After addition of dichloromethane, the organicphase was washed with saturated NaHCO₃ solution and dried over Na₂SO₄.The solvent was removed in vacuo. The crude product was purified byflash chromatography on silica gel, using a dichloromethane/methanolgradient for elution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenol was synthesized by the method described:

General Synthetic Method:

Step 1: A mixture of the amine (1 equivalent) and diglycol anhydride (2equivalents) was heated at 160° C. for 48 h. After addition ofdichloromethane, the organic phase was washed with saturated NaClsolution and dried over Na₂SO₄, and the solvent was removed in vacuo.The crude product was purified by flash chromatography on silica gelusing a dichloromethane/methanol gradient for elution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenol was synthesized by the method described:

General Synthetic Method:

AgNO₃ (2.1 equivalents) was added to a suspension of the appropriateamino alcohol hydrochloride (1 equivalent) and tert-butyldiphenylsilylchloride (1.2 equivalents) in a solution mixture of THF and pyridine(4:3; 1 ml/mmol of amino alcohol), a slight increase in temperatureoccurring. The suspension was stirred at room temperature (rt) for 16 hand filtered, and the residue was washed with ethyl acetate. Thefiltrate was diluted with ethyl acetate and washed with saturatedaqueous NaHCO₃ solution. The organic phase was dried with Na₂SO₄ andfiltered, and the solvent was removed in vacuo. The crude products werepurified by column chromatography.

The following silyl ethers were synthesized by the method described:

General Synthetic Method:

Step 1: A suspension of the bromide (1 equivalent), the imidazole (1.25equivalents), CuCl (0.06 equivalents) and K₂CO₃ (1 equivalent) in NMP (2ml/mmol bromide) was heated at 210° C. for 10 h. The mixture was cooledto it and diluted with water. The aqueous layer was extracted with ethylacetate and the combined organic layers washed with saturated NaClsolution, dried over Na₂SO₄, and the solvent was removed in vacuo. Thecrude product was purified by flash chromatography on silica gel usingan ethyl acetate/MeOH gradient for elution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: To a suspension of the aniline (1 equivalent) in thecorresponding nitrile (1 equivalent) at 0° C. AlCl₃ (1 equivalent) wasadded in small portions. The mixture was heated to 100° C. for 1 h whilea solution was formed. The reaction mixture was cooled to 0° C. andcarefully quenched with water. The aqueous suspension was adjusted to pH10 with aqueous 2N NaOH. The aqueous layer was extracted with ethylacetate, the combined organic layers washed with saturated NaClsolution, dried over Na₂SO₄, and the solvent was removed in vacuo. Thecrude product was purified by flash chromatography on silica gel usingethyl acetate/heptane/MeOH/NH₃ for elution.

Step 2: To a suspension of the amidine (1 equivalent) and NaHCO₃ (3equivalents) in dioxane (2 ml/mmol amidine) the α-chloro-ketone (1.1equivalent) was added and heated to 100° C. for 1 h. The mixture wascooled to rt, diluted with water and the aqueous layer extracted withethyl acetate. The combined organic layers were washed with saturatedNaCl solution, dried over Na₂SO₄, and the solvent was removed in vacuo.The crude product was purified by flash chromatography on silica gelusing ethyl acetate/MeOH for elution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: To a solution of the imidazol (1 equivalent) in THF (5 ml/mmolimidazol) at −78° C. nBuLi (1.1 equivalent, 1M in hexanes) was addeddropwise. The solution was allowed to reach −30° C. over a period of 30min. The solution was cooled to −50° C. and the dialkyldisulfide (1.1equivalent) was added. The cooling bath was removed and stirring wascontinued for 90 min while the suspension reached rt. Water was addedand the aqueous layer was extracted with ethyl acetate, the combinedorganic layers washed with saturated NaCl solution, dried over Na₂SO₄and the solvent was removed in vacuo. The crude product was purified byflash chromatography on silica gel using a ethyl acetate/heptanegradient for elution.

Step 2: To a solution of the alkyl sulfide (1 equivalent) at 0° C. inCH₂Cl₂ (12 ml/mmol sulphide) the peroxybenzoic acid (3 equivalents) wasadded in small portions. The turbid solution was vigorously stirred for14 h. The solution was diluted with CH₂Cl₂ and washed three times withaqueous Na₂CO₃ solution. The organic layer was dried over Na₂SO₄ and thesolvent was removed in vacuo. The crude product was purified by flashchromatography on silica gel using a ethyl acetate/MeOH gradient forelution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: To a solution of the imidazol (1 equivalent) in THF (5 ml/mmolimidazol) at −78° C. nBuLi was added dropwise. Within 30 min thesolution was allowed to reach −30° C. The solution was cooled to −78° C.and trimethylchlorosilane (1.1 equivalents) was added dropwise. The icebath was removed and within 60 min the solution reached rt. Again thesolution was cooled back to −78° C., the chloroformiate (1.1equivalents) was added and the ice bath removed. After 2 h the reactionmixture was poured into water and extracted with ethyl acetate, washedwith saturated NaCl solution, dried over Na₂SO₄ and the solvent wasremoved in vacuo. The crude product was purified by flash chromatographyon silica gel using an ethyl acetate/MeOH gradient for elution.

Step 2: The carboxylic ester (1 equivalent) was dissolved in a 2 M MeOHsolution of the corresponding amine (10 equivalents) and stirred for 12h at 60° C. The solvent was removed and the crude product purified byflash chromatography on silica gel using an ethyl acetate/methanolgradient for elution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: To a solution of the sulfonyl chloride (1 equivalent) in CH₂Cl₂(2 ml/mmol sulfonyl chloride) at 0° C. the amine (4 equivalents) wasadded dropwise. The suspension was stirred at it for 3 h. Water wasadded and the aqueous layer was extracted with CH₂Cl₂. The combinedorganic layers were washed with saturated NaCl solution, dried overNa₂SO₄ and the solvent was removed in vacuo. The crude product waspurified by flash chromatography on silica gel using an ethylacetate/methanol gradient for elution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: To a solution of the acyl hydrazine (1 equivalent) in toluene (3ml/mmol acyl hydrazine) at 0° C. triphosgene (0.33 equivalents) wasadded in portions. The suspension was heated to reflux for 2 h while asolution was formed. The solution was cooled to rt and the solventremoved in vacuo. The crude product was purified by flash chromatographyon silica gel using an ethyl acetate/heptane gradient for elution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

General Synthetic Method:

Step 1: To a solution of the acyl hydrazine (1 equivalent) in CH₂Cl₂(1.5 ml/mmol acyl hydrazine) at it the isocyanate (12 equivalents) wasadded. The solution was heated to 55° C. in a sealed vial. The solutionwas cooled to it and the solvent was removed in vacuo. The crude productwas purified by flash chromatography on silica gel using ethylacetate/heptane/MeOH for elution.

Step 2: NaOH (1.25 equivalents) was dissolved in MeOH (3 ml/mmol NaOH)and the diacyl hydrazine (1 equivalent) was added. The solution wasstirred at it for 16 h. The mixture was diluted with water and extractedwith ethyl acetate. The combined organic layers were washed withsaturated NaCl solution, dried over Na₂SO₄ and the solvent was removedin vacuo. The crude product was purified by flash chromatography onsilica gel using an ethyl acetate/MeOH gradient for elution.

The phenol ethers obtained in this way were cleaved as described inscheme 5.

The following phenols were synthesized by the method described:

Specific synthetic methods corresponding to: Scheme A/method A:Synthesis of compounds I via Mitsunobu inversion

Synthetic Method:

Step 1: A solution of the epoxide (1 equivalent) and the appropriatesecondary amine (1.05 equivalents) in acetonitrile (1 ml/mmol ofepoxide) was heated at 80° C. for 1-6 h, monitoring by TLC. The solventwas removed in vacuo and the crude products were purified by columnchromatography.

Step 2: A 1M solution of DIAD (diisopropylazodicarboxylate, 1.15equivalents) in THF was added dropwise to a solution/suspension of theamino alcohol (1 equivalent), PPh3 (1.15 equivalents) and theappropriate phenol (1.15 equivalents) in THF (3 ml/mmol of aminoalcohol). The solution was stirred at room temperature (rt) for 1-16 h,monitoring the reaction by TLC, and the solvent was removed in vacuo.The crude products were purified by column chromatography.

Step 3 (optional): tert-butyldiphenylsilyl ethers were cleaved eitherwith TBAF (tetra-n-butylammonium fluoride) or HF/pyridine complex. N-Bocprotective groups were removed with 4N HCl solution in dioxane or withTFA/CH₂Cl₂ 1/1.

Specific synthetic methods corresponding to: Scheme B/method B:Synthesis of compounds I via nucleophilic aromatic substitution (1)

Synthetic Method:

1 equivalent of the 2-bromo-1-indanone are dissolved indimethylformamide and, preferably at ice-bath temperature, the amineR—NH—R is added as quickly as possible, either in pure form as free baseor as DMF solution. After relatively short reaction times (30 seconds to1 hour), the reaction is stopped by adding sufficient dilutehydrochloric acid for the reaction mixture to have a pH of 1-5. Thesuspensions are extracted several times with acetic acid ethyl acetate,and 2-10 equivalents of sodium borohydride are added in portions to theremaining aqueous solution, which now contain the intermediate ketone.Stirring at room temperature for several hours is followed byconcentration, and the reaction mixture is taken up with water and madeweakly alkaline with concentrated sodium bicarbonate solution. Theproduct is obtained by extraction with acetic acid ethyl acetate,initially as mixture of cis/trans isomers which is subjected in mostcases to chromatography, it being possible in some cases for the isomersalso to be separated in this way. However, cis/trans mixtures are inmany cases employed for the following arylation and only then is aseparation of the isomers undertaken.

The following 1-indanols were synthesized by the method described:

Specific synthetic methods corresponding to: Scheme B/method B:Synthesis of compounds I via nucleophilic aromatic substitution (2)

Synthetic Method:

1 equivalent of an indanol of the general formula VI or X (either aspure stereoisomer or as mixture of cis/trans isomers) are dissolved in5-10 times the amount of absolute dimethyl sulfoxide, and 1.2 to 2equivalents of a suitable aryl halide, preferably an aryl fluoride oraryl chloride, are added. 1.2 to 5 equivalents of freshly powderedsodium hydroxide are added to the solution while stirring at roomtemperature, and the mixture is stirred at room temperature for about 1h or else at 60-80° C., for several hours, depending on the nature ofthe aryl halide. For workup, the mixture is diluted with water, theresulting suspension is extracted several times with acetic acid ethylacetate, and the combined extracts are washed with water, dried withMgSO4 and concentrated in a rotary evaporator and then subjected tochromatography on silica gel.

Specific synthetic methods corresponding to: Scheme C/method C:Synthesis of Mannich-like products (1)

Synthetic Method:

Step 1: 1 equivalent of an indan-2-one are dissolved in an inert solventsuch as tetrahydrofuran, dimethylformamide or acetonitrile, and 2-3equivalents of dimethylformamide dimethyl acetal are added, and themixture is boiled under reflux for several hours or, in the case of DMF,stirred at 80 to maximum of 120° C. with stirring for about 3-5 hours.An alternative possibility is also to dispense entirely with solvent,and in this case the precursor is dissolved in a sufficient amount ofdimethylformamide dimethyl acetal and then stirred at 120° C. untilconversion is complete. After cooling, the crystallized product canusually be directly filtered off with suction and further purified bychromatography or recrystallization.

Step 2: 1 equivalent of the 2-dimethylaminomethylene-1-indanone obtainedin this way is dissolved in dimethylformamide, and at least 2equivalents of the sec. amine NHR3R4 are added, either as free base oras hydrochloride. The mixture is stirred at temperatures of from 60° to120° for several hours. After cooling, the solution is diluted withwater and the product is isolated either by filtration with suction orby extraction with ethyl acetate.

Step 3: 1 equivalent of the 2-aminomethylene-1-indanone obtained in thisway are dissolved in methanol and 10-20 equivalents, divided into 10-20portions, are added in an interval of 15-30 minutes while stirring atroom temperature. After the precursor has virtually completelydisappeared, the solvent is removed in vacuo, and the residue is takenup with water. The crude product is obtained by extraction with aceticacid ethyl acetate, initially as mixture of cis/trans isomers, which isin most cases subjected to chromatography, it being possible in somecases also for the isomers to be separated in this way. However, in manycases, cis/trans mixtures are employed for the following arylation, andonly then is a separation of the isomers undertaken.

The following 2-aminomethyl-1-indanols were synthesized by the methoddescribed:

Specific synthetic methods corresponding to: Scheme C/method C:Synthesis of Mannich-like products (2)

Synthetic Method:

1 equivalent of an indanol of the general formula VI or X (either aspure stereoisomer or as mixture of cis/trans isomers) are dissolved in5-10 times the amount of absolute dimethyl sulfoxide, and 1.2 to 2equivalents of a suitable aryl halide, preferably an aryl fluoride oraryl chloride, are added. 1.2 to 5 equivalents of freshly powderedsodium hydroxide are added to the solution while stirring at roomtemperature, and the mixture is stirred at room temperature for about 1h or else at 60-80° C., for several hours, depending on the nature ofthe aryl halide. For workup, the mixture is diluted with water, theresulting suspension is extracted several times with acetic acid ethylacetate, and the combined extracts are washed with water, dried withMgSO4 and concentrated in a rotary evaporator and then subjected tochromatography on silica gel.

Specific synthetic methods corresponding to: Scheme D/method D:Synthesis of diamines with the trans configuration and subsequentBuchwald arylation

Synthetic Method:

Step 1: A 1M solution of DIAD (1.10 eq.) in THF was added dropwise to asolution of the amino alcohol (1 eq.), PPh₃ (1.10 eq.) and DPPA (1.10eq.) in THF (7 ml/mmol of amino alcohol) at 0° C. Thesolution/suspension was stirred at 0° C. for 60 min (LC/MS monitoring)and cooled to −10° C. At this temperature, LiAlH₄ (2.00 eq. based onamino alcohol employed) was cautiously added in one portion, and themixture was stirred while cooling in ice for a further 60 min. Thesuspension was poured onto ice-water and the aqueous phase was extractedwith ethyl acetate. The combined organic phases were dried with Na₂SO₄and filtered, and the solvent was removed in vacuo. The crude productswere purified by column chromatography.

Step 2: The aryl bromide (0.95 eq.) was added to a solution of thediamine (1. eq.), Pd₂(dba)₃ (0.04 eq.), rac-BINAP (0.08 eq.), NaO^(t)Bu(1.40 eq.) in toluene (12 ml/mmol of diamine), and the mixture washeated at 70° C. for 10-18 h (TLC monitoring). The reaction was dilutedwith ethyl acetate and washed with water. The aqueous phase wasextracted with ethyl acetate, and the combined organic phases were driedwith Na₂SO₄ and filtered, and the solvent was removed in vacuo. Thecrude product was purified by column chromatography.

Specific synthetic methods corresponding to: Scheme E/method E:Synthesis of compounds I via alkylation

Synthetic Method:

Step 1: A 2N aqueous NaOH solution (1.10 eq.) was added at rt to asolution of the benzoic ester (1 eq.) in acetone (20 ml/mmol of benzoicester), and the mixture was stirred at it for several hours until theprecursor was completely reacted (TLC monitoring). The solvent wasremoved in vacuo, and the residue was mixed with water. The aqueousphase was extracted with ethyl acetate, and the combined organic phaseswere dried with Na₂SO₄ and filtered, and the solvent was removed invacuo. The crude products were purified by column chromatography.

Step 2: NaH (1.30 eq. 80% in mineral oil) was added to a solution of theamino alcohol (1 eq.) in THF (7 ml/mmol of the amino alcohol) at 0° C.,the ice bath was removed, and the mixture was allowed to warm to rt overthe course of one hour. The alkylating reagent (1.10 eq.) was added, andthe reaction was stirred at it until the reaction showed no furtherconversion (TLC monitoring). The mixture was poured onto saturatedaqueous NaHCO₃ solution, and the aqueous phase was extracted with ethylacetate. The combined organic phases were dried with Na₂SO₄ andfiltered, and the solvent was removed in vacuo. The crude products werepurified by column chromatography.

Specific synthetic methods corresponding to: Scheme F: Optional furtherreactions of compounds I

Synthetic Method:

Step 1: A mixture of I—WH (1 eq.), of the bromide RBr (1.6-6 eq.) andK2CO3 (1-2 eq.) were stirred in acetonitrile (5 ml/mmol) at 80° C.(16-48 h). Addition of dichloromethane and saturated NaHCO₃ solution wasfollowed by extraction 3 times with dichloromethane. The collectedorganic phases were washed with sat. NaCl solution and dried (Na₂SO₄).The solvent was removed in vacuo, and the crude products were purifiedby column chromatography.

Step 2: (R═CF3) A solution of I—WH (1 eq.) and ethyl trifluoroacetate(1.3 eq.) was stirred in methanol overnight. The solvent was removed invacuo. Addition of dichloromethane and saturated NaHCO₃ solution wasfollowed by extraction 3 times with dichloromethane. The collectedorganic phases were washed with sat. NaCl solution and dried (Na₂SO₄).The solvent was removed in vacuo, and the crude products were purifiedby column chromatography.

Or:

(R═CH₃) A solution of the amine A (1 eq.) was stirred in aceticanhydride/pyridine 1/2 (9 ml/mmol of precursor). The solvent was removedin vacuo. The crude products were purified by column chromatography.

Step 3: A 1M solution of borane-THF complex in THF (2-9 eq.) was addeddropwise to a solution of the amide (1 eq.) in THF (5 ml/mmol ofprecursor) at 0° C. After heating under reflux, concentratedhydrochloric acid was cautiously added to the mixture at 0° C., and themixture was basified with NaOH and extracted 3 times withdichloromethane. The collected organic phases were washed with sat. NaClsolution and dried (Na₂SO₄). The solvent was removed in vacuo, and thecrude products were purified by column chromatography.

Specific synthetic methods corresponding to: scheme G/method G:Synthesis of compounds of the formula I via Pd catalyzed deprotection ofallyl amines

Synthetic Method:

Step 1: To a suspension of 1,3-dimethyl barbituric acid (2-6equivalents) and Pd(PPh₃)₄ (0.05-0.10 equivalents) in CH₂Cl₂ (1.0ml/mmol barbituric acid) under an argon atmosphere a solution of theallyl amine (1 equivalent) in CH₂Cl₂ (2.0 ml/mmol allyl amine) was addedat room temperature. The solution was heated to reflux until the eductwas completely converted (TLC control). The reaction mixture was cooledto room temperature and diluted with ethyl acetate. The organic layerwas washed with saturated aqueous Na₂CO₃ solution, dried over Na₂SO₄ andthe solvent removed in vacuo. The crude product was purified by flashchromatography on silica gel.

Synthesis of a Specific Example (Example 226) by Method A:

Step 1: A suspension of the 4,6-dichloro epoxide (500 mg, 1 equivalent)and the appropriate secondary amine (486 mg, 1.05 equivalents) inacetonitrile (2.5 ml) was heated at 80° C. for 6 h. The solvent wasremoved in vacuo, and the crude products were purified by columnchromatography (CH₂Cl₂/MeOH). 875 mg of a colorless foam were obtained.

Step 2: A 1M solution of DIAD (1.87 ml, 1.15 equivalents) in THF wasadded dropwise to a suspension of the amino alcohol (630 mg, 1equivalent), PPh₃ (490 mg, 1.15 equivalents) and 4-methylsulfonylphenol(310 mg, 1.15 equivalents) in THF (3 ml). The solution was stirred atroom temperature (rt) for 5 h, and the solvent was removed in vacuo. Thecrude products were purified by column chromatography (ethylacetate/heptane/methanol). The product was obtained as a colorless foamwhich still contained traces of OPPh₃ (930 mg).

Step 3 (optional): A 4 M HCl solution in dioxane (5 ml) was added to asolution of the Boc-protected precursor (930 mg) in dioxane (5 ml) at 0°C., and the mixture was stirred at rt for 3.5 h. The resultingsuspension was diluted with diethyl ether, filtered and washed withdiethyl ether. The white solid was suspended in saturated aqueous NaHCO₃solution, and the aqueous phase was extracted with ethyl acetate. Thecombined organic phases were dried with Na₂SO₄ and filtered, and thesolvent was removed in vacuo. The desired product was obtained as a paleyellow solid (600 mg).

Step 4 (optional): 1-Bromo-2-fluoroethane (164 mg, 3 equivalents) wasadded to a suspension of the deprotected 3-aminopyrrolidine (190 mg, 1equivalent) and K₂CO₃ (60 mg, 1 equivalent) in acetonitrile (4 ml) atrt, and the mixture was heated under reflux for 6 h. The solvent wasremoved in vacuo, the residue was suspended in water, and the aqueousphase was extracted with ethyl acetate. The combined organic phases weredried with Na₂SO₄ and filtered, and the solvent was removed in vacuo.The crude product was purified by column chromatography (CH₂Cl₂/MeOH).The desired product was obtained as a pale yellow oil (120 mg).

The following examples were synthesized in analogy to Example 226:

Synthetic Rt time MS [M + H+] Example Structure method LC method [min]ES+ 1

A 14 1.56 500.30 2

A 1 2.90 456.15 3

A 4 1.20 467.13 4

A 12 1.48 403.20 5

A 12 1.16 369.24 6

A 12 1.40 369.23 7

A 12 0.83 387.27 8

A 14 1.81 481.13 9

A 12 1.22 357.23 10

A 12 1.38 413.18 11

A 12 1.23 399.16 12

A 12 1.25 405.23 13

A 12 0.87 405.32 14

A 12 0.92 418.34 15

A 12 1.28 404.32 16

A 12 1.32 353.25 17

A 12 0.83 405.33 18

A 12 1.08 356.20 19

A 12 1.20 379.29 20

A 12 1.33 465.19 21

A 14 2.06 469.12 22

A 14 1.36 406.27 23

A 4 1.27 377.21 25

A 1 2.50 455.13 27

A 1 2.54 446.15 28

A 9 2.36 410.10 29

A 1 2.67 364.19 30

A 12 1.12 695.42 2M + H 31

A 6 1.20 455.14 32

A 1 2.43 359.14 33

A 12 1.16 345.15 34

A 1 2.27 383.19 35

A 1 2.60 415.09 36

A 9 2.41 401.09 37

A 6 1.10 421.18 38

A 1 2.57 371.14 39

A 1 2.32 371.16 40

A 1 2.30 358.14 41

A 1 2.45 408.14 42

A 1 2.40 371.16 43

A 1 2.47 355.18 44

A 1 2.37 371.16 45

A 1 2.22 401.1 46

A 1 2.65 367.2 47

A 12 1.16 380.18 48

A 9 2.23 408.25 49

A 12 1.18 393.17 50

A 1 2.64 407.13 51

A 1 2.45 359.15 52

A 1 2.52 375.1 53

A 1 2.60 371.14 54

A 1 2.40 387.15 55

A 1 1.92 357.17 56

A 1 2.50 389.1 57

A 1 2.40 341.15 58

A 12 0.88 406.27 59

A 12 1.38 392.30 60

A 1 2.29 391.17 61

A 1 2.20 390.17 62

A 12 1.00 376.20 63

A 1 2.55 431.09 64

A 1 2.54 387.13 65

A 1 2.64 371.15 66

A 1 2.48 357.13 67

A 1 2.05 380.25 68

A 1 2.57 408.13 69

A 1 2.64 409.11 70

A 1 2.37 341.12 71

A 9 1.88 389.22 72

A 12 0.82 375.21 73

A 1 2.22 401.13 74

A 1 2.47 369.15 75

A 1 1.97 407.25 76

A 12 0.80 393.27 77

A 9 2.52 391.14 78

A 1 2.47 402.17 79

A 1 2.40 392.14 80

A 1 2.34 388.21 81

A 1 2.57 358.14 82

A 12 1.05 344.16 83

A 12 1.08 353.20 84

A 1 2.02 374.18 85

A 12 0.85 360.23 86

A 12 0.66 619.42 2M + H 87

A 9 2.16 374.21 88

A 12 1.00 360.23 89

A 9 1.93 374.22 90

A 1 2.99 507.1 91

A 14 1.76 439.1 92

A 14 2.19 507.07 93

A 1 2.45 439.14 94

A 4 1.27 425.19 95

A 4 0.95 387.2 96

A 1 2.84 434.99 97

A 4 1.20 444.16 98

A 4 1.04 443.17 99

A 14 1.93 495.14 100

A 1 2.74 485.15 M + H + CH3CN 101

A 9 2.70 455.06 102

A 4 1.22 455.09 103

A 4 1.24 442.21 104

A 14 1.78 441.21 105

A 1 2.89 492.14 M + H + CH3CN 106

A 9 2.62 459.98 107

A 9 2.49 442.14 108

A 1 2.54 426.05 109

A 9 2.20 461.13 110

A 9 2.16 445.17 111

A 9 2.40 473.13 112

A 9 2.68 446.16 113

A 1 2.65 461.16 114

A 9 2.42 477.07 115

A 1 2.39 381.19 116

A 12 1.15 367.23 117

A 1 2.54 469.11 M + H{Hal} 118

A 12 1.32 453.10 119

A 1 2.82 423.12 120

A 1 2.42 407.17 121

A 14 1.42 404.26 122

A 9 2.28 493.01 123

A 1 2.75 483.17 124

A 9 2.50 472.08 125

A 9 2.62 475.02 126

A 9 2.42 495.04 127

A 1 2.48 487.19 128

A 9 2.41 487.14 130

A 9 2.27 477.25 131

A 9 2.41 473.12 132

A 1 2.40 473.09 133

A 9 2.22 459.25 134

A 1 2.59 468.18 135

A 9 2.83 459.1 136

A 1 2.90 476.09 137

A 1 2.77 448.16 138

A 8 2.91 477.16 139

A 1 2.39 459.08 140

A 1 2.55 438.21 141

A 1 2.40 471.28 142

A 1 2.32 461.15 143

A 9 2.11 443.13 144

A 1 2.34 443.13 145

A 9 2.11 425.13 146

A 9 2.87 456.03 147

A 1 2.39 364.16 148

A 1 2.34 362.18 149

A 1 2.43 359.13 150

A 1 3.00 417.09 M + H{Hal} 151

A 1 2.48 401.07 152

A 1 2.57 371.14 153

A 1 2.27 358.13 154

A 1 2.42 408.12 155

A 1 2.50 355.17 156

A 9 2.12 401.13 157

A 3 1.32 367.47 158

A 1 2.35 408.22 159

A 1 2.60 407.11 160

A 1 2.52 371.14 161

A 1 2.62 371.14 162

A 1 2.57 375.1 163

A 1 2.95 387.12 164

A 12 1.30 373.18 165

A 1 2.47 357.12 166

A 1 2.52 389.13 167

A 12 0.80 366.27 168

A 1 2.39 341.15 169

A 12 0.87 393.29 170

A 12 0.90 406.30 171

A 1 2.20 390.17 172

A 12 1.02 376.23 173

A 1 2.57 431.08 174

A 1 2.50 387.12 175

A 1 2.54 357.13 176

A 1 2.50 389.13 177

A 1 2.05 380.24 178

A 1 2.57 408.13 179

A 9 2.29 341.16 180

A 1 1.97 389.19 181

A 12 0.80 375.23 182

A 1 2.23 401.12 183

A 1 2.52 369.16 184

A 1 1.92 407.23 185

A 12 0.82 393.29 186

A 1 2.64 391.13 187

A 9 2.36 402.22 188

A 9 2.30 392.19 189

A 1 2.37 388.2 190

A 1 2.57 358.12 191

A 1 2.09 647.33 2M + H 192

A 1 2.27 374.19 193

A 1 2.04 374.18 194

A 12 0.83 360.23 195

A 4 1.28 509.18 196

A 1 2.68 444.13 197

A 9 2.69 455.06 198

A 1 2.65 442 199

A 1 2.54 440.98 200

A 17 2.40 477.21 201

A 1 2.14 405.22 202

A 1 2.40 381.2 203

A 1 2.68 467.08 204

A 12 1.30 453.16 205

A 9 2.63 407.17 206

A 1 2.40 459.09 207

A 8 2.77 458.2 208

A 14 2.06 481.14 209

A 14 1.88 453.14 210

A 9 2.86 493.15 211

A 9 3.17 509.10 212

A 12 1.16 340.18 213

A 1 2.57 379.15 214

A 12 1.15 723.48 2M + H 215

A 12 1.10 371.13 216

A 13 1.06 388.05 218

A 1 2.77 443.99 219

A 14 1.86 469.16 220

A 4 1.09 483.22 221

A 4 1.39 540.19 222

A 4 1.28 501.14 223

A 4 1.40 551.14 224

A 4 1.28 483.15 225

A 4 1.30 494.13 226

A 9 2.22 487.09 227

A 1 2.64 456.06 228

A 1 2.67 456.03 229

A 9 2.22 392.19 230

A 1 2.32 362.17 231

A 12 0.97 367.21 232

A 12 0.95 367.23 233

A 12 0.97 367.24 234

A 12 0.95 353.16 235

A 11 0.97 381.21 236

A 9 2.76 515.07 237

A 1 2.67 472.21 238

A 12 1.40 458.21 239

A 1 2.70 472.22 240

A 12 1.41 458.25 241

A 12 1.41 444.16 242

A 4 1.12 430.18 243

A 1 2.45 461.11 245

A 1 2.65 412.09 246

A 1 2.72 441.16 247

A 1 2.67 426.11 248

A 1 2.80 431.18 249

A 17 2.82 504.13 250

A 1 3.15 476.13 252

A 9 2.51 372.06 253

A 9 2.73 446.06 254

A 4 1.14 362.17 255

A 9 2.44 363.15 256

A 4 1.10 377.16 257

A 1 2.79 459.21 258

A 14 2.03 461.17 259

A 1 2.72 417.15 260

A 1 2.77 431.17 262

A 12 1.22 667.31 2M + H 263

A 4 1.27 426.19 264

A 6 1.30 426.06 265

A 6 1.34 392.15 266

A 12 1.12 343.11 267

A 12 1.22 379.09 268

A 14 1.77 392.13 269

A 4 1.09 358.14 270

A 11 0.87 379.22 271

A 4 1.13 372.15 272

A 4 1.05 373.26 273

A 4 1.09 358.18 275

A 12 0.97 346.16 276

A 4 1.32 430.17 277

A 4 1.30 455.26 279

A 4 1.35 469.17 281

A 4 1.31 439.15 282

A 4 1.27 424.13 283

A 4 1.24 425.14 284

A 4 1.21 410.11 285

A 4 1.18 376.22 286

A 14 1.84 455.16 287

A 4 1.33 441.08 288

A 14 1.90 455.15 289

A 4 1.19 407.24 290

A 14 2.32 493.09 291

A 14 1.94 424.1 292

A 14 1.90 425.11 293

A 14 1.85 410.09 294

A 1 1.10 391.25 295

A 9 2.50 489.06 296

A 4 1.35 444.19 297

A 4 1.14 443.2 298

A 14 1.92 455.1 299

A 4 1.51 497.31 300

A 4 1.54 497.32 301

A 14 2.11 509.18 302

A 14 2.07 509.07 303

A 14 2.02 501.13 304

A 1 2.84 513.05 305

A 14 1.98 469.11 306

A 4 1.37 455.15 307

A 1 2.60 428.04 308

A 1 2.77 441.07 309

A 1 2.87 447.19 310

A 9 2.75 494.04 311

A 9 2.97 496.07 312

A 17 2.67 474.19 313

A 17 2.72 478.13 314

A 17 2.80 480.15 315

A 9 2.85 447.07 316

A 9 2.68 461.08 317

A 9 2.70 446.30 318

A 17 2.60 462.17 319

A 1 2.77 462.05 320

A 9 2.74 446.08 321

A 9 2.87 481.03 322

A 9 2.72 495.04 323

A 9 2.54 464.10 324

A 17 2.43 503.16 325

A 9 2.59 446.04 326

A 1 2.17 420.17 327

A 1 2.70 415.18 328

A 1 2.15 420.17 329

A 1 2.67 478.09 330

A 9 2.79 480.05 331

A 1 2.62 460.1 332

A 9 2.75 462.06 333

A 9 2.71 447.05 334

A 9 2.59 461.04 335

A 9 2.86 494.03 336

A 9 2.90 481.01 337

A 9 2.82 495.05 338

A 9 2.58 462.29 339

A 9 2.78 478.04 340

A 9 2.97 480.10 341

A 9 2.74 465.11 342

A 12 1.16 353.16 343

A 11 1.16 453.12 344

A 9 2.17 506.12 345

A 1 2.65 520.24 346

A 1 2.59 504.26 347

A 14 1.73 472.23 348

A 9 2.40 530.34 349

A 9 2.32 486.18 350

A 9 3.03 530.25 351

A 4 1.39 481.14 352

A 4 1.30 376.13 353

A 2 1.85 411.07 354

A 14 1.83 483.08 355

A 12 1.37 429.06 356

A 12 1.24 401.15 357

A 4 1.19 427.15 358

A 4 1.42 511.11 359

A 4 1.20 457.07 360

A 12 1.18 470.13 361

A 4 1.14 457.1 362

A 4 1.39 455.16 363

A 9 2.43 399.13 364

A 3 1.41 363.32 365

A 1 2.34 400.12 366

A 1 2.55 382.09 367

A 9 2.40 366.16 368

A 1 2.12 366.18 369

A 1 2.59 426.04 370

A 1 2.29 400.11 371

A 1 2.57 382.12 372

A 1 2.48 366.13 373

A 1 2.12 366.18 374

A 12 1.18 352.20 375

A 12 1.27 354.11 376

A 12 1.22 382.16 377

A 4 1.17 456.2 378

A 14 1.74 481.17 379

A 4 1.36 499.02 380

A 1 2.27 408.19 381

A 12 1.28 417.17 382

A 1 2.25 408.19 383

A 4 1.28 499.18 384

A 4 1.20 451.3 385

A 14 1.91 499.22 386

A 12 0.97 405.27 387

A 11 0.94 391.19 388

A 12 0.97 419.27 392

A 4 1.31 339.14 393

A 12 1.25 380.20 394

A 15 1.85 435.07 395

A 1 2.72 395.11 396

A 1 2.64 353.13 397

A 12 1.20 364.23 398

A 12 1.16 364.22 399

A 1 2.65 363.17 400

A 1 2.37 361.14 401

A 12 0.84 295.31 402

A 14 1.69 427.13 403

A 14 2.01 455.1 404

A 14 1.44 375.24 405

A 14 1.50 375.24 406

A 9 2.22 443.13 407

A 1 2.85 375.12 408

A 9 2.82 389.21 409

A 9 2.40 365.15 410

A 11 0.88 364.19 411

A 12 0.92 352.22 412

A 1 2.10 366.18 413

A 12 0.90 352.22 414

A 12 0.93 352.24 415

A 12 0.92 338.15 416

A 9 2.76 508.03 417

A 9 2.58 480.05 418

A 17 2.74 481.12 419

A 9 2.69 449.08 420

A 9 2.64 492.08 421

A 9 2.48 464.05 422

A 17 2.65 510.13 423

A 17 2.79 524.15 424

A 17 2.75 497.13 425

A 17 2.59 490.16 426

A 17 2.43 462.14 427

A 9 2.65 463.08 428

A 17 2.68 479.11 429

A 1 2.65 449.09 430

A 17 2.75 510.16 431

A 9 2.88 524.03 432

A 9 3.16 524.99 433

A 17 2.67 496.11 434

A 9 2.82 483.04 435

A 9 2.60 494.10 436

A 9 2.77 508.06 437

A 9 2.88 508.99 438

A 17 2.55 480.14 439

A 9 2.87 467.09 444

A 13 1.26 434.23 M + H + CH3CN 445

A 12 1.25 380.21 446

A 9 2.74 422.14 447

A 4 1.33 421.16 448

A 9 2.08 401.21 453

A 14 1.56 361.21 454

A 2 2.01 377.08 455

A 15 1.94 320.13 456

A 2 2.12 406.12 457

A 1 2.59 427.11 458

A 15 1.77 405.15 461

A 15 1.85 391.17 463

A 13 1.04 428.2 464

A 4 1.12 387.23 465

A 4 1.04 373.19 466

A 12 1.05 359.25 467

A 14 1.88 338.25 468

A 4 1.30 305.13 469

A 4 1.30 441.22 470

A 4 1.35 455.16 471

A 4 1.13 393.14 472

A 4 1.10 373.14 473

A 4 1.15 393.11 474

A 4 1.12 377.16 475

A 4 1.08 373.13 476

A 6 1.14 393.1 477

A 14 2.12 406.12 479

A 2 2.02 420.14 480

A 1 2.47 456.15 483

A 1 3.39 491.11 484

A 1 2.99 477.12 485

A 2 2.14 420.14 488

A 9 2.14 403.23 489

A 1 2.80 393.23 490

A 14 1.57 409.2 491

A 9 2.13 409.13 492

A 9 2.31 443.16 493

A 1 2.42 443.07 494

A 9 2.37 407.21 495

A 9 2.46 481.02 496

A 8 2.83 463.14 497

A 9 2.16 403.18 498

A 9 2.28 443.13 499

A 9 2.46 461.19 500

A 14 1.70 443.17 501

A 1 2.43 427.09 502

A 1 2.30 409.12 503

A 9 2.74 393.2 504

A 12 1.10 360.26 505

A 12 1.28 374.26 506

A 1 2.39 388.08 507

A 1 2.77 395.12 508

A 1 2.35 388.11 509

A 1 2.59 384.12 510

A 1 2.42 366.14 511

A 1 2.55 376.2 512

A 1 2.55 412.12 513

A 1 2.60 415.12 514

A 1 2.57 382.14 515

A 1 2.42 366.15 516

A 1 2.32 348.15 517

A 1 2.68 424.18 518

A 12 1.12 456.13 519

A 12 1.12 456.07 520

A 6 1.35 484.17 521

A 12 1.27 368.16 522

A 12 1.22 352.18 523

A 12 1.20 368.13 524

A 12 0.88 352.23 525

A 12 0.88 352.23 526

A 4 1.05 389.23 527

A 13 1.00 375.21 528

A 1 2.59 384.13 529

A 1 2.54 382.12 530

A 1 2.43 366.15 531

A 1 2.60 415.12 532

A 1 2.59 382.12 533

A 9 2.35 366.15 534

A 1 2.60 393.16 535

A 1 2.32 348.15 536

A 12 1.12 456.12 537

A 12 0.88 352.22 538

A 12 1.10 456.12 539

A 12 1.32 362.25 540

A 12 1.25 368.18 541

A 12 1.22 368.17 542

A 12 1.08 442.01 543

A 12 1.20 354.08 544

A 11 0.91 338.16 545

A 11 1.09 470.10 546

A 12 1.22 382.14 547

A 11 1.15 382.15 548

A 12 0.85 366.23 549

A 4 1.28 431.1 550

A 4 1.37 525.98 M + H{Hal} 551

A 14 2.02 420.14 552

A 12 0.87 388.27 553

A 9 2.79 440.13 554

A 9 2.71 407.03 555

A 1 2.85 407.04 556

A 1 3.02 434.03 557

A 1 2.75 391.06 558

A 9 2.41 461.1 559

A 1 2.37 461.25 560

A 9 2.71 495.09 561

A 9 2.35 461.13 562

A 9 2.36 487.09 563

A 9 2.22 445.17 564

A 1 2.47 477.25 565

A 1 3.04 525.2 566

A 9 2.90 459.14 567

A 9 2.76 507.09 568

A 12 1.33 365.23 569

A 1 2.57 375.17 570

A 1 2.07 361.16 571

A 14 1.71 336.13 572

A 1 2.92 434.02 573

A 1 2.70 389.17 574

A 9 2.51 433.09 575

A 9 2.52 364.23 576

A 12 1.20 392.23 577

A 12 1.23 395.20 578

A 1 2.43 397.09 579

A 12 1.22 383.13 580

A 1 2.43 397.09 581

A 14 1.95 481.15 582

A 14 2.02 481.14 583

A 9 2.32 462.18 584

A 1 2.47 462.18 585

A 1 2.77 369.09 586

A 1 2.62 379.13 587

A 12 0.98 360.28 588

A 1 2.04 361.16 589

A 12 0.83 372.26 590

A 4 1.27 411.16 591

A 1 2.74 403.11 592

A 1 2.68 432.16 593

A 1 2.77 417.12 594

A 1 2.65 386.14 595

A 14 1.38 331.24 596

A 1 2.37 399.15 598

A 12 1.18 367.26 599

A 11 1.20 467.14 600

A 12 1.30 453.16 601

A 12 1.13 348.24 602

A 12 1.16 345.19 603

A 11 1.22 415.12 604

A 11 1.08 371.18 605

A 12 1.13 357.21 606

A 11 1.15 367.22 607

A 12 1.20 353.24 608

A 12 1.20 380.20 609

A 11 1.11 407.16 610

A 12 1.23 393.20 611

A 12 1.38 357.20 612

A 12 1.32 387.19 613

A 12 1.33 373.20 614

A 12 1.25 367.22 615

A 12 1.30 353.26 616

A 12 0.87 407.30 617

A 12 0.87 393.31 618

A 12 1.03 376.24 619

A 11 0.78 407.27 620

A 12 1.13 367.21 621

A 12 1.15 353.21 622

A 12 0.78 374.22 625

A 12 1.43 353.15 626

A 12 1.02 366.28 627

A 12 0.97 366.25 628

A 12 1.48 340.21 629

A 12 0.83 407.34 630

A 11 0.95 407.27 631

A 4 1.05 412.22 632

A 12 1.15 462.19 633

A 9 2.51 379.21 634

A 3 1.31 365.42 635

A 13 1.16 337.2 636

A 4 1.19 365.29 637

A 12 1.22 339.18 638

A 12 1.08 311.24 639

A 1 2.25 352.18 640

A 9 2.27 351.14 641

A 4 1.10 337.25 642

A 4 1.11 369.16 643

A 18 1.11 368.16 644

A 3 1.44 434.3 645

A 4 1.27 379.09 646

A 4 1.29 421.09 647

A 4 1.28 420.21 648

A 4 1.30 405.08 649

A 4 1.20 371.18 650

A 14 1.83 404.13 651

A 4 1.21 389.14 652

A 13 1.29 355.31 653

A 12 1.27 351.19 654

A 4 1.28 379.1 655

A 4 1.21 371.14 656

A 4 1.11 355.17 657

A 4 1.16 386.2 658

A 4 1.23 371.14 659

A 14 1.83 404.15 660

A 14 1.87 389.12 661

A 12 1.24 355.16 662

A 4 1.14 371.11 663

A 13 1.26 351.23 664

A 4 1.42 446.19 665

A 13 1.45 420.21 666

A 13 1.15 337.2 667

A 4 0.77 338.19 668

A 4 1.14 338.15 669

A 1 2.14 403.16 670

A 13 1.14 406.21 671

A 1 2.75 457.05 672

A 1 2.39 471.05 673

A 17 2.68 473.12 674

A 12 1.05 378.28 675

A 1 2.54 422.2 676

A 1 2.20 380.2 677

A 1 2.37 418.18 678

A 1 2.40 418.18 679

A 12 0.98 366.20 680

A 4 1.07 367.17 681

A 13 1.21 353.23 682

A 4 1.11 367.16 683

A 1 2.52 422.21 684

A 1 2.20 380.19 685

A 12 1.02 366.24 686

A 12 1.02 366.24 687

A 12 1.00 352.15 688

A 11 0.96 380.19 689

A 4 1.16 446.2 690

A 4 1.22 434.16 691

A 12 0.99 366.39 692

A 4 1.06 394.25 693

A 4 1.54 476.2 694

A 4 1.24 462.32 695

A 1 2.60 435.11 696

A 4 1.24 421.24 697

A 4 1.34 434.19 698

A 8 3.33 471.11 699

A 9 2.71 437.02 700

A 4 1.18 773.47 2M + H 702

A 15 1.90 430.00 704

A 15 1.74 465.07 710

A 15 1.88 521.06 712

A 24 1.70 472.14 714

A 24 1.75 486.13 715

A 24 1.76 487.14 716

A 24 1.79 501.12 719

A 24 1.68 456.27 720

A 24 1.72 470.26 721

A 24 1.70 471.29 722

A 24 1.75 485.30 724

A 24 1.87 512.30 725

A 24 1.76 490.20 726

A 23 3.19 491.96 727

A 24 1.73 476.14 728

A 24 1.64 430.14 729

A 24 1.85 518.24 731

A 21 1.30 508.14 732

A 21 1.18 472.18 733

A 21 1.38 462.09 735

A 25 2.74 448.02 736

A 25 2.67 475.05 737

A 21 1.33 489.19 738

A 25 2.27 460.15 739

A 20 1.42 526.03 740

A 20 1.39 506.05 741

A 20 1.36 461.03 742

A 20 1.30 526.17 743

A 20 1.31 443.09 744

A 20 1.43 513.13 745

A 20 1.43 478.14

Synthesis of a Specific Example (Example 623) by Method B:

Step 1: 1.055 g of 2-bromoindanone (5 mmol) are dissolved in 7.5 ml ofdimethylformamide and, while stirring with ice-bath cooling, 0.98 ml ofcyclopentylamine is added over the course of 60 seconds. After a further25 minutes at ice-bath temperature, 7.5 ml of 2N hydrochloric acid and15 ml of water are added, and the mixture is thoroughly stirred. It isextracted 3 times with 15 ml of ethyl acetate each time. The product,2-cyclopentylaminoindanone, is obtained as a solution in the aqueoushydrochloric acid phase.

Step 2: 0.5 g of sodium borohydride, divided into 4 portions, is addedover a period of about 1 hour while stirring to the2-cyclopentylaminoindanone obtained in step 1 in aqueous solution of pH3 (about 20 ml). After further stirring at room temperature for about3-4 hours, a white precipitate separates out. After filtration withsuction and drying in air, it is stirred with n-heptane. 320 mg oftrans-2-cyclopentylamino-1-hydroxyindane are obtained.

Step 3: 300 mg (1.38 mmol) of trans-2-cyclopentylamino-1-hydroxyindaneare dissolved in 3.5 ml of DMSO, and 481 mg (2.76 mmol) of4-fluorophenyl methyl sulfone and 300 mg of powdered sodium hydroxideare added. The mixture is stirred until the components have completelydissolved and is left at room temperature overnight. Addition of 5 ml ofwater is followed by extraction several times with acetic acid ethylacetate, and the combined ethyl acetate phases are briefly washed with alittle water until neutral and dried with magnesium sulfate, and thesolvent is stripped off in vacuo. The remaining residue is subjected toflash chromatography on a 20 g prepacked silica gel column. The productis eluted with pure ethyl acetate.

The following examples were synthesized in analogy to Example 623:

Synthesis Rt time MS [M + H+] Example Structure method LC method [min]ES+ 251

B  9 3.06 359.08 261

B  1 2.40 355.08 278

B  9 2.62 423.08 441

B  8 2.56 315.15 451

B  9 2.34 377.22 459

B  9 2.63 413.06 460

B  9 2.52 391.06 478

B  9 2.92 375.06 597

B  9 2.62 394.01 623

B  8 2.94 372.36 624

B 15 1.76 358.10 701

B  9 2.47 360.10 703

B 25 2.32 363.08 705

B 15 1.96 386.13 706

B 15 1.76 358.16 708

B 15 1.82 358.17 709

B 15 1.83 377.15 711

B 15 2.24 400.15 713

B 24 1.90 419.07 717

B 24 1.85 372.10 718

B 23 2.83 391.08 723

B 24 1.87 374.18 730

B 24 1.85 386.20 734

B 23 2.73 372.17

Synthesis of a Specific Example (Example 280) by Method C:

Step 1: 202 mg (1 mmol) of 4,6-dichloroindan-1-one are dissolved in 2 mlof tetrahydrofuran, and 263 mg of dimethylformamide dimethyl acetal (2.2mmol) are added. The solution is stirred at 83° C. for 3 hours andconcentrated in vacuo. The residue is triturated with diethyl ether andfiltered off with suction. 216 mg of yellow crystals of4,6-dichloro-2-[1-dimethylaminomethylidene]indan-1-one are obtained.

Step 2: 255 mg (1 mmol) of4,6-dichloro-2-[1-dimethylaminomethylidene]indan-1-one are dissolved in2.5 ml of dimethylformamide and, after addition of 140 mg ofpyrrolidine, stirred at 70° C. for 4.5 hours. The reaction mixture isstirred into hot water and left to crystallize at room temperature for 1day. Filtration with suction results in 270 mg of yellow crystals.

Step 3: The product obtained in stage2,4,6-dichloro-2-pyrrolidin-1-ylmethylindan-1-one, is dissolved in 5 mlof methanol and, over a period of 7 hours, a total of 700 mg of NaBH4(18.5 equivalents) are added in portions. The mixture is concentrated invacuo, and the residue is taken up in 50 ml of water. 4 extractions with10 ml of ethyl acetate each time are followed by drying with magnesiumsulfate and removal of the solvent. The residue is chromatographed onsilica gel with methanol and ethyl acetate in the ratio 3:10 as eluent.The product is obtained as a mixture of cis/trans isomers.

Step 4: The cis/trans mixture of4,6-dichloro-2-pyrrolidinylmethylindanol (84 mg) obtained in step 3 isdissolved in 1 ml of DMSO, and 100 mg of 4-fluorophenyl methyl sulfoneand 100 mg of powdered sodium hydroxide are added. The mixture isstirred at room temperature for up to 40 minutes. Addition of 5 ml ofwater is followed by extraction with acetic acid ethyl acetate severaltimes, and the combined ethyl acetate phases are briefly washed with alittle water until neutral and dried with magnesium sulfate, and thesolvent is stripped off in vacuo. The remaining residue is subjected toflash chromatography on a 20 g prepacked silica gel column. Elution withpure ethyl acetate firstly gives 64 mg oftrans-4,6-dichloro-1-(4-methylsulfonyl-phenyloxy)-2-pyrrolidinylmethylindaneand with ethyl acetate/methanol 9:1 subsequently gives 9 mg of thecorresponding cis isomer.

The following examples were synthesized in analogy to Example 280:

Synthesis Rt time MS [M + H+] Example Structure method LC method [min]ES+ 217

C  1 2.70 414.15 244

C  9 2.42 346.12 274

C  1 2.42 372.2  280

C  9 2.74 440   389

C  9 2.52 407.08 390

C  9 2.51 372.12 391

C  9 2.91 353.13 440

C  8 3.09 421.20 442

C  9 2.55 407.08 443

C  9 2.04 329.17 449

C  9 2.62 407.13 450

C 17 2.43 405.18 452

C  8 2.96 391.18 462

C  9 2.33 363.20 486

C  9 2.02 345.17 487

C  9 2.37 388.17

Synthesis of a Specific Example (Example 26) by Method D:

Step 1: A 1M solution of DIAD (0.84 ml, 1.10 eq.) in THF was addeddropwise to a solution of the silyl-protected amino alcohol (400 mg, 1eq.), PPh₃ (220 mg, 1.10 eq.) and DPPA (0.23 ml, 1.10 eq.) in anhydrousTHF (5 ml) at 0° C. under an Ar atmosphere. The suspension was stirredat 0° C. for 60 min (LC/MS monitoring) and cooled to −10° C. At thistemperature, LiAlH4 (57 mg, 2 mol eq.) was cautiously added in oneportion, and the mixture was stirred while cooling in ice for a further60 min. The suspension was poured onto ice-water, and the aqueous phasewas extracted with ethyl acetate. The combined organic phases were driedwith Na₂SO₄ and filtered, and the solvent was removed in vacuo. Thecrude products were purified by column chromatography (ethylacetate/methanol). The product was obtained as a colorless oil (90 mg).

Step 2: 4-Bromophenyl methyl sulfone (38.2 mg, 0.95 eq.) was added to asolution of the diamine (90 mg, 1. eq.), Pd₂(dba)₃ (6.3 mg, 0.04 eq.),rac-BINAP (8.5 mg, 0.08 eq.), NaOtBu (23.0 mg, 1.40 eq.) in toluene (2ml) and the mixture was heated at 70° C. for 10 h (TLC monitoring). Thereaction was diluted with ethyl acetate and washed with water. Theaqueous phase was extracted with ethyl acetate, and the combined organicphases were dried with Na₂SO₄ and filtered, and the solvent was removedin vacuo. The crude product was purified by column chromatography (ethylacetate/MeOH). The product was obtained as a colorless oil (75 mg).

Step 3: HF/pyridine (100 μl, 65-70% pure) was added to a solution of thesilyl-protected diamine (75 mg, 1 equivalent) in THF (2 ml) at rt, andthe mixture was stirred at rt for 6 h. It was poured into saturatedaqueous NaHCO₃ solution, and the aqueous phase was extracted with ethylacetate. The combined organic phases were dried with Na₂SO₄ andfiltered, and the solvent was removed in vacuo. The crude product waspurified by column chromatography (ethyl acetate/MeOH). The desiredproduct was obtained as a pale yellow oil (20 mg).

The following examples were synthesized in analogy to Example 26:

Synthesis MS [M + H+] Example Structure method LC method Rt time [min]ES+  26

D 16 2.03 441.10 481

D 19 1.94 469.10 707

D 15 1.73 357.16

Synthesis of a Specific Example (Example 482) by Method E:

Step 1: A 2N aqueous NaOH solution (3.59 ml, 1.10 eq.) was added to asolution of the benzoic ester (4.41 g, 1 eq.) in acetone (125 ml) at rt,and the mixture was stirred at rt for 5 h hours until the precursor wascompletely reacted (TLC monitoring). The acetone was removed in vacuo,and the residue was mixed with water. The aqueous phase was extractedwith ethyl acetate, and the combined organic phases were dried withNa₂SO₄ and filtered, and the solvent was removed in vacuo. The crudeproducts were purified by column chromatography (ethylacetate/n-heptane). The product was obtained as a pale yellow oil (3.20g).

Step 2: NaH (24 mg, 1.30 eq. 80% in mineral oil) was added to a solutionof the amino alcohol (300 mg, 1 eq.) in THF (4 ml) at 0° C., and the icebath was removed and the mixture was allowed to warm to it over thecourse of 1 hour. 4-Cyano-2-fluorobenzyl bromide (134 mg, 1.10 eq.) wasadded, and the reaction was stirred at it for 3 h (TLC check). Themixture was poured into saturated aqueous NaHCO₃ solution, and theaqueous phase was extracted with ethyl acetate. The combined organicphases were dried with Na₂SO₄ and filtered, and the solvent was removedin vacuo. The crude products were purified by column chromatography(CH₂Cl₂/MeOH). The product was obtained as a colorless oil (227 mg).

Step 3: A 1 M TBAF solution in THF (0.52 ml, 1.5 eq.) was added to asolution of the silyl-protected aminobenzyloxy alcohol (227 mg, 1equivalent) in THF (2 ml) at it, and the mixture was stirred at it for 2h. It was poured into saturated aqueous NaHCO₃ solution, and the aqueousphase was extracted with ethyl acetate. The combined organic phases weredried with Na₂SO₄ and filtered, and the solvent was removed in vacuo.The crude product was purified by column chromatography (CH₂Cl₂/MeOH).The desired product was obtained as a pale yellow oil (68 mg).

The following examples were synthesized in analogy to Example 482:

Synthesis MS [M + H+] Example Structure method LC method Rt time [min]ES+  24

E 15 2.00 489.03 482

E 15 2.06 420.08

Synthesis of a Specific Example (Example 755) by Method G:

Step 1: To a suspension of 1,3-dimethyl barbituric acid (364 mg, 2equivalents) and Pd(PPh₃)₄ (67 mg, 0.05 equivalents) in CH₂Cl₂ (2.0 ml)under an argon atmosphere a solution of the allyl amine (583 mg, 1equivalent) in CH₂Cl₂ (2.0 ml/mmol allyl amine) was added at roomtemperature. The solution was heated to reflux for 1 h. The reactionmixture was cooled to room temperature and diluted with ethyl acetate.The organic layer was washed with saturated aqueous Na₂CO₃ solution,dried over Na₂SO₄ and the solvent removed in vacuo. The crude productwas purified by flash chromatography on silica gel using ethylacetate/heptane/MeOH (5:10:1) for elution. The product was obtained as acolourless oil (211 mg).

The following examples were synthesized in analogy to Example 755:

Synthesis Rt time MS [M + H+] example structure method LC method [min]ES+ 746

G 23 3.28 475.16 747

G 22 1.02 440.15 748

G 25 2.79 459.22 749

G 20 1.31 459.16 750

G 20 1.38 443.10 751

G 20 1.41 424.10 752

G 20 1.41 461.19 753

G 20 1.37 462.19 754

G 20 1.42 508.16 755

G 20 1.43 460.20 756

G 20 1.46 460.19

Assay Method for Determining the Pharmacological Activity:

In this assay, the recovery of the intracellular pH (pH_(i)) of LAP1cells which stably express the sodium-proton exchanger of subtype 3(NHE3) after acidification was determined. The recovery occurs evenunder bicarbonate-free conditions with functional NHE3. To this end, thepH_(i) was determined using the pH-sensitive fluorescent dye BCECF(Molecular Probes, Eugene, Oreg., USA, employing the precursorsBCECF-AM). The cells were initially incubated with BCECF (5 μM BCECF-AM)in NH₄Cl buffer (NH₄Cl buffer: 115 mM cholineCl, 20 mM NH₄Cl, 5 mM KCl,1 mM CaCl₂, 1 mM MgCl₂, 20 mM Hepes, 5 mM glucose, a pH of 7.4 wasadjusted with 1 M KOH). The intracellular acidification was induced bywashing the cells incubated in NH₄Cl buffer with NH₄Cl-free buffer(133.8 mM choline chloride, 4.7 mM KCl, 1.25 mM CaCl₂, 1.25 mM MgCl₂,0.97 mM K₂HPO₄, 0.23 mM KH₂PO₄, 5 mM Hepes, 5 mM glucose, a pH of 7.4was adjusted with 1 M KOH). After the washing step, 90 μl of theNH₄Cl-free buffer were left on the cells. The pH recovery was started byadding 90 μl of Na⁺-containing buffer (133.8 mM NaCl, 4.7 mM KCl, 1.25mM CaCl₂, 1.25 mM MgCl₂, 0.97 mM Na₂HPO₄, 0.23 mM NaH₂PO₄, 10 mM Hepes,5 mM glucose, a pH of 7.4 was adjusted with 1 M NaOH) in a measuringinstrument (FLIPR, “Fluorometric Imaging Plate Reader”, MolecularDevices, Sunnyvale, Calif., USA). The BCECF fluorescence was determinedwith an excitation wavelength of 498 nm and the FLIPR emission filter 1(bandpass from 510 to 570 nm). The subsequent changes in fluorescence asa measure of pH recovery were recorded for two minutes. To calculate theNHE3-inhibitory power of the tested substances, the cells were initiallyinvestigated in buffers with which complete or absolutely no pH recoverytook place. For complete pH recovery (100%), the cells were incubated inNa⁺-containing buffer (see above), and to determine the 0% value wereincubated in Na⁺-free buffer (see above). The substances to be testedwere made up in Na⁺-containing buffer. The recovery of the intracellularpH at each tested concentration of a substance was expressed as percentof the maximum recovery.

The IC₅₀ of the respective substance for NHE3 was calculated from thepercentages of pH recovery using the program XLFit (idbs, Surrey, UK).

The inhibitory effect on NHE3 is detailed in the following table,divided into three activity ranges:

where the meanings areactivity range 1: 20-50% inhibition at 10 μMactivity range 2: IC₅₀ 1-10 μMactivity range 3: IC₅₀<1 μM

Activity Example range 1 2 2 2 3 3 4 2 5 2 6 2 7 2 8 3 9 2 10 2 11 2 123 13 2 14 2 15 2 16 2 17 2 18 2 19 2 20 2 21 3 22 2 23 2 24 1 25 3 26 227 3 28 2 29 2 30 2 31 3 32 1 33 2 34 1 35 1 36 1 37 3 38 1 39 1 40 1 412 42 1 43 1 44 1 45 1 46 1 47 3 48 1 49 2 50 1 51 1 52 1 53 1 54 1 55 156 1 57 1 58 2 59 2 60 2 61 2 62 3 63 1 64 1 65 1 66 1 67 1 68 1 69 1 701 71 2 72 3 73 3 74 1 75 1 76 2 77 1 78 1 79 3 80 2 81 1 82 2 83 2 84 385 2 86 2 87 1 88 2 89 2 90 2 91 3 92 1 93 3 94 1 95 3 96 1 97 3 98 3 993 100 3 101 3 102 3 103 3 104 3 105 2 106 3 107 2 108 2 109 3 110 3 1113 112 2 113 3 114 2 115 1 116 2 117 2 118 2 119 3 120 3 121 2 122 3 1232 124 2 125 1 126 3 127 3 128 3 130 3 131 3 132 3 133 3 134 3 135 1 1361 137 1 138 3 139 3 140 2 141 3 142 3 143 3 144 3 145 3 146 2 147 3 1481 149 1 150 1 151 1 152 1 153 1 154 2 155 1 156 1 157 1 158 1 159 1 1601 161 1 162 1 163 2 164 2 165 1 166 1 167 2 168 1 169 3 170 2 171 2 1722 173 1 174 1 175 1 176 1 177 1 178 1 179 1 180 1 181 2 182 2 183 1 1841 185 2 186 1 187 1 188 2 189 2 190 1 191 1 192 1 193 2 194 2 195 3 1963 197 3 198 3 199 3 200 3 201 2 202 1 203 1 204 2 205 1 206 3 207 3 2081 209 3 210 2 211 1 212 2 213 1 214 2 215 2 216 1 217 1 218 1 219 1 2203 221 3 222 3 223 3 224 3 225 3 226 3 227 2 228 2 229 1 230 1 231 3 2322 233 2 234 2 235 2 236 3 237 1 238 2 239 1 240 2 241 2 242 1 243 3 2441 245 1 246 2 247 1 248 3 249 1 250 1 251 1 252 1 253 1 254 3 255 2 2562 257 3 258 3 259 1 260 2 261 1 262 2 263 3 264 2 265 3 266 2 267 2 2681 269 1 270 2 271 2 272 2 273 3 274 2 275 2 276 3 277 3 278 2 279 3 2802 281 3 282 1 283 3 284 2 285 2 286 2 287 3 288 3 289 3 290 1 291 2 2923 293 2 294 2 295 3 296 1 297 1 298 3 299 3 300 2 301 1 302 1 303 3 3043 305 3 306 2 307 2 308 3 309 3 310 1 311 1 312 1 313 3 314 3 315 2 3162 317 2 318 3 319 2 320 2 321 3 322 3 323 3 324 3 325 3 326 2 327 1 3281 329 3 330 3 331 3 332 2 333 3 334 3 335 3 336 3 337 2 338 2 339 3 3403 341 3 342 2 343 2 344 3 345 3 346 3 347 3 348 3 349 3 350 2 351 1 3523 353 1 354 1 355 2 356 3 357 3 358 2 359 2 360 2 361 2 362 3 363 2 3642 365 2 366 1 367 1 368 2 369 1 370 3 371 1 372 1 373 3 374 2 375 2 3762 377 3 378 3 379 3 380 1 381 2 382 1 383 3 384 1 385 3 386 2 387 2 3882 389 2 390 1 391 1 392 2 393 2 394 2 395 1 396 1 397 2 398 2 399 1 4001 401 2 402 2 403 2 404 1 405 3 406 3 407 3 408 1 409 3 410 2 411 3 4121 413 2 414 2 415 2 416 2 417 2 418 2 419 2 420 2 421 2 422 3 423 2 4243 425 3 426 3 427 2 428 3 429 2 430 3 431 2 432 2 433 2 434 3 435 2 4362 437 2 438 2 439 3 440 1 441 2 442 2 443 1 444 3 445 3 446 1 447 3 4483 449 1 450 1 451 3 452 2 453 3 454 1 455 1 456 3 457 3 458 1 459 1 4603 461 1 462 1 463 2 464 3 465 3 466 3 467 2 468 2 469 2 470 2 471 1 4722 473 3 474 2 475 2 476 2 477 3 478 1 479 3 480 3 481 2 482 1 483 3 4841 485 1 486 1 487 1 488 3 489 1 490 3 491 3 492 3 493 3 494 2 495 2 4962 497 1 498 1 499 3 500 3 501 3 502 3 503 1 504 2 505 2 506 1 507 1 5081 509 2 510 3 511 1 512 1 513 1 514 2 515 2 516 3 517 1 518 3 519 3 5203 521 2 522 2 523 2 524 3 525 2 526 2 527 2 528 2 529 1 530 1 531 1 5322 533 3 534 1 535 2 536 2 537 2 538 2 539 2 540 2 541 2 542 3 543 2 5442 545 2 546 2 547 2 548 2 549 1 550 3 551 3 552 3 553 2 554 2 555 2 5563 557 2 558 3 559 3 560 3 561 3 562 2 563 3 564 3 565 3 566 3 567 2 5682 569 1 570 1 571 2 572 2 573 1 574 2 575 1 576 2 577 2 578 1 579 2 5801 581 3 582 2 583 2 584 2 585 1 586 1 587 2 588 1 589 2 590 1 591 1 5921 593 1 594 1 595 2 596 2 597 1 598 2 599 2 600 2 601 2 602 2 603 2 6043 605 2 606 2 607 2 608 2 609 2 610 2 611 2 612 2 613 2 614 2 615 2 6162 617 2 618 2 619 2 620 2 621 2 622 2 623 2 624 2 625 2 626 2 627 2 6282 629 2 630 2 631 3 632 3 633 2 634 2 635 1 636 3 637 2 638 2 639 1 6403 641 3 642 2 643 1 644 3 645 2 646 1 647 2 648 2 649 1 650 3 651 2 6522 653 2 654 1 655 2 656 2 657 2 658 3 659 3 660 2 661 3 662 2 663 3 6643 665 3 666 2 667 2 668 3 669 2 670 1 671 3 672 3 673 2 674 2 675 2 6762 677 3 678 3 679 3 680 2 681 2 682 2 683 2 684 1 685 2 686 2 687 2 6882 689 3 690 3 691 3 692 3 693 3 694 3 695 2 696 3 697 2 698 3 699 2 7003 701 2 702 3 703 2 704 3 705 2 706 1 707 2 708 2 709 3 710 2 711 1 7122 713 2 714 2 715 3 716 3 717 2 718 3 719 2 720 2 721 2 722 2 723 1 7241 725 2 726 3 727 3 728 2 729 2 730 2 731 3 732 2 733 2 734 2 735 2 7362 737 2 738 3 739 3 740 3 741 3 742 2 743 3 744 2 745 1 746 3 747 2 7482 749 2 750 2 751 2 752 2 753 2 754 3 755 2 756 2

1. A compound of the formula I

in which A is a 6 to 10 membered aryl radical or a 5 to 10 memberedheteroaryl radical, where the aryl and heteroaryl radical may be mono-or bicyclic, and the heteroaryl radical may comprise one or moreheteroatoms selected from the group of nitrogen, oxygen and sulfur;where one or more hydrogen atoms in said mono- or bicyclic aryl orheteroaryl radicals may be replaced by substituents R1 which areselected independently of one another from the group of F, Cl, Br, I,(C₁-C₁₀)-alkyl-, (C₂-C₁₀)-alkenyl-, (C₂-C₁₀)-alkynyl-,(C₃-C₁₄)-cycloalkyl-, (C₄-C₂₀)-cycloalkylalkyl-,(C₄-C₂₀)-cycloalkylalkyloxy-, (C₁-C₁₀)-alkoxy-, (C₁-C₁₀)-alkylthio-,(C₆-C₁₄)-aryl-, (C₂-C₁₃)-heteroaryl, —CN, —NR13R14, —C(O)R12, —SF₅,—S(O)_(n)R12, —C(O)OR12, —C(O)NR13R14 and —S(O)_(n)NR13R14; where twoadjacent radicals R1 may also form a saturated or partly unsaturated(C₅-C₁₀)-cycloalkyl radical or a saturated or partly unsaturated(C₂-C₉)-cycloheteroalkyl radicals, where the cycloheteroalkyl radicalmay comprise 1, 2 or 3 nitrogen, 1 or 2 oxygen, 1 or 2 sulfur, 1 or 2nitrogen and 1 oxygen or 1 sulfur atom; where said alkyl, alkenyl,alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy,cycloheteroalkyl, alkoxy, and alkylthio radicals may be substitutedindependently of one another one or more times by F, OH or(C₁-C₁₀)-alkoxy; B is a mono- or fused bicyclic radical selected fromthe group of 6 to 10 membered aryl radicals, of 5 to 10 memberedheteroaryl radicals, of 3 to 10 membered cycloalkyl radicals, of 9 to 14membered cycloalkylaryl radicals, of 8 to 14 memberedcycloalkylheteroaryl radicals, of 3 to 10 membered cycloheteroalkylradicals, of 9 to 14 membered cycloheteroalkylaryl radicals and of 8 to14 membered cycloheteroalkylheteroaryl radicals, where the cycloalkyl orcycloheteroalkyl units may be saturated or partly unsaturated, and wherethe heterocyclic groups may comprise one or more heteroatoms selectedfrom the group of nitrogen, oxygen and sulfur; where one or morehydrogen atoms in the radicals B may be replaced by substituents R5which are selected independently of one another from the group of(C₁-C₁₀)-alkyl radicals, of (C₂-C₁₀)-alkenyl radicals, of(C₂-C₁₀)-alkynyl radicals, of (C₁-C₁₀)-alkoxy radicals, of(C₁-C₁₀)-alkylthio radicals, of (C₃-C₁₄)-cycloalkyl radicals, of(C₄-C₂₀)-cycloalkylalkyl radicals, of (C₄-C₂₀)-cycloalkylalkyloxy, of(C₂-C₁₉)-cycloheteroalkyl radicals, of (C₃-C₁₉)-cycloheteroalkylalkylradicals, of (C₃-C₁₁)-cycloalkyloxy radicals, of(C₂-C₁₁)-cycloheteroalkyloxy radicals, of (C₆-C₁₀)-aryl radicals, of(C₁-C₉)-heteroaryl radicals, of (C₉-C₁₄)-cycloalkylaryl radicals, of(C₅-C₁₃)-cycloalkylheteroaryl radicals, (C₇-C₁₃)-cycloheteroalkylarylradicals and (C₄-C₁₂)-cycloheteroalkylheteroaryl radicals, where thecycloalkyl and cycloheteroalkyl units may be saturated or partlyunsaturated, and where one or more hydrogen atoms in said radicals R5may be replaced by further radicals which are selected independently ofone another from the group of R11 radicals, it is further possible forR5 to be one or more radicals which are selected independently of oneanother from the group of OH, (═O), NH₂, F, Cl, Br, I, CN, NO₂,—NR17R18, —NR16COR17, —NR16COOR17, —NR16CONR17R18, —NR16-S(O)₂—R17,—NR16-S(O)₂—NR17R18, —COOR16, —COR16; —CO(NR17R18), S(O)_(n)R16 and—S(O)₂NR17R18, where R16, R17 and R18 independently of one another for aradical selected from the group of H, (C₂-C₁₉)-cycloheteroalkyl,(C₃-C₁₄)-cycloalkyl, (C₆-C₁₀)-aryl and (C₁-C₁₀)-alkyl radicals, all ofwhich may be substituted independently of one another by OH, (═O), F,Cl, Br, I, CN, NO₂, —NR13R14, —NR13COR12, —NR13COOR12, —NR12CONR13R14,—NR13-S(O)₂—R12, —NR12-S(O)₂—R13R14, —COOR12, —COR12; —CO(NR13R14),—S(O)_(n)R12, —S(O)₂NR13R14, (C₃-C₁₄)-cycloalkyl,(C₄-C₂₀)-cycloalkylalkyl, (C₂-C₁₉)-cycloheteroalkyl,(C₃-C₁₉)-cycloheteroalkylalkyl, (C₆-C₁₀)-aryl or (C₁-C₉)-heteroaryl, andwhere R17 and R18 can form together with the nitrogen to which they arebonded a 4-7 membered, saturated, unsaturated or partly unsaturatedheterocycle having 1 to 13 carbon atoms which may additionally compriseone or more heteroatoms from the list —O—, —S(O)_(n)—, ═N— and —NR15-,where the heterocycle formed may be substituted independently of oneanother one or more times by F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-alkyl,(C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₃-C₁₄)-cycloalkyl,(C₄-C₂₀)-cycloalkylalkyl, (C₂-C₂₀)-cycloheteroalkyl,(C₃-C₁₉)-cycloheteroalkylalkyl, each of which may in turn carryindependently of one another one or more radicals F, OH, (═O), NH₂,NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy; L is a covalentbond; X is a group —O—; R2 is absent or is one or more substituentswhich may be selected independently of one another from the group of F,(C₁-C₁₀)-alkyl and (C₁-C₁₀)-alkoxy radical, where the alkyl and alkoxyradicals may be substituted independently of one another one or moretimes by F; R3 and R4 are independently of one another a hydrogenradical or a radical which is selected from the group of (C₁-C₁₀)-alkylradicals, of (C₂-C₁₀)-alkenyl radicals, of (C₂-C₁₀)-alkynyl radicals, of(C₃-C₁₄)-cycloalkyl radicals, of (C₄-C₂₀)-cycloalkylalkyl radicals, of(C₂-C₁₉)-cycloheteroalkyl radicals, of (C₃-C₁₉)-cycloheteroalkylalkylradicals, of (C₆-C₁₀)-aryl radicals, of (C₇-C₂₀)-arylalkyl radicals, of(C₁-C₉)-heteroaryl radicals and of (C₂-C₁₉)-heteroarylalkyl radicals,where the radicals R3 and R4 may be substituted independently of oneanother one or more times by a radical from the group of OH, NH₂, (═O),F, Cl, Br, I, CN, NO₂, —NR13R14, —NR13COR12, —NR13COOR12,—NR12CONR13R14, —NR13-S(O)₂—R12, —NR13-S(O)₂—NR13R14, —COOR12, —COR12;—CO(NR13R14) and S(O)_(n)R12, —S(O)₂R13R14, or R3 and R4 form togetherwith the nitrogen to which they are bonded a 4-10 membered, saturated,unsaturated or partly unsaturated heterocycle which may additionallycomprise one or more heteroatoms from the list —O—, —S(O)_(n)—, ═N— and—NR8-, where the heterocyclic radicals may be substituted independentlyof one another one or more times by radicals selected from the group ofR7 and R9, and where the heterocyclic radicals formed by R3 and R4 maybe bridged by a bond, by a saturated or unsaturated (C₁-C₁₀)-alkyl or(C₁-C₉)-heteroalkyl chain or by —NR15-, —O— or —S—, and where the alkyland heteroalkyl chains may also form a spirocyclic ring system with thering system formed by R3 and R4, where the alkyl and heteroalkyl bridgesmay be substituted independently of one another one or more times byradicals selected from the group of R7 and R9, and where R8 in the group—NR8- may form with the ring which R3 and R4 may form a furthersaturated, unsaturated or partly unsaturated heterocycle which may besubstituted independently of one another one or more times by radicalsselected from the group of R7 and R9, and may additionally comprise oneor more heteroatoms from the list —O—, —S(O)_(n)—, —N═ and —NR19-; R7are a (C₁-C₁₀)-alkyl radical or (C₁-C₁₄)-cycloalkyl radical, where thealkyl radical may be substituted independently of one another one ormore times by R9; R8 is an H, a (C₁-C₁₀)-alkyl radical or(C₁-C₁₄)-cycloalkyl radical, COR12, —CO(NR13R14), S(O)_(n)R12 or—S(O)₂NR13R14, where the alkyl radical may be substituted independentlyof one another one or more times by R10; R9 is a radical selected fromthe group of OH, (═O), F, Cl, Br, I, CN, NO₂, —NR13R14, —NR13COR12,—NR13COOR12, —NR12CONR13R14, —NR13-S(O)₂—R12, —NR13-S(O)₂—NR13R14,—COOR12, —COR12, —CO(NR13R14), S(O)_(n)R12, —S(O)₂NR13R14,(C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl, (C₁-C₁₀)-alkoxy,(C₂-C₁₉)-cycloheteroalkyl, (C₃-C₁₉)-cycloheteroalkylalkyl, (C₆-C₁₀)-arylradicals and (C₁-C₉)-heteroaryl radicals; R10 is a radical selected fromthe group of F, OH, CN, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-alkylthio, NO₂,—NR13R14, —NR13COR12, —NR13COOR12, —NR13CONR13R14, —NR13-S(O)₂—R12,—NR12-S(O)₂—NR13R14, —COOR12, —COR12, —CO(NR13R14), S(O)_(n)R12 and—S(O)₂NR13R14; R11 is a radical selected from the group of(C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, (C₁-C₁₀)-alkoxy,(C₁-C₂₀)-alkylthio, (C₃-C₁₄)-cycloalkyl, (C₄-C₁₀)— cycloalkylalkyl,(C₂-C₁₃)-cycloheteroalkyl, (C₄-C₁₉)-cycloheteroalkylalkyl,(C₃-C₁₄)-cycloalkyloxy and (C₂-C₁₃)-cycloheteroalkyloxy, all of whichmay be substituted independently of one another one or more times byR10; (═O), Cl, Br, I and R10; R12, R13 and R14 may independently of oneanother be H, (C₁-C₁₀)-alkyl, (C₂-C₁₀)— alkenyl, (C₂-C₁₀)-alkynyl,(C₃-C₁₄)-cycloalkyl, (C₄-C₁₀)-cycloalkylalkyl,(C₂-C₁₃)-cycloheteroalkyl, (C₃-C₁₉)-cycloheteroalkylalkyl,(C₆-C₁₀)-aryl, each of which may be substituted independently of oneanother one or more times by F, OH, (═O), NH₂, NH(C₁-C₄)alkyl,N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy; or R13 and R14 may formtogether with the nitrogen to which they are bonded a 4-7 membered,saturated, unsaturated or partly unsaturated heterocycle having 1 to 13carbon atoms, which may additionally comprise one or more heteroatomsfrom the list —O—, —S(O)_(n)—, ═N— and —NR15-, where the formedheterocycle may be substituted independently of one another one or moretimes by F, OH, (═O), NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN or(C₁-C₁₀)-alkoxy, (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl,(C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl, (C₂-C₂₀)-cycloheteroalkylor (C₃-C₁₉)-cycloheteroalkylalkyl, each of which may in turn carryindependently of one another one or more radicals F, OH, (═O), NH₂,NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy; R15 is aradical selected from the group of H, (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl,(C₂-C₁₀)-alkynyl, (C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl,(C₂-C₁₃)-cycloheteroalkyl and (C₃-C₁₉)-cycloheteroalkylalkyl, each ofwhich may be substituted independently of one another one or more timesby F, OH, CN or (C₁-C₁₀)-alkoxy; R19 is an H, a (C₁-C₁₀)-alkyl radicalor (C₁-C₁₄)-cycloalkyl radical, COR12, —CO(NR13R14), S(O)_(n)R12 or—S(O)₂NR13R14, where the alkyl radical may be substituted independentlyof one another one or more times by R10; and in which n is 0, 1 or 2; pis 1 or 2 and q is 0, and the pharmaceutically acceptable salts thereof,and in which i) in the case where A is phenyl, B is phenyl orbenzodioxolanyl and R3 and R4 are H, (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkylor (C₇-C₂₀)-arylalkyl or R3 and R4 together are an unsubstitutedpyrrolidinyl, morpholinyl, piperidinyl, piperazinyl radical or4-methylpiperazinyl radical, at least one R5 radical which is not a(C₁-C₁₀)-alkyl, (C₁-C₁₀)-alkoxy, OH, CF₃, F, Cl, Br or I radical must bepresent, ii) in the case where A is phenyl and R3 and R4 are a(C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl or a (C₄-C₂₀)-cycloalkylalkylradical, at least one R5 radical which is not an F, Cl, Br, I,(C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, CF₃, OCF₃, CN, NO₂, NH₂,—NH((C₁-C₁₀)-alkyl), —N((C₁-C₁₀)-alkyl)₂, unsubstituted or substitutedbenzoyl or an unsubstituted or substituted phenyl-(CH₂)_(r)—Y—(CH₂)_(s)—radical, with Y being a bond or an oxygen and r and s being 0 to 4,where r+s is not greater than 4, must be present.
 2. A compound asclaimed in claim 1 with formula Ic

where B is a 6 to 10 membered monocyclic or fused bicyclic aryl group, a5 to 10 membered monocyclic or fused bicyclic heteroaryl group, a 9 to14 membered fused bicyclic cycloalkylaryl group, an 8 to 14 memberedfused bicyclic cycloalkylheteroaryl group, a fused 9 to 14 memberedbicyclic cycloheteroalkylaryl group or an 8 to 14 membered fusedbicyclic cycloheteroalkylheteroaryl group, each of which may besubstituted independently of one another one or more times by R5, wherethe cycloalkyl and cycloheteroalkyl units may be saturated or partlyunsaturated, and where the cycloheteroalkylaryl groups may comprise asheteroatoms 1 or 2 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfuratoms, 1 nitrogen atom and 1 oxygen or 1 sulfur atom or 1 oxygen and 1sulfur atom, and the heteroaryl and cycloalkylheteroaryl groups maycomprise 1, 2, 3 or 4 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or2 nitrogen atoms and 1 oxygen or 1 sulfur atom or 1 oxygen and 1 sulfuratom, and the cycloheteroalkylheteroaryl group may comprise asheteroatoms 1, 2, 3 or 4 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2sulfur atoms, 1, 2 or 3 nitrogen atom and 1 oxygen or 1 sulfur atom or 1oxygen and 1 sulfur atom, R2 is absent or is one or more substituentswhich may be selected independently of one another from the group of Fand of (C₁-C₆)-alkyl radicals, where the alkyl radicals may besubstituted independently of one another one or more times by F, wherethe radicals A, X, L, q, R1, R3, R4 and R5 have the meaning stated inclaim 1, and the pharmaceutically acceptable salts thereof.
 3. Acompound as claimed in claim 1 or 2, where A is a phenyl or a 5 to 6membered heteroaryl radical, where the heteroaryl radical may compriseas heteroatoms 1, 2 or 3 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1or 2 nitrogen and 1 oxygen or 1 sulfur atom, where one or more hydrogenatoms in the phenyl or heteroaryl radical may be replaced independentlyof one another by a radical R1; B is a 6 to 10 membered monocyclic orfused bicyclic aryl group, a 5 to 10 membered monocyclic or fusedbicyclic heteroaryl group, a 9 to 14 membered fused bicycliccycloalkylaryl group, an 8 to 14 membered fused bicycliccycloalkylheteroaryl group, a fused 9 to 14 membered bicycliccycloheteroalkylaryl group or an 8 to 14 membered fused bicycliccycloheteroalkylheteroaryl group, each of which may be substitutedindependently of one another one or more times by R5, where thecycloalkyl and cycloheteroalkyl units may be saturated or partlyunsaturated, and where the cycloheteroalkylaryl groups may comprise asheteroatoms 1 nitrogen atom, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, 1nitrogen atom and 1 oxygen or 1 sulfur atom or 1 oxygen and 1 sulfuratom, and the heteroaryl and cycloalkylheteroaryl groups may comprise 1,2 or 3 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 nitrogen and 1oxygen or sulfur atom or 1 oxygen and one sulfur atom, and thecycloheteroalkylheteroaryl group may comprise as heteroatoms 1, 2, 3 or4 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, 1 or 2nitrogen atoms and 1 oxygen or 1 sulfur atom or 1 oxygen and 1 sulfuratom; R2 is absent or is one or more substituents which may be selectedindependently of one another from the group of F and of (C₁-C₆)-alkylradicals, where the alkyl radicals may be substituted independently ofone another one or more times by F; where said radical X, L, q, R1, R3,R4 and R5 have the meaning stated in claim 1, and the pharmaceuticallyacceptable salts thereof.
 4. A compound as claimed in any of claims 1, 2or 3 with formula Id

where B is a phenyl group, a naphthyl group, a pyridinyl group, aquinolinyl group, an isoquinolinyl group, an indolyl group, abenzothiophenyl group, a benzodihydrothiophenyl group, a benzofuranylgroup, a benzodihydrofuranyl group, a benzopyrrolidinyl group, anisobenzodihydrofuranyl, a benzoimidazolyl group, a benzopyrazolyl group,a benzotriazolyl group, a benzothiazolyl group, a benzoxathiolyl group,an indolinyl group, benzodioxolyl group, a tetrahydroisoquinolinyl groupor a tetrahydroquinolinyl group, where one, two, three or four hydrogenatoms in the group B may be replaced by radicals from the group R5,where each R5 radical is selected independently of one another from thegroup of (C₁-C₄)-alkyl which may be wholly or partly fluorinated, or onehydrogen may be replaced by a CN, NH₂, OH, NH(C₁-C₄)alkyl,N((C₁-C₄)alkyl)₂, (C₁-C₄)alkoxy, (C₁-C₄)-alkoxy which may be wholly orpartly fluorinated, (C₁-C₄)-alkylthio which may be wholly or partlyfluorinated, (C₂-C₅)-cycloheteroalkyl,(C₂-C₅)-cycloheteroalkyl-(C₁-C₄)-alkyl, where the cycloheteroalkyl ringmay be saturated or partly unsaturated and may comprise 1 or 2 nitrogenatoms, 1 oxygen atom, 1 nitrogen and 1 sulfur atom or 1 nitrogen and 1oxygen atom, and where the cycloheteroalkyl ring may carry furthersubstituents from the group of —F, —Cl, —Br, ═O, —NH₂, —CN,(C₁-C₄)-alkyl, (C₃-C₁₀)-cycloalkyl, OH, NH(C₁-C₄)-alkyl,N((C₁-C₄)-alkyl)₂ and (C₁-C₁₀)-alkoxy, phenyl, naphthyl,(C₁-C₆)-heteroaryl, where the heteroaryl ring may be a monocyclic orfused bicyclic ring which may comprise 1, 2, 3 or 4 nitrogen atoms, 1oxygen atom, 1 sulfur atom, 1 or 2 nitrogen atoms and 1 oxygen or sulfuratom, and where the heteroaryl ring may carry further substituents fromthe group of —F, —Cl, —Br, ═O, —NH₂, —CN, (C₁-C₄)-alkyl,(C₃-C₁₀)-cycloalkyl, OH, NH(C₁-C₄)-alkyl, N((C₁-C₄)-alkyl)₂,(C₁-C₁₀)-alkoxy and —C(O)O—(C₁-C₄)-alkyl, H, OH, (═O), F, Cl, Br, CN,NO₂, —NR17R18, —NR16COR17, —NR16COOR17, —NR16CONR17R18, —NR16-S(O)₂—R17,—NR16-S(O)₂—NR17R18, —COOR16, —COR16; —CO(NR17R18), S(O)_(n)R16, withn=1 or 2 and —S(O)₂NR17R18, where R16, R17 and R18 may be independentlyof one another a hydrogen radical or a radical selected from the groupof unsubstituted or substituted (C₁-C₄)-alkyl radicals, where thesubstituents of the alkyl radicals are selected from F, OH, (═O), NH₂,NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN and (C₁-C₁₀)-alkoxy, R17 and R18may form together with the nitrogen to which they are bonded a 5-6membered, saturated, unsaturated or partly unsaturated heterocyclehaving 1 to 5 carbon atoms, which may additionally comprise one or moreheteroatoms from the list —O—, —S(O)_(n)— with n=0, 1 or 2, ═N—, —NH—and N((C₁-C₄)alkyl)-, where the formed heterocycle independently of oneanother one or more times by (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl,(C₄-C₂₀)-cycloalkylalkyl, (C₂-C₂₀)-cycloheteroalkyl or(C₃-C₁₉)-cycloheteroalkylalkyl, each of which may in turn carryindependently of one another one or more radicals F, OH, (═O), NH₂,NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy; R1 is absent oris one, two or three radicals which are selected independently of oneanother from the group of F, Cl, Br, I, (C₁-C₆)-alkyl and(C₁-C₆)-alkoxy, where the alkyl and alkoxy radical may be substitutedone or more times by F; R3 and R4 are independently of one another aradical selected from the group of H, (C₁-C₄)-alkyl,(C₃-C₇)-cycloalkyl-, (C₃-C₇)-cycloalkyl-(C₁-C₄)-alkyl-,(C₃-C₆)-cycloheteroalkyl-, phenyl-, phenyl-(C₁-C₄)-alkyl- and(C₁-C₅)-heteroaryl, where the radicals R3 and R4 may be substitutedindependently of one another one, two or three times by a radical fromthe group of OH, (═O), F, Cl, Br, CN, NO₂, —NR13R14, —NR13COR12,—NR13COOR12, —NR12CONR13R14, —NR13-S(O)₂—R12, —NR13-S(O)₂—NR13R14,—COOR12, —COR12; —CO(NR13R14), —S(O)_(n)R12 and —S(O)₂NR13R14, whereR12, R13 and R14 are independently of one another H or (C₁-C₄)-alkyl, orR3 and R4 form together with the nitrogen to which they are bonded a 4-8membered, saturated, unsaturated or partly unsaturated heterocycle whichmay additionally comprise one or more heteroatoms from the list —O—,—S(O)_(n)—, with n=0, 1 or 2, ═N— and —NR8-, where the heterocyclicradicals may be substituted independently of one another one or moretimes by a radical selected from the group of radicals R7 and R9, wherethe heterocyclic radicals may be bridged by a bond, (C₁-C₇)-alkyl,(C₁-C₆)-saturated or unsaturated heteroalkyl chains or by —NH— or—N(C₁-C₄)-alkyl-, and where the alkyl and heteroalkyl chains may alsoform a spirocyclic ring system with the ring system formed by R3 and R4,and where R8 in the group NR8 may form with the ring which the radicalsR3 and R4 may form a further saturated, unsaturated or partlyunsaturated heterocycle which may additionally comprise one or twoheteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1 or 2, ═N— and—NR19-, with R19 equal to H or (C₁-C₄)-alkyl; where the radicals R7, R8and R9 have the meaning stated in claim 1, and the pharmaceuticallyacceptable salts thereof.
 5. A compound as claimed in any of claims 1,2, 3 or 4, where B is a phenyl group, a naphthyl group, a pyridinylgroup, a quinolinyl group, an isoquinolinyl group, an indolyl group, abenzothiophenyl group, a benzodihydrothiophenyl group, a benzofuranylgroup, a benzodihydrofuranyl group, an isobenzodihydrofuranyl group, abenzopyrrolidinyl group, a benzoimidazolyl group, a benzopyrazolylgroup, a benzotriazolyl group, a benzothiazolyl group, a benzoxathiolylgroup, an indolinyl group, benzodioxolyl group, atetrahydroisoquinolinyl group, a tetrahydroquinolinyl group, where one,two, three or four hydrogen atoms in group B may be replaced by radicalsfrom the group R5, where one of the R5 radicals is selected from thegroup of (C₂-C₅)-cycloheteroalkyl, where the cycloheteroalkyl ring maybe saturated or partly unsaturated and may comprise 1 or 2 nitrogenatoms, 1 oxygen atoms, 1 nitrogen and 1 sulfur atom or 1 nitrogen and 1oxygen atom, and where the cycloheteroalkyl ring may carry furthersubstituents from the group of —F, —Cl, —Br, ═O, —NH₂—, —CN,(C₁-C₄)-alkyl and (C₃-C₁₀)-cycloalkyl, (C₁-C₆)-heteroaryl, where theheteroaryl ring may be a monocyclic or fused bicyclic ring which maycomprise 1, 2, 3 or 4 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or2 nitrogen atoms and 1 oxygen or sulfur atom, and where the heteroarylring may carry further substituents from the group of —F, —Cl, —Br, ═O,—NH₂, —CN, (C₁-C₄)-alkyl, (C₃-C₁₀-cycloalkyl and —C(O)O—(C₁-C₄)-alkyl,OH, (═O), NH₂, NO₂, —NR17R18, —NR16COR17, —NR16COOR17, —NR16CONR17R18,—NR16-S(O)₂—R17, —NR16-S(O)₂—NR17R18, —COOR16, —COR16; —CO(NR17R18),S(O)₂R16 and —S(O)₂NR17R18, where R16, R17 and R18 may be independentlyof one another a hydrogen radical or a radical selected from the groupof unsubstituted or substituted (C₁-C₄)-alkyl radicals, where thesubstituents of the alkyl radicals are selected from F, OH, (═O), NH₂,NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN and (C₁-C₁₀)-alkoxy R17 and R18 mayform together with the nitrogen to which they are bonded a 5-6 membered,saturated, unsaturated or partly unsaturated heterocycle having 1 to 5carbon atoms which may additionally comprise one or more heteroatomsfrom the list —O—, —S(O)_(n)—, with n=0, 1 or 2, ═N—, —NH— and—N((C₁-C₄)-alkyl)-, where the formed heterocycle independently of oneanother may be substituted one or more times by (C₁-C₁₀)-alkyl,(C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl, (C₂-C₂₀)-cycloheteroalkylor (C₃-C₁₉)-cycloheteroalkylalkyl, each of which in turn may carryindependently of one another one or more radicals F, OH, (═O), NH₂,NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy, and furtherradicals R5 are selected independently of one another from the group of(C₁-C₄)-alkyl which may be wholly or partly fluorinated, or a hydrogenmay be replaced by a CN, NH₂, OH, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂ or(C₁-C₄)-alkoxy, (C₁-C₄)-alkoxy which may be wholly or partlyfluorinated, (C₁-C₄)-alkylthio which may be wholly or partlyfluorinated, phenyl, OH, (═O), F, Cl, Br, CN, —NR17R18, NR16COR17,—COOR16, —COR16 and —CO(NR17R18), where R16, R17 and R18 may beindependently of one another a hydrogen radical or a radical selectedfrom the group of unsubstituted or substituted (C₁-C₄)-alkyl radicals,where the substituents of the alkyl radicals are selected from F, OH,(═O), NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN and (C₁-C₁₀)-alkoxy-, orR17 and R18 may form together with the nitrogen to which they are bondeda 4-7 membered, saturated, unsaturated or partly unsaturated heterocyclehaving 1 to 5 carbon atoms, which may additionally comprise one or moreheteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1 or 2, ═N—, —NH—and N((C₁-C₄)alkyl)-, where the formed heterocycle independently of oneanother may be substituted one or more times by (C₁-C₁₀)-alkyl,(C₃-C₁₄)-cycloalkyl, (C₄-C₂₀)-cycloalkylalkyl, (C₂-C₂₀)-cycloheteroalkylor (C₃-C₁₉)-cycloheteroalkylalkyl, each of which in turn may carryindependently of one another one or more radicals F, OH, (═O), NH₂,NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN or (C₁-C₁₀)-alkoxy; R1 is absent oris one, two or three radicals which are selected independently of oneanother from the group of F, Cl, Br, I, (C₁-C₆)-alkyl and(C₁-C₆)-alkoxy, where the alkyl and alkoxy radical may be substitutedone or more times by F; R3 and R4 are independently of one another aradical selected from the group of H, (C₁-C₅)-alkyl-,phenyl-(C₁-C₄)-alkyl-, NH₂—(C₁-C₄)-alkyl-,N((C₁-C₄)-alkyl)₂-(C₁-C₄)-alkyl-, (C₁-C₄)-alkoxy-(C₁-C₄)-alkyl-,(C₃-C₇)-cycloalkyl-(C₁-C₄)-alkyl- and (C₄-C₆)-cycloheteroalkyl- thatcomprises an —NH—, —O— or —S— group, or R3 and R4 form together with thenitrogen to which they are bonded a 4-8 membered, saturated, unsaturatedor partly unsaturated heterocycle which may additionally comprise one ormore heteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1 or 2, ═N—and —NR8-, where the heterocyclic radicals may be substitutedindependently of one another one or more times by radicals selected fromthe group of radicals R7 and R9, where the heterocyclic radicals may bebridged by a bond, (C₁-C₇)-alkyl, (C₁-C₆)-saturated or unsaturatedheteroalkyl chains or by —NH—, N((C₁-C₄)alkyl)-, and where the alkyl andheteroalkyl chains may also form a spirocyclic ring system with the ringsystem formed by R3 and R4, and where R8 may form with the ring whichthe radicals R3 and R4 form a further saturated, unsaturated or partlyunsaturated heterocycle which may additionally comprise one or twoheteroatoms from the list —O—, —S(O)_(n)—, with n=0, 1 or 2, —NH— and—N((C₁-C₄)alkyl)-; R7 is H, a (C₁-C₅)-alkyl radical or(C₃-C₆)-cycloalkyl radical, where the alkyl radical may be substitutedindependently of one another one or more times by R9; R8 is an H, a(C₁-C₅)-alkyl radical or (C₁-C₆)-cycloalkyl radical, where the alkylradical may be substituted independently of one another one or moretimes by F, OH, NH₂, CN, NO₂, (C₁-C₁₀)-alkoxy, (C₁-C₁₀)-alkylthio,—NR13R14, —NR13COR12, —NR13COOR12, —NR13CONR13R14, —NR13-S(O)₂—R12,—NR12-S(O)₂—NR13R14, —COOR12, —COR12; —CO(NR13R14), S(O)_(n)R12,—S(O)₂NR13R14, COR12, —CO(NR13R14), S(O)_(n)R12 or —S(O)₂NR13R14; R9 isa radical selected from the group of OH, NH₂, (═O), F, Cl, Br, I, CN,—NR13R14, —NR13COR12, —NR13COOR12, —NR12CONR13R14, —NR13-S(O)₂—R12,—NR13-S(O)₂—NR13R14, —COOR12, —COR12; —CO(NR13R14), S(O)_(n)R12,—S(O)₂NR13R14, (C₃-C₆)-cycloalkyl, (C₄-C₇)-cycloalkylalkyl,(C₁-C₅)-alkoxy, (C₂-C₆)-cycloheteroalkyl, (C₃-C₁₀)—cycloheteroalkylalkyl, phenyl or (C₁-C₅)-heteroaryl radicals, where R12,R13 and R14 are independently of one another a hydrogen radical or aradical selected from the group of unsubstituted or substituted(C₁-C₄)-alkyl radicals, where the substituents of the alkyl radicals areselected from F, OH, (═O), NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, CN and(C₁-C₁₀)-alkoxy; and the pharmaceutically acceptable salts thereof.
 6. Acompound as claimed in claim 1 with formula Ia

where A is a phenyl or 5 to 6 membered heteroaryl radical, where theheteroaryl radical may comprise as heteroatoms 1, 2 or 3 nitrogen atoms,1 oxygen atom, 1 sulfur atom, 1 or 2 nitrogen and 1 oxygen or 1 sulfuratom, where one or more hydrogen atoms in said phenyl or heteroarylradical may be replaced independently of one another by a radical R1; Bis a 6 to 10 membered monocyclic or fused bicyclic aryl group, a 5 to 10membered monocyclic or fused bicyclic heteroaryl group, a 9 to 14membered fused bicyclic cycloalkylaryl group, an 8 to 14 membered fusedbicyclic cycloalkylheteroaryl group, a 9 to 14 membered fused bicycliccycloheteroalkylaryl group or an 8 to 14 membered fused bicycliccycloheteroalkylheteroaryl group, each of which may be substitutedindependently of one another one or more times by R5 where thecycloalkyl and cycloheteroalkyl units may be saturated or partlyunsaturated, and where the cycloheteroalkylaryl groups may comprise asheteroatoms 1 or 2 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfuratoms, 1 nitrogen atom and 1 oxygen or 1 sulfur atom or 1 oxygen and 1sulfur atom, and the heteroaryl and cycloalkylheteroaryl groups maycomprise 1, 2, 3 or 4 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or2 nitrogen atoms and 1 oxygen or sulfur atom or 1 oxygen and 1 sulfuratom, and the cycloheteroalkylheteroaryl group may comprise asheteroatoms 1, 2, 3 or 4 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2sulfur atoms, 1, 2 or 3 nitrogen atom and 1 oxygen or 1 sulfur atom or 1oxygen and 1 sulfur atom; R2 is absent or is one or more substituentswhich may be selected independently of one another from the group of Fand of (C₁-C₆)-alkyl radicals, where the alkyl radicals may besubstituted independently of one another one or more times by F; wherethe radicals X, L, q, R1, R3, R4 and R5 have the meaning stated in claim1, and the pharmaceutically acceptable salts thereof.
 7. A compound asclaimed in claim 1 with formula Ib

where B is a phenyl group, a naphthyl group, a pyridinyl group, aquinolinyl group, an isoquinolinyl group, an indolyl group, abenzothiophenyl group, a benzodihydrothiophenyl group, a benzofuranylgroup, a benzodihydrofuranyl group, an isobenzodihydrofuranyl group, abenzopyrrolidinyl group, a benzoimidazolyl group, a benzopyrazolylgroup, a benzotriazolyl group, a benzothiazolyl group, a benzoxathiolylgroup, an indolinyl group, benzodioxolyl group, atetrahydroisoquinolinyl group or a tetrahydroquinolinyl group, whereone, two, three or four hydrogen atoms in group B may be replaced byradicals from the group R5, where each R5 radical is selectedindependently of one another from the group of (C₁-C₄)-alkyl which maybe wholly or partly fluorinated, or a hydrogen may be replaced by a CN,NH₂, OH, NH(C₁-C₄)alkyl, N((C₁-C₄)-alkyl)₂ or (C₁-C₄)-alkoxy,(C₁-C₄)-alkoxy which may be wholly or partly fluorinated,(C₁-C₄)-alkylthio which may be wholly or partly fluorinated,(C₂-C₅)-cycloheteroalkyl, (C₂-C₅)-cycloheteroalkyl-(C₁-C₄)-alkyl, wherethe cycloheteroalkyl ring may be monocyclic, bicyclic, saturated orpartly unsaturated, and may comprise 1 or 2 nitrogen atoms, 1 oxygenatoms, 1 nitrogen and 1 sulfur atom or 1 nitrogen and 1 oxygen atom, andwhere the cycloheteroalkyl ring may carry further substituents from thegroup of —F, —Cl, —Br, ═O, —NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂,(C₁-C₄)-alkoxy, —CN, (C₁-C₄)-alkyl and (C₃-C₁₀)— cycloalkyl, phenyl,naphthyl, (C₁-C₆)-heteroaryl, where the heteroaryl ring may be amonocyclic or fused bicyclic ring which may comprise 1, 2, 3 or 4nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or 2 nitrogen atoms and1 oxygen or sulfur atom, and where the heteroaryl ring may carry furthersubstituents from the group of —F, —Cl, —Br, ═O, —NH₂, OH,NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, (C₁-C₄)-alkoxy, —CN, (C₁-C₄)-alkyl,(C₃-C₁₀)-cycloalkyl and —C(O)O—(C₁-C₄)-alkyl, H, OH, (═O), F, Cl, Br,CN, NO₂, —NR17R18, —NR16COR17, —NR16COOR17, —NR16CONR17R18,—NR16-S(O)₂—R17, —NR16-S(O)₂—NR17R18, —COOR16, —COR16; —CO(NR17R18),—S(O)_(n)R16, with n=1 or 2, and —S(O)₂NR17R18, where R16, R17 and R18may independently of one another be a hydrogen radical or a radicalselected from the group of unsubstituted or substituted (C₁-C₄)-alkylradicals, where the substituents of the alkyl radicals are selected fromF, OH, (═O), NH₂, NH(C₁-C₄)alkyl, N((C₁-C₄)alkyl)₂, —CN or(C₁-C₁₀)-alkoxy, R17 and R18 may form together with the nitrogen towhich they are bonded a 5-6 membered, saturated, unsaturated or partlyunsaturated heterocycle having 1 to 5 carbon atoms, which mayadditionally comprise one or more heteroatoms from the list —O—,—S(O)_(n)— with n=0, 1 or 2, ═N—, —NH— and —N((C₁-C₄)alkyl), where theformed heterocycle independently of one another may be substituted oneor more times by (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl,(C₄-C₂₀)-cycloalkylalkyl, (C₂-C₂₀)-cycloheteroalkyl,(C₃-C₁₉)-cycloheteroalkylalkyl, each of which may in turn carryindependently of one another one or more radicals F, OH, (═O) or(C₁-C₁₀)-alkoxy; R1 is absent or is one, two or three radicals which areselected independently of one another from the group of F, Cl, Br, I,(C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, where the alkyl and alkoxy radical may besubstituted one or more times by F; R3 and R4 are independently of oneanother a radical selected from the group of H, (C₁-C₄)-alkyl-,(C₃-C₇)-cycloalkyl-, (C₃-C₆)-cycloheteroalkyl, phenyl,phenyl-(C₁-C₄)-alkyl and (C₁-C₅)-heteroaryl, where the radicals R3 andR4 may be substituted independently of one another one, two or threetimes by a radical from the group of OH, (═O), F, Cl, Br, CN, NO₂,—NR13R14, —NR13COR12, —NR13COOR12, —NR12CONR13R14, —NR13-S(O)₂—R12,—NR13-S(O)₂—NR13R14, —COOR12, —COR12; —CO(NR13R14), —S(O)_(n)R12,—S(O)₂NR13R14, where R12, R13 and R14 independently of one another are Hor (C₁-C₄)-alkyl; or R3 and R4 form together with the nitrogen to whichthey are bonded a 4-8 membered, saturated, unsaturated or partlyunsaturated heterocycle which may additionally comprise one or moreheteroatoms from the list —O—, —S(O)_(n)— with n=0, 1 or 2, ═N— and—NR8-, where the heterocyclic radicals may be substituted independentlyof one another one or more times by radicals selected from the group ofR7 and R9, where the heterocyclic radicals may be bridged by a bond,(C₁-C₇)-alkyl, saturated or unsaturated (C₁-C₆)-heteroalkyl chains or by—NH— or —N(C₁-C₄)-alkyl-, and where the alkyl and heteroalkyl chains mayalso form a spirocyclic ring system with the ring system formed by R3and R4, and where R8 may form with the ring which the radicals R3 and R4may form a further saturated, unsaturated or partly unsaturatedheterocycle which may additionally comprise one or two heteroatoms fromthe list —O—, —S(O)_(n)—, with n=0, 1 or 2, ═N—, —NH— and—N((C₁-C₄)-alkyl); where R7, R8 and R9 have the meaning indicated inclaim 1, and the pharmaceutically acceptable salts thereof.
 8. Acompound as claimed in any of claims 1, 2, 3, 4, 5 or 6, where R3 and R4form together with the nitrogen to which they are bonded a 4-10membered, saturated, unsaturated or partly unsaturated heterocycle whichmay additionally comprise one or more heteroatoms from the list —O—,—S(O)_(n)—, ═N— and —NR8-, where the heterocyclic radicals may besubstituted independently of one another one or more times by radicalsselected from the group of R7 and R9, and where the heterocyclicradicals formed by R3 and R4 may be bridged by a bond, by a saturated orunsaturated (C₁-C₁₀)-alkyl or (C₁-C₉)-heteroalkyl chain or by —NR15-,—O— or —S—, and where the alkyl and heteroalkyl chains may also form aspirocyclic ring system with the ring system formed by R3 and R4, wherethe alkyl and heteroalkyl bridges may be substituted independently ofone another one or more times by radicals selected from the group of R7and R9, and where R8 in the group —NR8- may form with the ring which R3and R4 may form a further saturated, unsaturated or partly unsaturatedheterocycle which may be substituted independently of one another one ormore times by radicals selected from the group of R7 and R9, and mayadditionally comprise one or more heteroatoms from the list —O—,—S(O)_(n)—, —N═ and —NR19-; where n, R7, R8, R9 and R19 have the meaningindicated in claim 1, and the pharmaceutically acceptable salts thereof.9. A compound as claimed in any of claims 1, 2, 3, 4, 5, 6, 7 or 8,where R3 and R4 form together with the nitrogen to which they are bondeda 4-8 membered, saturated, unsaturated or partly unsaturated heterocyclewhich may additionally comprise one or more heteroatoms from the list—O—, —S(O)_(n)—, with n=0, 1 or 2, ═N— and —NR8-, where the heterocyclicradicals may be substituted independently of one another one or moretimes by radicals selected from the group of radicals R7 and R9, andwhere R8 may form with the ring which the radicals R3 and R4 form mayform together with an adjacent C atom a fused triazole or pyrrolidinering; where R7, R8 and R9 have the meaning indicated in claim 1, and thepharmaceutically acceptable salts thereof.
 10. A compound as claimed inany of claims 1, 2, 3, 4, 5, 6 or 7, where R3 and R4 are independentlyof one another a hydrogen radical or a radical which is selected fromthe group of (C₁-C₁₀)-alkyl radicals, of (C₂-C₁₀)-alkenyl radicals, of(C₂-C₁₀)-alkynyl radicals, of (C₃-C₁₄)-cycloalkyl radicals, of(C₄-C₂₀)-cycloalkylalkyl radicals, of (C₂-C₁₉)-cycloheteroalkylradicals, of (C₃-C₁₉)-cycloheteroalkylalkyl radicals, of (C₆-C₁₀)-arylradicals, of (C₇-C₂₀)-arylalkyl radicals, of (C₁-C₉)-heteroaryl radicalsand of (C₂-C₁₉)-heteroarylalkyl radicals, where the radicals R3 and R4may be substituted independently of one another one or more times by aradical from the group of OH, NH₂, (═O), F, Cl, Br, I, CN, NO₂,—NR13R14, —NR13COR12, —NR13COOR12, —NR12CONR13R14, —NR13-S(O)₂—R12,—NR13-S(O)₂—NR13R14, —COOR12, —COR12; —CO(NR13R14), S(O)_(n)R12 and—S(O)₂R13R14; where R12, R13 and R14 have the meaning indicated in claim1, and the pharmaceutically acceptable salts thereof.
 11. A compound ofthe formula I as claimed in claim 1, wherein the compound is selectedfrom the group consisting of:(R)-1-[rac-trans-(1,2)-1-(1H-benzotriazol-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2,6-dimethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-bromophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-chloro-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-chloro-6-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-chloropyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-chloroquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-fluoro-4-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-fluoro-5-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-morpholin-4-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-trifluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3,4-difluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-chloro-4-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-chloro-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-chlorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-difluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-tetrazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-bromo-3-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-chloro-2-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-chloro-3-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-chlorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-dimethylaminomethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-fluoro-2-isoxazol-5-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-fluoro-3-trifluoromethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-methylsulfanylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-trifluoromethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(5,7-dimethylquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(5-fluoroquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(6-aminonaphthalen-1-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(isoquinolin-7-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(quinolin-3-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(quinolin-5-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(R)-1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;(R)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;(R)-1-{rac-trans-(1,2)-1-[4-chloro-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;(R)-1-{rac-trans-(1,2)-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(1H-benzotriazol-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(1H-indol-6-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-bromophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-chloro-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-chloropyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-chloroquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-fluoro-5-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-morpholin-4-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(2-trifluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-chloro-2-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-chloro-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-chloro-5-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-chlorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-difluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-bromo-3-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-chloro-2-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-chlorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-difluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-dimethylaminomethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-fluoro-2-isoxazol-5-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-methylsulfanylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-trifluoromethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(5,7-dimethylquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(5-fluoroquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(6-aminonaphthalen-1-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(pyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(quinolin-3-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(quinolin-5-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;(S)-1-{rac-trans-(1,2)-1-[3-(2-aminoethyl)-1H-indol-5-yloxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;(S)-1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;(S)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;(S)-1-{rac-trans-(1,2)-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;[3-methoxy-2-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)phenyl]acetonitrile;{2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-methoxyphenyl}acetonitrile;{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}acetonitrile;{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}carbamicacid benzyl ester;{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}carbamicacid benzyl ester;1-[1,3-dichloro-4-(4-methanesulfonylphenoxy)-4,5,6,7-tetrahydrobenzo[c]thiophen-5-yl]pyrrolidine;1-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3,5-difluorophenyl}propan-1-one;1-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}pyrrolidine-2,5-dione;2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-chlorobenzamide;2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-chlorobenzonitrile;2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-6-fluorobenzonitrile;2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzamide;2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-bromobenzonitrile;2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-chlorobenzamide;2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-chlorobenzonitrile;2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-6-fluorobenzonitrile;2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzamide;2-{-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}-N,N-dimethylacetamide;2-{-4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}-N,N-dimethylacetamide;2-chloro-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;2-Fluoro-4-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)benzonitrile;2-methyl-4-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)-1H-indole;3-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzamide;4-[4-((4S,5S)-1,3-dichloro-5-pyrrolidin-1-yl-4,5,6,7-tetrahydrobenzo[c]thiophen-4-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(1,3-dichloro-5-pyrrolidin-1-yl-4,5,6,7-tetrahydrobenzo[c]thiophen-4-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[rac-trans-(1,2)-1-(2-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]morpholine;4-[rac-trans-(1,2)-1-(4-fluoro-2-isoxazol-5-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]morpholine;4-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]morpholine;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2,3-difluorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2-fluorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3,5-dimethylbenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chloro-5-methoxy-benzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chlorobenzoicacid methyl ester;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-fluorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]biphenyl-4-carbonitrile;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2,3-difluorobenzonitrile;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2-chlorobenzonitrile;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2-fluorobenzonitrile;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chlorobenzoicacid methyl ester;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-fluorobenzonitrile;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-nitrobenzonitrile;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzonitrile;5-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)-naphthalen-2-ylamine;5-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;5,7-dimethyl-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;5-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzo[1,3]oxathiol-2-one;5-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzo[1,3]oxathiol-2-one;5-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}oxazole-4-carboxylicacid ethyl ester;5-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}oxazole-4-carboxylicacid ethyl ester;5-chloro-2-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)benzonitrile;5-fluoro-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;7-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)-isoquinoline;8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline-2-carbonitrile;8-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]quinoline-2-carbonitrile;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-4-propylphenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-4-propylphenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}acetamide;and the pharmaceutically acceptable salts thereof.
 12. A compound of theformula I as claimed in claim 1, wherein the compound is selected fromthe group consisting of:(S)-1-[rac-trans-(1,2)-1-(3-dimethylaminomethylphenoxy)indan-2-yl]piperidin-3-ylamine;{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenylcarbamoyloxy}aceticacid;{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}carbamicacid benzyl ester;1-[1-(4-methanesulfonylphenoxy)-2-methylindan-2-yl]pyrrolidine;2-{5-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-1H-indol-3-yl}acetamide;2-{5-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]-1H-indol-3-yl}acetamide;2-{5-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-1H-indol-3-yl}acetamide;4-[4-(rac-trans-(1,2)-3,3-dimethyl-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]-triazole;N,N-dimethyl-2-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzyl]acetamide;((R)-1-{trans-(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}piperidin-3-yl)-(3,3,3-trifluoropropyl)amine;2-[rac-trans-(1,2)-1-(2,4-dichloro-3-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(3-chloro-2-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2-bromophenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(3-piperidin-1-ylmethylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(3-piperidin-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(4-fluoro-2-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}-octahydropyrrolo[3,4-c]pyrrole;2-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}-octahydropyrrolo[3,4-c]pyrrole;(4-methylpiperazin-1-yl)[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]methanone;(R)-1-(trans-(1R,2R)-4,6-dichloro-1-phenoxyindan-2-yl)piperidin-3-ylamine;(R)-1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[(1S,2S)-4,6-dichloro-1-(5-fluoroquinolin-8-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(1H-indol-4-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2,3-dichloro-4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-piperidin-1-ylmethylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-piperidin-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(benzo[1,3]dioxol-5-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(isoquinolin-7-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(pyridin-4-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(quinolin-4-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1R,2R)-4,6-dichloro-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}piperidin-3-ylamine;(R)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-3-ylamine;(R)-1-{trans-(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-piperidin-1-ylmethylphenoxy)indan-2-yl]piperidin-3-ylamine,(S)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(quinolin-5-yloxy)indan-2-yl]piperidin-3-ylamine;(S)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-3-ylamine;[3-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)phenyl]urea;[rac-trans-(1,2)-1-(1H-indol-4-yloxy)indan-2-yl]methylpiperidin-3-ylamine;[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]methylpiperidin-4-ylamine;[rac-trans-(1,2)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]-dimethylamine;[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-(2-methoxyethyl)methylamine;{(R)-1-[trans-(1S,2S)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(2,2,2-trifluoroethyl)amine;{(R)-1-[trans-(1S,2S)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine;{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}urea;{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}urea;{3-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}urea;{3-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]phenyl}urea,{3-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]phenyl}urea;{4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}carbamicacid benzyl ester;{4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]phenyl}carbamicacid benzyl ester;{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-(2-methoxyethyl)methylamine;1-[1-(2-chloro-4-nitrophenoxy)indan-2-yl]pyrrolidine;1-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-1,3-dihydroimidazol-2-one;1-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidin-2-one;1-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidine-2,5-dione;1-[rac-cis-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]-1H-imidazole;1-[rac-trans-(1,2)-1-(1H-indol-6-yloxy)indan-2-yl]pyrrolidin-3-ylamine;1-[rac-trans-(1,2)-1-(2,3-dichloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine,1-[rac-trans-(1,2)-1-(2,6-dichloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]pyrrolidin-3-ylamine;1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;1-[rac-trans-(1,2)-1-(3-chloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(3-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;1-[rac-trans-(1,2)-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(quinolin-4-yloxy)indan-2-yl]pyrrolidin-3-ylamine;1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}pyrrolidin-3-ylamine;1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-4-ylamine;1-methyl-3-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-1,3-dihydroimidazol-2-one;2,2,2-trifluoro-N-{(R)-1-[trans-(1S,2S)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}acetamide;2,3-dichloro-4-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)benzenesulfonamide;2,3-dichloro-4-(rac-trans-(1,2)-2-dimethylaminoindan-1-yloxy)benzenesulfonamide;2,3-dichloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;2,3-dichloro-4-[rac-trans-(1,2)-2-((R)-3-methoxypyrrolidin-1-yl)indan-1-yloxy]benzenesulfonamide;2,3-dichloro-4-[rac-trans-(1,2)-2-(methylpiperidin-3-ylamino)indan-1-yloxy]benzenesulfonamide;2,3-dichloro-4-[trans-(1S,2S)-2-(3-hydroxypiperidin-1-yl)indan-1-yloxy]benzenesulfonamide;2,3-dichloro-N,N-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;2-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]isothiazolidine1,1-dioxide;2-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]thiazole;2-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-6-fluorobenzonitrile;2-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]-5-chlorobenzonitrile;2-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-5-chlorobenzonitrile;2-{-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}-thiazole-4-carbonitrile;2-chloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzonitrile;2-chloro-4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile;2-fluoro-4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile;2-fluoro-6-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile;3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenylamine;3,5-dichloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3,5-dichloro-N,N-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3,5-dimethyl-4-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole;3,5-dimethyl-4-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole;3,5-dimethyl-4-[4-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)-3-trifluoromethylphenyl]-4H-[1,2,4]triazole;3,5-dimethyl-4-[4-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-isoxazole;3,5-dimethyl-4-[5-methyl-2-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]isoxazole;3-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]oxazolidin-2-one;3-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzamide;3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;3-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]benzamide;3-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]benzamide;3-chloro-4-(2-pyrrolidin-1-ylindan-1-yloxy)pyridine;3-chloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3-chloro-4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile;3-chloro-N,N-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3-cyclopropyl-5-methyl-4-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole;3-fluoro-4-(2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3-methyl-4-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole;4-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-3-fluorobenzonitrile;4-((1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-3-fluorobenzonitrile;4-(2-benzylaminoindan-1-yloxy)-3-fluorobenzenesulfonamide;4-(2-cyclopentylaminoindan-1-yloxy)-3-fluorobenzenesulfonamide;4-(rac-trans-(1,2)-(R)-2-[1,3′]bipyrrolidinyl-1′-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-2-azepan-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-2-piperidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzoic acid methylester; 4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzonitrile;4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-N-(2,2,2-trifluoroethyl)benzenesulfonamide;4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-N-(3,3,3-trifluoropropyl)benzenesulfonamide;4-(trans-(1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-3-fluorobenzonitrile;4-[(1R,2S)-1-(2-chloro-4-nitrophenoxy)indan-2-yl]morpholine;4-[(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]-3-fluorobenzonitrile;4-[(1S,2S)-4,6-dichloro-2-(4-methylpiperazin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;4-[2,3-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[2-fluoro-5-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethylisoxazole;4-[3-chloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[3-chloro-4-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[3-fluoro-4-(-2-methyl-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[5-fluoro-2-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethylisoxazole;4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-1H-indole;4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-2,6-dimethylbenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2,3-dichloro-N,N-dimethylbenzenesulfonamide;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2-chlorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2-fluorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;4-[rac-trans-(1,2)-2-((R)-3-hydroxymethylpyrrolidin-1-yl)indan-1-yloxy]benzenesulfonamide;4-[rac-trans-(1,2)-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]benzenesulfonamide;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-2,6-dimethylbenzonitrile;4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-2-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]benzamide;4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-2-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]benzamide;4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]-3-fluorobenzonitrile;4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzenesulfonamide;4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;4-[trans-(1S,2S)-4,6-dichloro-2-((S)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;4-[trans-(1S,2S)-4,6-dichloro-2-(4-methyl-[1,4]diazepan-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;4-[trans-(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;5-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)-1,3-dimethyl-1,3-dihydro-indol-2-one,5-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-3H-isobenzofuran-1-one;5-[5-fluoro-2-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-1H-pyrazole;5-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-2-methylbenzothiazole;5-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzo[1,3]oxathiol-2-one;5-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzo[1,3]oxathiol-2-one;6-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-1H-indole;7-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-isoquinoline;7-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine;8-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-5-fluoroquinoline;8-((1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-5-fluoroquinoline;8-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)-5-fluoroquinoline;8-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)quinoline;benzyl[1-(4-methanesulfonylphenoxy)indan-2-yl]amine;C-(1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}pyrrolidin-3-yl)-methylamine;C-(1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-4-yl)methylamine;C-(1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}pyrrolidin-3-yl)methylamine;C-{1-[rac-trans-(1,2)-1-(1H-indol-4-yloxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-chloro-2-methylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-ethoxyphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-ethoxyphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(benzo[1,3]dioxol-5-yloxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(benzo[1,3]dioxol-5-yloxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(quinolin-4-yloxy)indan-2-yl]piperidin-4-yl}methylaminecyclopentyl-[1-(4-methanesulfonylphenoxy)indan-2-yl]amine;cyclopropylmethyl-[1-(4-methanesulfonylphenoxy)indan-2-yl]amine;diethyl-[rac-trans-(1,2)-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]amine;diethyl-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]amine;diethyl-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]amine;diethyl-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}amine;methyl-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-ylamine;methyl-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-ylamine;N-(3-{trans-(1S,2S)-2-[(R)-3-(2-fluoroethylamino)piperidin-1-yl]indan-1-yloxy}phenyl)acetamide;N-(3-{trans-(1S,2S)-2-[(R)-3-(3,3,3-trifluoropropylamino)piperidin-1-yl]indan-1-yloxy}phenyl)acetamide;N,N-diethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzamide;N-[2-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide,N-[3-(rac-trans-(1,2)-2-azepan-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-dimethylaminoindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide,N-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-thiomorpholin-4-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-dimethylaminoindan-1-yloxy)phenyl]acetamide;N-[3-(trans-(1S,2S)-2-piperidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)pyridin-2-yl]acetamide;N-[6-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)pyridin-2-yl]acetamide;N-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]-N,N′,N′-trimethylpropane-1,3-diamine;N-[rac-trans-(1,2)-3-((R)-2-[1,3′]bipyrrolidinyl-1′-ylindan-1-yloxy)phenyl]acetamide;N-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-N,N′,N′-trimethylethane-1,2-diamine;N-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-N,N′,N′-trimethylpropane-1,3-diamine;N-{3-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-hydroxymethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-methoxypyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-((R)-3-dimethylaminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-ethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;tert-butyl-[1-(4-methanesulfonylphenoxy)indan-2-yl]amine;3-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]-3,8-diazabicyclo[3.2.1]octane;2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-5-methyloctahydropyrrolo[3,4-c]pyrrole;(3R,5S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3,5-dimethylpiperazine;(R)-1-[(1S,2S)-4,6-difluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1′-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,3′]bipyrrolidinyl;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-fluoropyrrolidine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methylpiperazine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine-3-carbonitrile;(R)-1-[trans-(1S,2S)-6-chloro-1-(2-chloro-4-methanesulfonylphenoxy)-4-fluoroindan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-6-chloro-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-{(1S,2S)-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4,6-difluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]-4,6-difluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-3-methylpyrrolidin-3-ol;(R)-1-{(1S,2S)-4,6-dichloro-1-[4-(5-methyltetrazol-1-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-3-ylamine;(R)-1-{(1S,2S)-4,6-dichloro-1-[5-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[3-(1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(2,4-dimethylthiazol-5-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-difluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-methylphenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}piperidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidine-3-carbonitrile;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylisoxazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylpyrazol-1-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(2H-pyrazol-3-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(S)-1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methylpyrrolidin-3-ol;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-2-pyrrolidin-1-ylmethylpyrrolidine;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-fluoropyrrolidine;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methylpiperazine;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;(S)-1-{(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(S)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(S)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ylamine;(S)-2-[(S)-4-(S)-chloro-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]octahydropyrrolo[1,2-a]pyrazine;(S)-2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-2,5-diazabicyclo[2.2.1]heptane;(S)-3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-4-isopropyloxazolidin-2-one;(S)-3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-4-isopropyloxazolidin-2-one;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(2-fluoroethyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}dimethylamine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamino}acetonitrile;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-yl}-(2-fluoroethyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-yl}methanol;{(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-2-yl}methanol;{-4-[rac-trans-(1,2)-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazin-1-yl}acetonitrile;1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]azetidine;1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[(1S,2S)-4,6-dichloro-1-(3-tetrazol-1-ylphenoxy)indan-2-yl]piperazine;1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methanesulfonylpyrrolidine;1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4,4-difluoropiperidine;1-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]-3-methyl-1,3-dihydroimidazol-2-one;1-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]-3-methylimidazolidin-2-one;1-[4-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)phenyl]pyrrolidin-2-one,1-[4-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidin-2-one;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1H-imidazole;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methyl-[1,4]diazepane;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-5,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[rac-trans-(1,2)-5,7-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6,7-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[rac-trans-(1,2)-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]-4-methylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]-4-methylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-propylpiperidin-3-ylamine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-propylpiperidin-3-ylamine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-trifluoromethylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-trifluoromethylpyrrolidin-3-ylamine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-(2-fluoroethyl)-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-(2-methoxyethyl)-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methyl-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-azetidin-3-ol;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-{(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperazine;1-{2-chloro-5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{2-chloro-5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-2-methylphenyl}-3-methyl-1,3-dihydroimidazol-2-one,1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methylimidazolidin-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{3-[(1S,2S)-4,6-difluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{3-[trans-(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-1,3-dihydroimidazol-2-one;1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-2,6-dimethyl-1H-pyridin-4-one;1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1,3-dihydroimidazol-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3-methylimidazolidin-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-chloro-3-[(1S,2S)-4,6-difluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-methyl-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}-4-methyl-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-(2-methoxyethyl)-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-methyl-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylisoxazol-4-yl)phenoxy]indan-2-yl}-4-(2-methoxyethyl)-[1,4]diazepane;1-cyclopropyl-4-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;2-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-5-chlorobenzamide;2,3-dichloro-4-(rac-trans-(1,2)-4,6-dichloro-2-morpholin-4-ylindan-1-yloxy)benzenesulfonamide;2-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-2,7-diaza-spiro[4.4]nonane;2-{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamino}ethanol;2-{4-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepan-1-yl}ethanol;2-{4-[rac-trans-(1,2)-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazin-1-yl}ethanol;2-{4-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepan-1-yl}ethanol;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}imidazolidine-2,4-dione;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}oxazolidine-2,4-dione;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}imidazolidine-2,4-dione;3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione;3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}thiazolidine-2,4-dione;3-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethyloxazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dlone,3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethyloxazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-chloro-4-[trans-(1S,2S)-6-chloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]benzoicacid methyl ester;4-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-4-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-4-methyl-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-6-methyl-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-7-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-[(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]benzenesulfonamide;4-[(1S,2S)-4,6-dichloro-2-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)indan-1-yloxy]benzenesulfonamide;4-[(1S,2S)-4,6-dichloro-2-(4,4-difluoropiperidin-1-yl)indan-1-yloxy]benzenesulfonamide;4-[3-chloro-4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[3-chloro-4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(rac-trans-(1,2)-5,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]morpholine;4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzoicacid methyl ester;4-{3-chloro-4-[trans-(1S,2S)-6-chloro-2-((R)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{3-chloro-4-[trans-(1S,2S)-6-chloro-2-((S)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}morpholine-3,5-dione;4-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{4-[trans-(1S,2S)-4,6-dichloro-2-((S)-2-methoxymethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{4-[trans-(1S,2S)-6-chloro-2-((R)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}morpholine;4-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}thiomorpholine1,1-dioxide;4-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}morpholine;4-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}thiomorpholine1,1-dioxide;5-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-2-methylbenzothiazole;5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3,4-dihydro-1H-quinolin-2-one;5-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1-methyloctahydropyrrolo[3,4-b]pyrrole;5-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1-methyloctahydropyrrolo[3,4-b]pyrrole;N-[3-(rac-trans-(1,2)-2-thiomorpholin-4-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-[1,4]diazepan-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-morpholin-4-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-chloro-6-fluoro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-chloro-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-methyl-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-5,7-dichloro-2-dimethylaminoindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-5-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-5-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-4-fluoro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-4-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-7-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(trans-(1S,2S)-4,6-dichloro-2-3,8-diazabicyclo[3.2.1]oct-3-ylindan-1-yloxy)phenyl]acetamide;N-[3-(trans-(1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-N-methylmethanesulfonamide;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-4-chloro-6-fluoroindan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-6-chloro-4-fluoroindan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-4,6-dichloro-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-(3-amino-3-propylpiperidin-1-yl)-4,6-dichloroindan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-dimethylaminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxymethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-(4-methylpiperazin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-N-methylmethanesulfonamide;2-{[trans-(1S,2S)-4,6-Dichloro-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-methyl-amino}-ethanol;4-(rac-trans-(1,2)-2-Cyclopropylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide;2-({trans-(1S,2S)-4,6-Dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}-methyl-amino)-ethanol;Cyclopentylmethyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;Cyclobutyl-[rac-cis-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;Cyclobutyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;4-(rac-trans-(1,2)-2-Cyclobutylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide;Cycloheptyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-ethyl-4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;4-(rac-trans-(1,2)-2-Cycloheptylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-isopropyl-4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3-ethyl-5-isopropyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;Cyclobutylmethyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;4-[rac-trans-(1,2)-2-(Cyclobutylmethyl-amino)-indan-1-yloxy]-3-fluoro-benzenesulfonamide;(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(2-ethyl-4-methyl-imidazol-1-yl)-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-4-fluoro-1-[4-(2-isopropyl-4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-4-fluoro-1-[4-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(3-ethyl-5-isopropyl-[1,2,4]triazol-4-yl)-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(1-Ethyl-propyl)-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;(R)-1-{trans-(1S,2S)-1-[4-(4-tert-Butyl-2-isopropyl-imidazol-1-yl)-phenoxy]-6-chloro-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[5-(2-ethyl-4-methyl-imidazol-1-yl)-2-fluoro-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;N-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}-N,N′,N′-trimethyl-ethane-1,2-diamine;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2,4-dimethyl-imidazol-1-yl)-2-fluoro-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-4,6-Dichloro-1-(4-imidazol-1-yl-phenoxy)-indan-2-yl]-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-1-[4-(4-tert-Butyl-2-methyl-imidazol-1-yl)-2-fluoro-phenoxy]-4,6-dichloro-indan-2-yl}-pyrrolidin-3-ol;Cyclopentyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-methyl-amine;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-methanesulfonyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-isopropyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;3-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-5-methyl-3H-[1,3,4]oxadiazol-2-one;Cyclobutyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-methyl-amine;3-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-3H-[1,3,4]oxadiazol-2-one;2-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-4-ethyl-2,4-dihydro-[1,2,4]triazol-3-one;2-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-4-ethyl-5-methyl-2,4-dihydro-[1,2,4]triazol-3-one;(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(2,4-dimethyl-imidazol-1-yl)-2-fluoro-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[2-fluoro-4-(2-methanesulfonyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;1-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-3-fluoro-phenyl}-1H-imidazole-2-carboxylicacid methyl ester;4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-3-fluoro-benzenesulfonamide;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(4-methyl-piperazine-1-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-benzenesulfonamide;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(morpholine-4-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;1-{5-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-2-fluoro-phenyl}-3-methyl-1,3-dihydro-imidazol-2-one;Cyclopentyl-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}-amine;Cyclopentyl-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;4-(trans-(1S,2S)-4,6-Dichloro-2-cyclopentylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide;{trans-(1S,2S)-6-Chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-4-fluoro-indan-2-yl}-cyclopentyl-amine;4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-benzenesulfonamide;[trans-(1S,2S)-6-Chloro-4-fluoro-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-cyclopentyl-amine;1-[4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-phenyl]pyrrolidine-2,5-dione;3-[4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-phenyl]-imidazolidine-2,4-dione;{trans-(1S,2S)-6-Chloro-4-fluoro-1-[2-fluoro-4-(2-methanesulfonyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-cyclopentyl-amine;1-[4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-phenyl]-3-methyl-1,3-dihydro-imidazol-2-one;1-[3-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-4-fluoro-phenyl]-3-methyl-1,3-dihydro-imidazol-2-one;and the pharmaceutically acceptable salts thereof.
 13. A compound of theformula I as claimed in claim 4, wherein the compound is selected fromthe group consisting of:((R)-1-{trans-(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}piperidin-3-yl)-(3,3,3-trifluoropropyl)amine;2-[rac-trans-(1,2)-1-(2,4-dichloro-3-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(3-chloro-2-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2-bromophenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(3-piperidin-1-ylmethylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(3-piperidin-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(4-fluoro-2-methylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}-octahydropyrrolo[3,4-c]pyrrole;2-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}-octahydropyrrolo[3,4-c]pyrrole;(4-methylpiperazin-1-yl)-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]methanone;(R)-1-(trans-(1R,2R)-4,6-dichloro-1-phenoxyindan-2-yl)piperidin-3-ylamine;(R)-1-[(1S,2S)-4,6-dichloro-1-(5-fluoroquinolin-8-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(1H-indol-4-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2,3-dichloro-4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-piperidin-1-ylmethylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(3-piperidin-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(benzo[1,3]dioxol-5-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(isoquinolin-7-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(pyridin-4-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-1-(quinolin-4-yloxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1R,2R)-4,6-dichloro-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}piperidin-3-ylamine;(R)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-3-ylamine;(R)-1-{trans-(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(3-piperidin-1-ylmethylphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(S)-1-[rac-trans-(1,2)-1-(quinolin-5-yloxy)indan-2-yl]piperidin-3-ylamine;(S)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-3-ylamine;[3-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)phenyl]urea;[rac-trans-(1,2)-1-(1H-indol-4-yloxy)indan-2-yl]methylpiperidin-3-ylamine;[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]-methylpiperidin-4-ylamine;[rac-trans-(1,2)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]-dimethylamine;[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-(2-methoxyethyl)methylamine;{(R)-1-[trans-(1S,2S)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(2,2,2-trifluoroethyl)amine;{(R)-1-[trans-(1S,2S)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine;{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}urea;{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}urea;{3-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}urea;{3-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]phenyl}urea;{3-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]phenyl}urea;{-4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}carbamicacid benzyl ester;{-4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]phenyl}carbamicacid benzyl ester;{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-(2-methoxyethyl)methylamine;1-[1-(2-chloro-4-nitrophenoxy)indan-2-yl]pyrrolidine;1-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-1,3-dihydroimidazol-2-one;1-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidin-2-one;1-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidine-2,5-dione;1-[rac-cis-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]-1H-imidazole;1-[rac-trans-(1,2)-1-(1H-indol-6-yloxy)indan-2-yl]pyrrolidin-3-ylamine;1-[rac-trans-(1,2)-1-(2,3-dichloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(2,6-dichloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]pyrrolidin-3-ylamine;1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;1-[rac-trans-(1,2)-1-(3-chloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(3-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;1-[rac-trans-(1,2)-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-1-(quinolin-4-yloxy)indan-2-yl]pyrrolidin-3-ylamine;1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}pyrrolidin-3-ylamine;1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-4-ylamine;1-methyl-3-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-1,3-dihydroimidazol-2-one;2,2,2-trifluoro-N-{(R)-1-[trans-(1S,2S)-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}acetamide;2,3-dichloro-4-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)benzenesulfonamide;2,3-dichloro-4-(rac-trans-(1,2)-2-dimethylaminoindan-1-yloxy)benzenesulfonamide;2,3-dichloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;2,3-dichloro-4-[rac-trans-(1,2)-2-((R)-3-methoxypyrrolidin-1-yl)indan-1-yloxy]benzenesulfonamide;2,3-dichloro-4-[rac-trans-(1,2)-2-(methylpiperidin-3-ylamino)indan-1-yloxy]benzenesulfonamide;2,3-dichloro-4-[trans-(1S,2S)-2-(3-hydroxypiperidin-1-yl)indan-1-yloxy]benzenesulfonamide;2,3-dichloro-N,N-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;2-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]isothiazolidine1,1-dioxide;2-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]thiazole;2-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-6-fluorobenzonitrile;2-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]-5-chlorobenzonitrile;2-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-5-chlorobenzonitrile;2-{-4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}-thiazole-4-carbonitrile;2-chloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzonitrile;2-chloro-4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile;2-fluoro-4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile;2-fluoro-6-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile;3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenylamine;3,5-dichloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3,5-dichloro-N,N-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3,5-dimethyl-4-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole;3,5-dimethyl-4-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole;3,5-dimethyl-4-[4-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)-3-trifluoromethylphenyl]-4H-[1,2,4]triazole;3,5-dimethyl-4-[4-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-isoxazole;3,5-dimethyl-4-[5-methyl-2-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]isoxazole;3-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]oxazolidin-2-one;3-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzamide;3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;3-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]benzamide;3-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]benzamide;3-chloro-4-(2-pyrrolidin-1-ylindan-1-yloxy)pyridine;3-chloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3-chloro-4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzonitrile;3-chloro-N,N-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3-cyclopropyl-5-methyl-4-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole;3-fluoro-4-(2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;3-methyl-4-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-4H-[1,2,4]triazole4-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-3-fluorobenzonitrile;4-((1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-3-fluorobenzonitrile;4-(2-benzylaminoindan-1-yloxy)-3-fluorobenzenesulfonamide;4-(2-cyclopentylaminoindan-1-yloxy)-3-fluorobenzenesulfonamide;4-(rac-trans-(1,2)—(R)-2-[1,3′]bipyrrolidinyl-1′-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-2-azepan-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-2-piperidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzoic acid methylester; 4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzonitrile;4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-N-(2,2,2-trifluoroethyl)benzenesulfonamide;4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-N-(3,3,3-trifluoropropyl)benzenesulfonamide;4-(trans-(1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-3-fluorobenzonitrile;4-[(1R,2S)-1-(2-chloro-4-nitrophenoxy)indan-2-yl]morpholine;4-[(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]-3-fluorobenzonitrile;4-[(1S,2S)-4,6-dichloro-2-(4-methylpiperazin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;4-[2,3-dimethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[2-fluoro-5-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethylisoxazole;4-[3-chloro-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[3-chloro-4-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[3-fluoro-4-(-2-methyl-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[5-fluoro-2-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethylisoxazole;4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-1H-indole;4-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-2,6-dimethylbenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2,3-dichloro-N,N-dimethylbenzenesulfonamide;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2-chlorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-2-fluorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;4-[rac-trans-(1,2)-2-((R)-3-hydroxymethylpyrrolidin-1-yl)indan-1-yloxy]benzenesulfonamide;4-[rac-trans-(1,2)-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]benzenesulfonamide;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]benzamide;4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-2,6-dimethylbenzonitrile;4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-2-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]benzamide;4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-2-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]-3-chlorobenzonitrile;4-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]benzamide;4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]-3-fluorobenzonitrile;4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzenesulfonamide;4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;4-[trans-(1S,2S)-4,6-dichloro-2-((S)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;4-[trans-(1S,2S)-4,6-dichloro-2-(4-methyl-[1,4]diazepan-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;4-[trans-(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzonitrile;5-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)-1,3-dimethyl-1,3-dihydro-indol-2-one;5-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)-3H-isobenzofuran-1-one;5-[5-fluoro-2-(trans-(1S,2S)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-1H-pyrazole;5-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-2-methylbenzothiazole;5-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]benzo[1,3]oxathiol-2-one;5-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]benzo[1,3]oxathiol-2-one;6-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-1H-indole;7-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]-isoquinoline;7-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine;8-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-5-fluoroquinoline;8-((1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-5-fluoroquinoline;8-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)-5-fluoroquinoline;8-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)quinoline;benzyl[1-(4-methanesulfonylphenoxy)indan-2-yl]amine;C-(1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}pyrrolidin-3-yl)methylamine;C-(1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-4-yl)methylamine;C-(1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}pyrrolidin-3-yl)methylamine;C-{1-[rac-trans-(1,2)-1-(1H-indol-4-yloxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(2-tert-butyl-4-ethylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-chloro-2-methylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-ethoxyphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-ethoxyphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(benzo[1,3]dioxol-5-yloxy)indan-2-yl]piperidin-4-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(benzo[1,3]dioxol-5-yloxy)indan-2-yl]pyrrolidin-3-yl}methylamine;C-{1-[rac-trans-(1,2)-1-(quinolin-4-yloxy)indan-2-yl]piperidin-4-yl}methylamine;cyclopentyl[1-(4-methanesulfonylphenoxy)indan-2-yl]amine;cyclopropylmethyl[1-(4-methanesulfonylphenoxy)indan-2-yl]amine;diethyl[rac-trans-(1,2)-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]amine;diethyl[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]amine;diethyl[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]amine;diethyl{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]indan-2-yl}amine;methyl[rac-trans-(1,2)-1-(3-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-ylamine;methyl[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)indan-2-yl]piperidin-4-ylamine;N-(3-{trans-(1S,2S)-2-[(R)-3-(2-fluoroethylamino)piperidin-1-yl]indan-1-yloxy}phenyl)acetamide;N-(3-{trans-(1S,2S)-2-[(R)-3-(3,3,3-trifluoropropylamino)piperidin-1-yl]indan-1-yloxy}phenyl)acetamide;N,N-diethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzamide;N-[2-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-azepan-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-diethylaminoindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-dimethylaminoindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-2-thiomorpholin-4-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-dimethylaminoindan-1-yloxy)phenyl]acetamide;N-[3-(trans-(1S,2S)-2-piperidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)pyridin-2-yl]acetamide;N-[6-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)pyridin-2-yl]acetamide;N-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)indan-2-yl]-N,N′,N′-trimethylpropane-1,3-diamine;N-[rac-trans-(1,2)-3-((R)-2-[1,3′]bipyrrolidinyl-1′-ylindan-1-yloxy)phenyl]acetamide;N-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-N,N′,N′-trimethylethane-1,2-diamine;N-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-N,N′,N′-trimethylpropane-1,3-diamine;N-{3-[rac-trans-(1,2)-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-hydroxymethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-methoxypyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-(3-aminomethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-(3-aminopyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-(4-aminomethylpiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-((R)-3-dimethylaminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-ethyl-4-(rac-trans-(1,2)-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;tert-butyl[1-(4-methanesulfonylphenoxy)indan-2-yl]amine;3-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]-3,8-diazabicyclo[3.2.1]octane;2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-5-methyloctahydropyrrolo[3,4-c]pyrrole;(3R,5S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3,5-dimethylpiperazine;(R)-1-[(1S,2S)-4,6-difluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine,(R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1′-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,3′]bipyrrolidinyl;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-fluoropyrrolidine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methylpiperazine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine-3-carbonitrile;(R)-1-[trans-(1S,2S)-6-chloro-1-(2-chloro-4-methanesulfonylphenoxy)-4-fluoroindan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-6-chloro-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-{(1S,2S)-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4,6-difluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]-4,6-difluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-3-methylpyrrolidin-3-ol;(R)-1-{(1S,2S)-4,6-dichloro-1-[4-(5-methyltetrazol-1-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-3-ylamine;(R)-1-{(1S,2S)-4,6-dichloro-1-[5-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[3-(1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(2,4-dimethyl-thiazol-5-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-difluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-methylphenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}piperidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidine-3-carbonitrile;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylisoxazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylpyrazol-1-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(2H-pyrazol-3-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(S)-1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methylpyrrolidin-3-ol;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-2-pyrrolidin-1-ylmethylpyrrolidine;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-fluoropyrrolidine;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methylpiperazine;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;(S)-1-{(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(S)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(S)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ylamine;(S)-2-[(S)-4-(S)-chloro-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]octahydropyrrolo[1,2-a]pyrazine;(S)-2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-2,5-diazabicyclo[2.2.1]heptane;(S)-3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-4-isopropyloxazolidin-2-one;(S)-3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-4-isopropyloxazolidin-2-one;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(2-fluoroethyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}dimethylamine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamino}acetonitrile;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-yl}-(2-fluoroethyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-yl}methanol;{(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-2-yl}methanol;{4-[rac-trans-(1,2)-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazin-1-yl}acetonitrile;1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]-azetidine;1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[(1S,2S)-4,6-dichloro-1-(3-tetrazol-1-ylphenoxy)indan-2-yl]piperazine;1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methanesulfonylpyrrolidine;1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4,4-difluoropiperidine;1-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]-3-methyl-1,3-dihydroimidazol-2-one;1-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]-3-methylimidazolidin-2-one;1-[4-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)phenyl]pyrrolidin-2-one;1-[4-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidin-2-one;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1H-imidazole;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methyl-[1,4]diazepane;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-5,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[rac-trans-(1,2)-5,7-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6,7-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[rac-trans-(1,2)-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]-4-methylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]-4-methylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-propylpiperidin-3-ylamine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-propylpiperidin-3-ylamine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-trifluoromethylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-trifluoromethylpyrrolidin-3-ylamine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-(2-fluoroethyl)-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-(2-methoxyethyl)-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methyl-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-azetidin-3-ol;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-{(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperazine;1-{2-chloro-5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{2-chloro-5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-2-methylphenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methylimidazolidin-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{3-[(1S,2S)-4,6-difluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{3-[trans-(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-1,3-dihydroimidazol-2-one;1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-2,6-dimethyl-1H-pyridin-4-one;1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1,3-dihydroimidazol-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3-methylimidazolidin-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-chloro-3-[(1S,2S)-4,6-difluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-methyl-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}-4-methyl-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-(2-methoxyethyl)-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-methyl-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylisoxazol-4-yl)phenoxy]indan-2-yl}-4-(2-methoxyethyl)-[1,4]diazepane;1-cyclopropyl-4-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;2-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-5-chlorobenzamide;2,3-dichloro-4-(rac-trans-(1,2)-4,6-dichloro-2-morpholin-4-ylindan-1-yloxy)benzenesulfonamide;2-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-2,7-diaza-spiro[4.4]nonane;2-{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamino}ethanol;2-{-4-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepan-1-yl}ethanol;2-{4-[rac-trans-(1,2)-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazin-1-yl}ethanol;2-{4-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepan-1-yl}ethanol;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}imidazolidine-2,4-dione;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}oxazolidine-2,4-dione;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}imidazolidine-2,4-dione;3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione;3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}thiazolidine-2,4-dione;3-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethyloxazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethyloxazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-chloro-4-[trans-(1S,2S)-6-chloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]benzoicacid methyl ester;4-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-4-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-4-methyl-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-6-methyl-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-7-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-[(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]benzenesulfonamide;4-[(1S,2S)-4,6-dichloro-2-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)indan-1-yloxy]benzenesulfonamide;4-[(1S,2S)-4,6-dichloro-2-(4,4-difluoropiperidin-1-yl)indan-1-yloxy]benzenesulfonamide;4-[3-chloro-4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[3-chloro-4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(rac-trans-(1,2)-5,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]-triazole;4-[4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]morpholine;4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzoicacid methyl ester;4-{3-chloro-4-[trans-(1S,2S)-6-chloro-2-((R)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{3-chloro-4-[trans-(1S,2S)-6-chloro-2-((S)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}morpholine-3,5-dione;4-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{4-[trans-(1S,2S)-4,6-dichloro-2-((S)-2-methoxymethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{4-[trans-(1S,2S)-6-chloro-2-((R)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}morpholine;4-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}thiomorpholine1,1-dioxide;4-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}morpholine;4-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}thiomorpholine1,1-dioxide;5-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-2-methylbenzothiazole;5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3,4-dihydro-1H-quinolin-2-one;5-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1-methyloctahydropyrrolo[3,4-b]pyrrole;5-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1-methyloctahydropyrrolo[3,4-b]pyrrole;N-[3-(rac-trans-(1,2)-2-thiomorpholin-4-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-[1,4]diazepan-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-morpholin-4-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-chloro-6-fluoro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-chloro-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-methyl-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-5,7-dichloro-2-dimethylaminoindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-5-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide,N-[3-(rac-trans-(1,2)-5-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-4-fluoro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-4-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-7-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(trans-(1S,2S)-4,6-dichloro-2-3,8-diazabicyclo[3.2.1]oct-3-ylindan-1-yloxy)phenyl]acetamide;N-[3-(trans-(1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-N-methylmethanesulfonamide;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-4-chloro-6-fluoroindan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-6-chloro-4-fluoroindan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-4,6-dichloro-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-(3-amino-3-propylpiperidin-1-yl)-4,6-dichloroindan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-dimethylaminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxymethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-(4-methylpiperazin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-N-methylmethanesulfonamide;(R)-1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;2-{[trans-(1S,2S)-4,6-Dichloro-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-methyl-amino}-ethanol;4-(rac-trans-(1,2)-2-Cyclopropylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide;2-({trans-(1S,2S)-4,6-Dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}-methyl-amino)-ethanol;Cyclopentylmethyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;Cyclobutyl-[rac-cis-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;Cyclobutyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;4-(rac-trans-(1,2)-2-Cyclobutylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide;Cycloheptyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;4-(rac-trans-(1,2)-2-Cycloheptylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide;Cyclobutylmethyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;4-[rac-trans-(1,2)-2-(Cyclobutylmethyl-amino)-indan-1-yloxy]-3-fluoro-benzenesulfonamide;(1-Ethyl-propyl)-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;N-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}-N,N′,N′-trimethyl-ethane-1,2-diamine;Cyclopentyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-methyl-amine;Cyclobutyl-[rac-trans-(1,2)-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-methyl-amine;Cyclopentyl-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}-amine;Cyclopentyl-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-amine;4-(trans-(1S,2S)-4,6-Dichloro-2-cyclopentylamino-indan-1-yloxy)-3-fluoro-benzenesulfonamide;{trans-(1S,2S)-6-Chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluoro-phenoxy]-4-fluoro-indan-2-yl}-cyclopentyl-amine;4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-benzenesulfonamide;[trans-(1S,2S)-6-Chloro-4-fluoro-1-(4-methanesulfonyl-phenoxy)-indan-2-yl]-cyclopentyl-amine;1-[4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-phenyl]-pyrrolidine-2,5-dione;3-[4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-phenyl]-imidazolidine-2,4-dione;1-[4-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-3-fluoro-phenyl]-3-methyl-1,3-dihydro-imidazol-2-one;1-[3-(trans-(1S,2S)-6-Chloro-2-cyclopentylamino-4-fluoro-indan-1-yloxy)-4-fluoro-phenyl]-3-methyl-1,3-dihydro-imidazol-2-one;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-ethyl-4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-isopropyl-4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3-ethyl-5-isopropyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(2-ethyl-4-methyl-imidazol-1-yl)-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-4-fluoro-1-[4-(2-isopropyl-4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-4-fluoro-1-[4-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(3-ethyl-5-isopropyl-[1,2,4]triazol-4-yl)-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-1-[4-(4-tert-Butyl-2-isopropyl-imidazol-1-yl)-phenoxy]-6-chloro-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[5-(2-ethyl-4-methyl-imidazol-1-yl)-2-fluoro-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2,4-dimethyl-imidazol-1-yl)-2-fluoro-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-4,6-Dichloro-1-(4-imidazol-1-yl-phenoxy)-indan-2-yl]-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-1-[4-(4-tert-Butyl-2-methyl-imidazol-1-yl)-2-fluoro-phenoxy]-4,6-dichloro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-isopropyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;3-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-5-methyl-3H-[1,3,4]oxadiazol-2-one;3-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-3H-[1,3,4]oxadiazol-2-one;2-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-4-ethyl-2,4-dihydro-[1,2,4]triazol-3-one;2-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-4-ethyl-5-methyl-2,4-dihydro-[1,2,4]triazol-3-one;(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(2,4-dimethyl-imidazol-1-yl)-2-fluoro-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;1-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-3-fluoro-phenyl}-1H-imidazole-2-carboxylicacid methyl ester;4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-3-fluoro-benzenesulfonamide;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(4-methyl-piperazine-1-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-benzenesulfonamide;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(morpholine-4-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;1-{5-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-2-fluoro-phenyl}-3-methyl-1,3-dihydro-imidazol-2-one;and the pharmaceutically acceptable salts thereof.
 14. A compound of theformula I as claimed in claim 5, wherein the compound is selected fromthe group consisting of:3-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]-3,8-diazabicyclo[3.2.1]octane;2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-5-methyloctahydropyrrolo[3,4-c]pyrrole;(3R,5S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3,5-dimethylpiperazine;(R)-1-[(1S,2S)-4,6-difluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1′-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,3′]bipyrrolidinyl;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-fluoropyrrolidine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methylpiperazine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol,(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine-3-carbonitrile;(R)-1-[trans-(1S,2S)-6-chloro-1-(2-chloro-4-methanesulfonylphenoxy)-4-fluoroindan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-6-chloro-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(R)-1-{(1S,2S)-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4,6-difluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{(1S,2S)-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]-4,6-difluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-3-methylpyrrolidin-3-ol;(R)-1-{(1S,2S)-4,6-dichloro-1-[4-(5-methyltetrazol-1-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperidin-3-ylamine;(R)-1-{(1S,2S)-4,6-dichloro-1-[5-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[3-(1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(2,4-dimethylthiazol-5-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-difluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-methylphenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}piperidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidine-3-carbonitrile;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylisoxazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylpyrazol-1-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(2H-pyrazol-3-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2,3-dimethylphenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]-4-fluoroindan-2-yl}pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-chloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(S)-1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methylpyrrolidin-3-ol;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-2-pyrrolidin-1-ylmethylpyrrolidine;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-fluoropyrrolidine;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methylpiperazine;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ylamine;(S)-1-{(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}pyrrolidin-3-ol;(S)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ol;(S)-1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}pyrrolidin-3-ylamine;(S)-2-[(S)-4-(S)-chloro-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]octahydropyrrolo[1,2-a]pyrazine;(S)-2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-2,5-diazabicyclo[2.2.1]heptane;(S)-3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-4-isopropyloxazolidin-2-one;(S)-3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-4-isopropyloxazolidin-2-one;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(2-fluoroethyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}-(3,3,3-trifluoropropyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-yl}dimethylamine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamino}acetonitrile;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-yl}-(2-fluoroethyl)amine;{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-yl}methanol;{(S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-2-yl}methanol;{-4-[rac-trans-(1,2)-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazin-1-yl}acetonitrile;1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]-azetidine;1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[(1S,2S)-4,6-dichloro-1-(3-tetrazol-1-ylphenoxy)indan-2-yl]piperazine;1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-methanesulfonylpyrrolidine;1-[(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4,4-difluoropiperidine;1-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]-3-methyl-1,3-dihydroimidazol-2-one;1-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]-3-methylimidazolidin-2-one;1-[4-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)phenyl]pyrrolidin-2-one;1-[4-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]pyrrolidin-2-one;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1H-imidazole;1-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methyl-[1,4]diazepane;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-5,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[rac-trans-(1,2)-5,7-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6,7-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[rac-trans-(1,2)-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonyl-3-methylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidine;1-[rac-trans-(1,2)-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(2-chloro-4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]-4-methylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-imidazol-1-ylphenoxy)indan-2-yl]-4-methylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-propylpiperidin-3-ylamine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-propylpiperidin-3-ylamine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-trifluoromethylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3-trifluoromethylpyrrolidin-3-ylamine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-(2-fluoroethyl)-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-(2-methoxyethyl)-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methyl-[1,4]diazepane;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-4-methylpiperazine;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-azetidin-3-ol;1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine,1-{(1S,2S)-4,6-dichloro-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]indan-2-yl}piperazine;1-{2-chloro-5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{2-chloro-5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-2-methylphenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methylimidazolidin-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{3-[(1S,2S)-4,6-difluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{3-[trans-(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-1,3-dihydroimidazol-2-one;1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-2,6-dimethyl-1H-pyridin-4-one;1-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1,3-dihydroimidazol-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3-methylimidazolidin-2-one;1-{-4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one,1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidine-2,5-dione;1-{4-chloro-3-[(1S,2S)-4,6-difluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methyl-1,3-dihydroimidazol-2-one;1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-3-methylimidazolidin-2-one;1-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}pyrrolidin-2-one;1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-methyl-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}-4-methyl-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-(2-methoxyethyl)-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}-4-methyl-[1,4]diazepane;1-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethylisoxazol-4-yl)phenoxy]indan-2-yl}-4-(2-methoxyethyl)-[1,4]diazepane;1-cyclopropyl-4-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazine;2-((1S,2S)-2-azetidin-1-yl-4,6-dichloroindan-1-yloxy)-5-chlorobenzamide;2,3-dichloro-4-(rac-trans-(1,2)-4,6-dichloro-2-morpholin-4-ylindan-1-yloxy)benzenesulfonamide;2-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-2,7-diaza-spiro[4.4]nonane;2-{(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamino}ethanol;2-{-4-[rac-trans-(1,2)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepan-1-yl}ethanol;2-{-4-[rac-trans-(1,2)-6-chloro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperazin-1-yl}ethanol;2-{4-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-[1,4]diazepan-1-yl}ethanol;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}imidazolidine-2,4-dione;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}oxazolidine-2,4-dione;3-{3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}imidazolidine-2,4-dione;3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione;3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{3-chloro-4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidine-2,4-dione;3-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}thiazolidine-2,4-dione;3-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethyloxazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-1-methylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethylimidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-5,5-dimethyloxazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}imidazolidine-2,4-dione;3-{4-chloro-3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}oxazolidin-2-one;3-chloro-4-[trans-(1S,2S)-6-chloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]benzoicacid methyl ester;4-((1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-4-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-4-methyl-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-6-methyl-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-(rac-trans-(1,2)-7-chloro-2-pyrrolidin-1-ylindan-1-yloxy)benzenesulfonamide;4-[(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]benzenesulfonamide;4-[(1S,2S)-4,6-dichloro-2-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)indan-1-yloxy]benzenesulfonamide;4-[(1S,2S)-4,6-dichloro-2-(4,4-difluoropiperidin-1-yl)indan-1-yloxy]benzenesulfonamide;4-[3-chloro-4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[3-chloro-4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(rac-trans-(1,2)-5,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[4-(trans-(1S,2S)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;4-[rac-trans-(1,2)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]morpholine;4-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]-2,3-dichlorobenzenesulfonamide;4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorobenzoicacid methyl ester;4-{3-chloro-4-[trans-(1S,2S)-6-chloro-2-((R)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{3-chloro-4-[trans-(1S,2S)-6-chloro-2-((S)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}morpholine-3,5-dione;4-{4-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{4-[trans-(1S,2S)-4,6-dichloro-2-((S)-2-methoxymethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{4-[trans-(1S,2S)-6-chloro-2-((R)-3-fluoropyrrolidin-1-yl)indan-1-yloxy]-3-fluorophenyl}-3,5-dimethyl-4H-[1,2,4]triazole;4-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}morpholine;4-{trans-(1S,2S)-4,6-dichloro-1-[4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-2-fluorophenoxy]indan-2-yl}thiomorpholine1,1-dioxide;4-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}morpholine;4-{trans-(1S,2S)-6-chloro-1-[2-chloro-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)phenoxy]indan-2-yl}thiomorpholine1,1-dioxide;5-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)-2-methylbenzothiazole;5-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-3,4-dihydro-1H-quinolin-2-one;5-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1-methyloctahydropyrrolo[3,4-b]pyrrole;5-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-1-methyloctahydropyrrolo[3,4-b]pyrrole;N-[3-(rac-trans-(1,2)-2-thiomorpholin-4-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-[1,4]diazepan-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-morpholin-4-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4,6-dichloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-chloro-6-fluoro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-chloro-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-4-methyl-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-5-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-5-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-4-fluoro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-chloro-4-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-6-fluoro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(rac-trans-(1,2)-7-chloro-2-pyrrolidin-1-ylindan-1-yloxy)phenyl]acetamide;N-[3-(trans-(1S,2S)-4,6-dichloro-2-3,8-diazabicyclo[3.2.1]oct-3-ylindan-1-yloxy)phenyl]acetamide;N-[3-(trans-(1S,2S)-4,6-dichloro-2-piperazin-1-ylindan-1-yloxy)phenyl]acetamide;N-{3-[(1S,2S)-6-chloro-4-fluoro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]-4-fluorophenyl}-N-methylmethanesulfonamide;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-4-chloro-6-fluoroindan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-6-chloro-4-fluoroindan-1-yloxy]phenyl}acetamide;N-{3-[rac-trans-(1,2)-4,6-dichloro-2-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-((R)-3-aminopiperidin-1-yl)-4,6-dichloroindan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-2-(3-amino-3-propylpiperidin-1-yl)-4,6-dichloroindan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-dimethylaminopiperidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxymethylpyrrolidin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-ylindan-1-yloxy]phenyl}acetamide;N-{3-[trans-(1S,2S)-4,6-dichloro-2-(4-methylpiperazin-1-yl)indan-1-yloxy]phenyl}acetamide;N-{4-[(1S,2S)-4,6-dichloro-2-((R)-3-hydroxypyrrolidin-1-yl)indan-1-yloxy]phenyl}-N-methylmethanesulfonamide;(R)-1-[(1S,2S)-4,6-dichloro-1-(2-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-ethyl-4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-isopropyl-4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(3-ethyl-5-isopropyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(2-ethyl-4-methyl-imidazol-1-yl)-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-4-fluoro-1-[4-(2-isopropyl-4-methyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-4-fluoro-1-[4-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(3-ethyl-5-isopropyl-[1,2,4]triazol-4-yl)-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-1-[4-(4-tert-Butyl-2-isopropyl-imidazol-1-yl)-phenoxy]-6-chloro-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[5-(2-ethyl-4-methyl-imidazol-1-yl)-2-fluoro-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2,4-dimethyl-imidazol-1-yl)-2-fluoro-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;(R)-1-[trans-(1S,2S)-4,6-Dichloro-1-(4-imidazol-1-yl-phenoxy)-indan-2-yl]-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-1-[4-(4-tert-Butyl-2-methyl-imidazol-1-yl)-2-fluoro-phenoxy]-4,6-dichloro-indan-2-yl}-pyrrolidin-3-ol;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(2-isopropyl-imidazol-1-yl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;3-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-5-methyl-3H-[1,3,4]oxadiazol-2-one;3-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-3H-[1,3,4]oxadiazol-2-one;2-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-4-ethyl-2,4-dihydro-[1,2,4]triazol-3-one;2-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-phenyl}-4-ethyl-5-methyl-2,4-dihydro-[1,2,4]triazol-3-one;(R)-1-{trans-(1S,2S)-6-Chloro-1-[4-(2,4-dimethyl-imidazol-1-yl)-2-fluoro-phenoxy]-4-fluoro-indan-2-yl}-pyrrolidin-3-ol;1-{4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-3-fluoro-phenyl}-1H-imidazole-2-carboxylicacid methyl ester;4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-3-fluoro-benzenesulfonamide;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(4-methyl-piperazine-1-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-benzenesulfonamide;(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(morpholine-4-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;1-{5-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-2-fluoro-phenyl}-3-methyl-1,3-dihydro-imidazol-2-one;and the pharmaceutically acceptable salts thereof.
 15. A compound of theformula I as claimed in any of claims 1 to 14 and the pharmaceuticallyacceptable salts thereof, wherein the radical XLBR5 bonded at position 1is directed downwards and the radical —(CH₂)_(q)NR3R4 bonded at position2 is directed upwards, with the direction being determined starting froma plane which is spanned by the three carbon atoms in positions 1, 2 and3, and the compounds are oriented as in formula Ie


16. A compound of the formula I and/or the pharmaceutically acceptablesalts thereof as claimed in one or more of claims 1 to 15 for use as amedicament.
 17. The use of a compound as claimed in any of claims 1 to15 and/or the pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment or prophylaxis ofdisorders through complete or partial inhibition of the Na⁺/H⁺ exchangeby NHE3.
 18. The use of a compound of the formula I and/or itspharmaceutically acceptable salts as claimed in one or more of claims 1to 15 for the manufacture of a medicament for the treatment orprophylaxis of impairments of respiratory drive, of respiratorydisorders, sleep-related respiratory disorders, sleep apneas, ofsnoring, of cystic fibrosis, of upper and lower airway diseases that areassociated with viscous mucus, of acute and chronic renal disorders, ofacute renal failure and of chronic renal failure, of impairments ofbowel function, of constipation, of impairments of bilary function, ofhigh blood pressure, of essential hypertension, of cardiovasculardisorders, of diabetes mellitus, of the metabolic syndrome and ofhyperlipidemias.
 19. The use of a compound of the formula I and/or itspharmaceutically acceptable salts as claimed in one or more of claims 1to 15 in combination with other pharmaceuticals or active ingredientsfor the manufacture of a medicament for the treatment or prophylaxis ofimpairments of respiratory drive, of respiratory disorders,sleep-related respiratory disorders, sleep apneas, of snoring, of cysticfibrosis, of upper and lower airway diseases that are associated withviscous mucus, of acute and chronic renal disorders, of acute renalfailure and of chronic renal failure, of impairments of bowel function,of constipation, of impairments of bilary function, of high bloodpressure, of essential hypertension, of cardiovascular disorders, ofdiabetes mellitus, of the metabolic syndrome and of hyperlipidemias. 20.A compound of the formula I and/or the pharmaceutically acceptable saltsthereof as claimed in one or more of claims 1 to 15 alone or incombination with other pharmaceuticals or active ingredients for use inthe treatment or prophylaxis of impairments of the respiratory driveand/or of sleep-related respiratory impairments.
 21. A compound of theformula I and/or the pharmaceutically acceptable salts thereof asclaimed in one or more of claims 1 to 15 alone or in combination withother pharmaceuticals or active ingredients for use in the treatment orprophylaxis of sleep apneas.
 22. A compound of the formula I and/or thepharmaceutically acceptable salts thereof as claimed in one or more ofclaims 1 to 15 alone or in combination with other pharmaceuticals oractive ingredients for use in the treatment or prophylaxis of snoring.23. A compound of the formula I and/or the pharmaceutically acceptablesalts thereof as claimed in one or more of claims 1 to 15 alone or incombination with other pharmaceuticals or active ingredients for use inthe treatment of cystic fibrosis.
 24. A compound of the formula I and/orthe pharmaceutically acceptable salts thereof as claimed in one or moreof claims 1 to 15 alone or in combination with other pharmaceuticals oractive ingredients for use in the mucolytic treatment of upper and lowerairway diseases that are associated with viscous mucus.
 25. Apharmaceutical preparation for human, veterinary or phytoprotective usecomprising an effective amount of a compound of the formula I and/or ofa pharmaceutically acceptable salt thereof as claimed in one or more ofclaims 1 to
 15. 26. A pharmaceutical preparation for human, veterinaryor phytoprotective use comprising an effective amount of a compound ofthe formula I and/or of a pharmaceutically acceptable salt thereof asclaimed in one or more of claims 1 to 15, in combination with otherpharmacological active ingredients or pharmaceuticals.
 27. A solvate,prodrug or crystal modification of a compound of the formula I asclaimed in any of claims 1 to 15, and the pharmaceutically acceptablesalts thereof.